

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 03/000928 A2

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number: **PCT/IB02/03534**

(22) International Filing Date: **19 June 2002 (19.06.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
PA 2001 00992 25 June 2001 (25.06.2001) DK
60/301,818 2 July 2001 (02.07.2001) US

(71) Applicant (for all designated States except US): **ODIN MEDICAL A/S [DK/DK]**; Blegdamsvej 9, DK-2100 Copenhagen Ø (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **POULSEN, Hans**, Skovgaard [DK/DK]; Tuborg Boulevard 24 st, th, DK-2900 Hellerup (DK). **PEDERSEN, Nina** [DK/DK]; Lundtoftegade 46, st.tv., DK-2200 Copenhagen N. (DK). **MORTENSEN, Shila** [DK/DK]; Middelvej 29, DK-2820 Gentofte (DK). **Sørensen, Susanne, Berg** [DK/DK]; Lille Strandvej 26, 1.mf., DK-2900 Hellerup (DK). **PETERSEN, Mikkel, Wandahl** [DK/DK]; Osterbrogade 139, 3.tv., DK-2100 Copenhagen Ø (DK). **ELSNER, Henrik, Irgang** [DK/DK]; Svend Gønges Vej 36, DK-2700 Brønshøj (DK).

(74) Agent: **HØIBERG A/S**; Store Kongensgade 59 B, DK-1264 Copenhagen K. (DK).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE

(utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ONCOLOGY DRUG INNOVATION**

(57) Abstract: The present invention describes methods for identification of molecules expressed at a different level on the cell surface of cancer cells compared to non-malignant cells and methods of identification of cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer. The invention furthermore describes targeting complexes targeted to cell surface molecules identified by the methods of the invention. In embodiments of the invention said targeting complexes comprise the promoters identified by the methods of the invention. In addition the invention describes methods of identifying binding partners for the cell surface molecules and the binding partners per se. Methods of treatment using the targeting complexes and uses of the targeting complexes for the preparation of a medicament are also disclosed by the invention. Furthermore, the invention describes uses of the cell surface molecules or fragments thereof for preparation of vaccines.

BEST AVAILABLE COPY

WO 03/000928 A2

Oncology drug innovation

Field of invention

- 5 The present invention relates to methods of identification of molecules on the cell surface of cancer cells and a method of identification of cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer.

10 Background of the invention

- Approximately half of all patients with cancer have disseminated disease at the time of diagnosis. Existing cancer therapies are able to cure only 5-7% of these patients. Consequently, there is a great need for more effective drugs, which can be administered systemically alone or in combination with existing treatments. Methods utilising gene therapy to deliver efficient and specific treatment of cancer cells is there-
15 fore a promising strategy. However, strategies applied to this date have only had limited success and the development of suitable delivery systems need further development.

20 Delivery vectors

- The choice of the delivery vector for gene therapy is a major issue. Many vector systems have been tested for their suitability for gene transfer, including viral vectors such as retrovirus, adenovirus, adeno-associated virus, lentivirus and non viral vectors such as complexing with liposomes, cationic lipids or polycations. However,
25 all of these vectors have specific advantages and limitations. Retrovirus requires mitotic division for transduction, but mediate long term expression, as they integrate in the genome. Adenovirus will transduce both dividing and non-dividing cells, but only transiently as they remain episomal. Adenovirus, however, are highly immunogenic and retrovirus are rapidly inactivated by the human complement system. Len-
30 tivus does not induce immune response, but involve specific safety concerns, as it is a member of the immunodeficiency virus. More than 75% of all protocols so far have used viral vectors despite these are difficult and expensive to produce, there is a limited insert size of the therapeutic gene and there are many safety considera-

tions to be made. Therefore, the majority of the protocols used for adenoviral vectors have administered the therapeutic gene by local delivery (injection into the tumour) to increase the local titer of the virus and avoid immunogenic response, but even the highest titer system has not yet been sufficient to cure local tumours. A major disadvantage of viral vector systems is that their uptake is unspecific and not targeted to the cancer cells. However, as adenovirus still is the preferred vector due to its efficiency of delivery, ways of reducing the immune response and target the virus to specific cells are under development. On the other hand, liposomes and polycation complexes, which are less immunogenic, easier to produce and do not need the safety considerations of viral vectors have much lower transfection efficiency than viral transduction and also lack the cell specificity. However, polycations have the ability to compact and neutralise the charge of the delivered DNA and PEI complexes appear relatively stable in the blood system (Goula et al., 1998; reviewed in Mountain, 2000).

To assure high specificity and to limit undesired side effects of the treatment, it is of importance to design a vector or vehicle, which targets and delivers the therapeutic gene in question to the cancer cells efficiently and with high specificity. However, as described below, this involves assembly of a multi component vector.

Receptor targeting.

Functional receptors or other cell surface molecules, which can internalise by ligand or antibody binding on the cancer cell surfaces, can be used to target the gene delivery to the cells. Receptor targeted gene delivery by means of DNA conjugated to a ligand of the receptor offers a promising approach. The major advantages of targeted gene delivery are that receptor targeting can be performed without virus, thus eliminating many of the obstacles present in current strategies of gene therapy. Successful deliverance of genes to cancer cells using receptor targeting has been reported to a variety of different surface receptors including receptors for epidermal growth factor (Cristano and Roth, 1996, Frederiksen et al., 2000), folate (Gottschalk et al., 1994), transferrin (Wagner et al., 1990). High expression of a specific receptor is not always a pre-requisite for efficient receptor mediated uptake, as has been demonstrated for the epidermal growth factor receptor (Frederiksen et al., 2000). However, many of the receptors expressed by cancer cells are also expressed by normal cells to some extent, meaning that normal cells will often be targeted as well. This issue emphasises the need for further requirements for specificity for the expression or nature of the therapeutic gene.

Molecular conjugates

For targeted gene therapy it is essential that the ligand to be internalised and DNA expressing the therapeutic gene are physically associated for receptor mediated uptake. Several methods have been used for preparing non-viral, synthetic vectors of targeted DNA molecular conjugates by associating cationic polymers, such as poly-L-lysine (Frederiksen et al., 2000) or polyethylenimine (PEI) (Kircheis et al., 1997) (polyplexes) with the ligand and DNA. Successful gene targeting has been reported for a number of molecular conjugates. The ligand has either been covalently linked to the polycation, or biotinylated ligand and polylysine were complexed via streptavidine to form condensed conjugates with DNA, which are internalised by the receptor of the ligand. One of the advantages of these system over virus mediated transfer is the lack of size limitation of the DNA. PEI complexes, in addition, appear to be able to pass the capillary barrier in lung, making this compound one agent for molecular conjugates.

Endosomal release of molecular conjugate.

After endocytosis of the DNA/ligand conjugate by the receptor, the normal pathway would lead to degradation and loss of DNA. It has therefore proven essential to include an endosomolytic agent in the molecular conjugate. Adenovirus, replication deficient adenovirus and the viral capsid have all proven to be very efficient for endosomal lysis, when included in the molecular conjugate. However, all the reservations of unspecific uptake, safety and immunogenic response applying to use of using adenovirus as vectors also apply for this system. Inclusion of other fusogenic peptides containing amino acid sequences from e.g. influenza virus, toxins or synthetic peptides in the molecular conjugate have been tested for cytoplasmic release. These have the advantage of less immunogenicity and lower cost, but have been shown to be less effective in endosomal lysis than adenovirus. However, if the molecular conjugate is formed using the polycationic PEI, inclusion of endosomolytic agents are not necessary, as PEI has an intrinsic endosome-buffering capacity resulting in endosomal swelling and rupture.

Cancer specific promoters

An increase in the specificity of the targeting of a therapeutic gene to cancer cells can be obtained if a tumour specific promoter controlling the expression can be used (reviewed in Nettelbeck et al., 2000). Promoters for genes, whose expression is specific for the malignant phenotype, but show no tissue specificity such as telomer-

ase have been used. Also, promoters regulating oncofetal antigens, which are not normally expressed in the adult, have been found to be active in tumor cells, such as carcinoembryonic antigen (CEA). However, the activity of these promoters (compared to strong, constitutive active viral promoters) have often proven not to mediate sufficient expression of the therapeutic gene, wherefore the tumour specific genes have been used for activation of another, stronger promoter controlling the therapeutic gene. Another disadvantage of oncofetal promoters is that these promoters will only be active in a subset of tumour types, depending on the tissue origin of the tumour. Alternatively, synthetic promoters have been designed taking advantage of the fact that many oncogenes which are overexpressed in cancer cells are transcription factors, which can mediate high transcriptional activity from their respective DNA recognition sequences.

Therapeutic genes

The product of a therapeutic gene must be able to effectively induce cell death. Gene therapy strategies for cancer treatment have used many different approaches. These include immunogene therapy such as cytokine stimulation of immune system (enhancing the immune response against tumour cells), selective prodrug activation, suicide genes, restoration of tumor suppressor genes and inhibition of activated oncogenes (reviewed in Frederiksen et al., 1999; Gunji et al., 2000). Indeed, most of the present therapeutic protocols in clinical trials against cancer involve immunotherapy. However, as the molecular phenotype of many types of cancer regarding aberrant expression or mutations of oncogenes and tumour suppressor genes, these are obvious candidates to target. Therapeutic gene products reducing expression or activity of oncogenes, such as antisense RNA or neutralising antibody fragments, have been tried and shown to inhibit proliferation. However, oncogene inactivation does not necessarily kill the cells and is therefore probably not applicable for short term treatment. One of the at present promising strategies is to reintroduce tumour suppressor genes, as most cancer cells exhibit loss of function of one or more of these genes. Of particular interest is the tumour suppressor gene *TP53* encoding p53, which is a transcription factor, which activates genes known to be involved in cell cycle arrest and induction of apoptosis. Reintroduction of wild type p53 has been shown to markedly reduce tumour cell growth or induce apoptosis of cancer cells in both in vitro and in vivo systems (Roth et al., 1996; Nielsen and Maneval, 1998).

However, gene products rendering cells sensitive to otherwise harmless drugs has also been extensively used for gene therapy trials. In particular, the herpes simplex

virus thymidine kinase (HSV-tk) in combination with the nucleoside analogue drug gangcyclovir has been used. However, the conversion of the drug to a toxic nucleoside analogue by the enzyme only will kill cells, which are dividing. However, the toxic products are transmitted to surrounding cells by the so-called "by-stander" effect, making the approach potential for systems with low targeting efficiency.

Summary of the invention

- Accordingly, it is a first objective of the present invention to provide methods for identifying a plurality of cell surface molecules, which are expressed at a different level in malignant cells compared with normal cells, comprising the steps of:
- i) Providing at least 3 malignant cell lines selected from the group consisting of CPH 54 A, CPH 54 B, GLC 2, GLC 3, GLC 14, GLC 16, GLC 19, GLC 26, GLC 28, DMS 53, DMS 79, DMS 92, DMS 114, DMS 153, DMS 273, DMS 406, DMS 456, NCI H69, NCI N417, MAR H24, MAR 86 MI, SHP-77, NCI-H2171, NCI-H2195, NCI-H2196, NCI-H2198, NCI-H2227, NCI-H2286, NCI-H2330, NCI-H735, NCI-H1339, NCI-H1963, NCI-H2107, NCI-H2108, NCI-H1304, NCI-H1341, NCI-H1417, NCI-H1436, NCI-H1522, NCI-H1618, NCI-H1672, NCI-H1694, NCI-H1836, NCI-H1870, NCI-H1876, NCI-H1882, NCI-H1926, NCI-H1930, NCI-H1994, NCI-H2029, NCI-H2059, NCI-H2066, NCI-H2081, NCI-H2141, NCI-H211, NCI-H220, NCI-H250, NCI-H524, NCI-H592, NCI-H711, NCI-H719, NCI-H740, NCI-H748, NCI-H774, NCI-H841, NCI-H847, NCI-H865, NCI-H1048, NCI-H1059, NCI-H1092, NCI-H1105, NCI-H1184, NCI-H1238, NCI-H1284, NCI-H1688, NCI-H187, NCI-H378, NCI-H526, NCI-H660, NCI-H889, NCI-H60, NCI-H196, NCI-H446, NCI-H209, NCI-H146, NCI-H82, NCI-H460, NCI-H345, NCI-H510A, NCI-128, NCI-446, SW 1271
 - ii) Providing at least 3 total RNA samples derived from normal tissue selected from the group consisting of liver, heart, kidney, lung, adrenal gland, colon, pancreas, small intestine, spleen, skeletal muscle, trachea, prostate, placenta, salivary gland, testes, leucocytes, leucocytes, brain, adipose tissue, bladder, breast, cervix,

esophagus, larynx, ovary, rectum, skin, spinal cord, stomach, thymus, thyroid and uterus.

iii) Comparing the expression of mRNA in the cell lines according to step i) and tissue samples according to step ii)

5 iv) Identifying nucleic acid sequences, wherein

a) there is a difference between the amount of mRNA expressed in one or more cell lines according to i) and the amount of mRNA expressed in one or more tissues according to ii); and/or

10

b) there is essentially no difference in the amount of mRNA expressed in at least two cell lines according to i); and/or

c) there is essentially no difference in the amount of mRNA expressed in at least two tissue samples according to ii); and

15

v) Selecting among the nucleic acid sequences according to iv), nucleic acid sequences encoding for potential cell surface molecules.

20 It is a second objective of the present invention to provide methods of identifying first nucleic acid sequences, which are capable of directing expression of second nucleic acid sequences operably linked thereto, wherein the level of said expression is different in malignant cells compared with normal cells comprising the steps of:

25 i) Providing at least 3 malignant cell lines selected from the group consisting of CPH 54 A, CPH 54 B, GLC 2, GLC 3, GLC 14, GLC 16, GLC 19, GLC 26, GLC 28, DMS 53, DMS 79, DMS 92, DMS 114, DMS 153, DMS 273, DMS 406, DMS 456, NCI H69, NCI N417, MAR H24, MAR 86 MI, SHP-77, NCI-H2171, NCI-H2195, NCI-H2196, NCI-
30 H2198, NCI-H2227, NCI-H2286, NCI-H2330, NCI-H735, NCI-H1339, NCI-H1963, NCI-H2107, NCI-H2108, NCI-H1304, NCI-H1341, NCI-H1417, NCI-H1436, NCI-H1522, NCI-H1618, NCI-H1672, NCI-H1694, NCI-H1836, NCI-H1870, NCI-H1876, NCI-H1882, NCI-H1926, NCI-H1930, NCI-H1994, NCI-H2029, NCI-H2059, NCI-
35 H2066, NCI-H2081, NCI-H2141, NCI-H211, NCI-H220, NCI-H250,

NCI-H524, NCI-H592, NCI-H711, NCI-H719, NCI-H748, NCI-H774, NCI-H841, NCI-H847, NCI-H865, NCI-H1048, NCI-H1059, NCI-H1092, NCI-H1105, NCI-H1184, NCI-H1238, NCI-H1284, NCI-H1688, NCI-H187, NCI-H378, NCI-H526, NCI-H660, NCI-H889, NCI-H60, NCI-H196, NCI-H446, NCI-H209, NCI-H146, NCI-H82, NCI-H460, NCI-H345, NCI-H510A, NCI-128, NCI-446, SW 1271

- ii) Providing at least 3 RNA samples derived from normal tissue samples derived from the group consisting of liver, heart, kidney, lung, adrenal gland, colon, pancreas, small intestine, spleen, skeletal muscle, trachea, prostate, placenta, salivary gland, testes, leucocytes, brain, adipose tissue, bladder, breast, cervix, esophagus, larynx, ovary, rectum, skin, spinal cord, stomach, thymus, thyroid and uterus.
- iii) Comparing the expression of mRNA in the cell lines according to i) and tissue samples according to ii)
- iv) Identifying second nucleic acid sequences, wherein
 - a) there is a difference between the amount of mRNA expressed in one or more cell lines according to i) and the amount of mRNA expressed in one or more tissues according to ii); and/or
 - b) there is essentially no difference in the amount of mRNA expressed in at least two cell lines according to i); and/or
 - c) there is essentially no difference in the amount of mRNA expressed in at least two tissue samples according to ii)
- v) Identifying first nucleic acid sequences operably linked to the second nucleotide sequences identified in step iv)

It is a third objective of the present invention to provide uses of a pharmaceutically effective amount of the cell surface molecules identified according to the present invention for the preparation of a vaccine. Furthermore, the present invention provides uses of a pharmaceutically effective amount of a nucleic acid sequence encoding a cell surface molecule identified according to the methods of the present

invention for the preparation of a vaccine. The present invention also provides uses of a pharmaceutically effective amount of a cell surface molecule and/or a nucleic acid sequence encoding such a cell surface molecule for the preparation of a vaccine, wherein said cell surface molecule preferably comprises or essentially consists of or for example is GRIA2, such as LPR8, for example is CHRNA5, such as TMEFF, for example is NPTXR, such as Transferrin receptor; such as type II membrane protein clone: for example is HP10481; such as type II membrane protein clone: such as HP10390; for example is PG40; such as TRC8; for example is TR2-11; such as OA3 antigenic surface determinant; for example is integrin alpha 6, For example GPIIb; such as vitronectin receptor alpha subunit; for example is integrin alpha-7; such as integrin alpha E precursor; for example is integrin alpha 6B; such as integrin alpha 5 subunit; for example is integrin beta-5 subunit; such as integrin alpha-3 chain; for example is RYK; such as amyloid precursor protein-binding protein 1; for example is putative transmembrane GTPase; such as membrane cofactor protein; FOR EXAMPLE GLVR1; for example is Mr 110,000 antigen; for example is syndecan-1; such as putative seven transmembrane domain protein; for example is LCA-homolog/ LAR protein; such as M6 antigen; for example is Me491/CD63 antigen; such as multispanning membrane protein; for example is DDR; such as auto-crine motility factor receptor; for example is insulin receptor precursor; such as IGF1R, for example is insulin-like growth factor II receptor; such as SAS; for example is TAPA-1; such as MICB; for example is MHC class II HLA-DR7-associated glycoprotein beta-chain; such as HLA-DP; for example is bone small proteoglycan I biglycan; such as CAR; for example is MEA11; such as interferon-gamma receptor alpha chain; for example is Polymeric immunoglobulin receptor; such as metabotropic glutamate receptor type 4; for example is metabotropic glutamate receptor 8; such as CLPTM1; for example is MAGE-4b; such as MAGE5a; for example is MAGE-3; such as MAGE-1; for example is MAGE6; such as MAGE-9; for example is MAGE11; such as CD24; for example is CD59; such as CD44; for example is low density lipoprotein receptor; such as very low density lipoprotein receptor; for example is N-CAM; such as lamin B receptor homolog TM7SF2; for example is putative T1/ST2 receptor binding protein precursor; such as NTR2 receptor; for example is RAGE-4; such as HLA-G1; for example is MOAT-C; such as alpha 2 delta calcium channel subunit isoform I; for example is LFA-3; such as L1-CAM; for example is AVPR2; such as C1 p115 C1; for example is TE2; such as RbP; for example is HCF1; such as IRAK; for example is CD151; such as surface antigen; for example is

MAG; such as GPR19; for example is pcta-1; such as PRAME; for example is vaso-
pressin activated calcium mobilizing receptor-like protein; such as serotonin receptor
5-HT4B; for example is serotonin 1D receptor (5-HT1D~); such as CD9; for example
is LDL receptor member LR3; such as DR6; for example is tumor necrosis factor
5 receptor; such as HG38; for example is urokinase-type plasminogen receptor; such
as FGF receptor; for example is nerve growth factor receptor; such as cys-
tine/glutamate transporter; for example is CB1 cannabinoid receptor (CNR1); such
as PSG; for example is PSG13'; such as CPE-receptor; for example is CRH2R;
such as OCI5; for example is TRAIL receptor 2; such as HNMP-1; for example is
10 kidney alpha-2-adrenergic receptor; such as erythropoietin receptor; for example is
chondroitin sulphate proteoglycan versican V1; for example is mGluR1beta; such as
CD97; for example is L6; such as NY-ESO-1; for example is T-cell receptor alpha
delta; such as ror1; for example is ror2; such as SSTR2; for example is VESPR;
such as IgG Fc receptor; for example is glutamate receptor subunit GluRC; such as
15 HEK2; for example is PVR; such as CEA; for example is CC-chemokine-binding
receptor JAB61; such as HER2; for example is HER3; such as hypothetical protein
FLJ22357 similar to Epidermal growth factor receptor-related protein; for example is
putative endothelin receptor type B-like protein; such as GLVR2; for example is
P2X4 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clear-
20 ance receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B re-
ceptor; for example is GFRA3; such as GRPR; for example is CDH1; such as
CDH2; for example is TGFBR1; such as TGFBR2; for example is TGFBR3; such as
precursor of epidermal growth factor receptor.

25 It is a fourth objective of the present invention to provide uses of a cell surface
molecule identified according to the methods described by the present invention as
a drug target, wherein said drug target is capable of binding a binding partner and
internalising said binding partner into cells expressing said cell surface molecule.
Furthermore, the present invention provides uses of a cell surface molecule which
30 preferably comprises or essentially consists of or for example is GRIA2, such as
LPR8, for example is CHRNA5, such as TMEFF, for example is NPTXR, such as
Transferrin receptor; such as type II membrane protein clone: for example is
HP10481; such as type II membrane protein clone: such as HP10390; for example
is PG40; such as TRC8; for example is TR2-11; such as OA3 antigenic surface
35 determinant; for example is integrin alpha 6, For example GPIIb; such as vitronectin

receptor alpha subunit; for example is integrin alpha-7; such as integrin alpha E precursor; for example is integrin alpha 6B; such as integrin alpha 5 subunit; for example is integrin beta-5 subunit; such as integrin alpha-3 chain; for example is RYK; such as amyloid precursor protein-binding protein 1; for example is putative transmembrane GTPase; such as membrane cofactor protein; FOR EXAMPLE GLVR1; for example is Mr 110,000 antigen; for example is syndecan-1; such as putative seven transmembrane domain protein; for example is LCA-homolog/ LAR protein; such as M6 antigen; for example is Me491/CD63 antigen; such as multispinning membrane protein; for example is DDR; such as autocrine motility factor receptor; for example is insulin receptor precursor; such as IGF1R, for example is insulin-like growth factor II receptor; such as SAS; for example is TAPA-1; such as MICB; for example is MHC class II HLA-DR7-associated glycoprotein beta-chain; such as HLA-DP; for example is bone small proteoglycan I biglycan; such as CAR; for example is MEA11; such as interferon-gamma receptor alpha chain; for example is Polymeric immunoglobulin receptor; such as metabotropic glutamate receptor type 4; for example is metabotropic glutamate receptor 8; such as CLPTM1; for example is MAGE-4b; such as MAGE5a; for example is MAGE-3; such as MAGE-1; for example is MAGE6; such as MAGE-9; for example is MAGE11; such as CD24; for example is CD59; such as CD44; for example is low density lipoprotein receptor; such as very low density lipoprotein receptor; for example is N-CAM; such as lamin B receptor homolog TM7SF2; for example is putative T1/ST2 receptor binding protein precursor; such as NTR2 receptor; for example is RAGE-4; such as HLA-G1; for example is MOAT-C; such as alpha 2 delta calcium channel subunit isoform I; for example is LFA-3; such as L1-CAM; for example is AVPR2; such as C1 p115 C1; for example is TE2; such as RbP; for example is HCF1; such as IRAK; for example is CD151; such as surface antigen; for example is MAG; such as GPR19; for example is pcta-1; such as PRAME; for example is vasopressin activated calcium mobilizing receptor-like protein; such as serotonin receptor 5-HT4B; for example is serotonin 1D receptor (5-HT1D~); such as CD9; for example is LDL receptor member LR3; such as DR6; for example is tumor necrosis factor receptor; such as HG38; for example is urokinase-type plasminogen receptor; such as FGF receptor; for example is nerve growth factor receptor; such as cystine/glutamate transporter; for example is CB1 cannabinoid receptor (CNR1); such as PSG; for example is PSG13; such as CPE-receptor; for example is CRH2R; such as OC15; for example is TRAIL receptor 2; such as HNMP-

1; for example is kidney alpha-2-adrenergic receptor; such as erythropoietin receptor; for example is chondroitin sulphate proteoglycan versican V1; for example is mGluR1beta; such as CD97; for example is L6; such as NY-ESO-1; for example is T-cell receptor alpha delta; such as ror1; for example is ror2; such as SSTR2; for example is VESPR; such as IgG Fc receptor; for example is glutamate receptor subunit GluRC; such as HEK2; for example is PVR; such as CEA; for example is CC-chemokine-binding receptor JAB61; such as HER2; for example is HER3; such as hypothetical protein FLJ22357 similar to Epidermal growth factor receptor-related protein; for example is putative endothelin receptor type B-like protein; such as GLVR2; for example is P2X4 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clearance receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B receptor; for example is GFRA3; such as GRPR; for example is CDH1; such as CDH2; for example is TGFBR1; such as TGFBR2; for example is TGFBR3; such as precursor of epidermal growth factor receptor as drug target, wherein said drug target is capable of binding a binding partner and internalising said binding partner into cells expressing said cell surface molecule.

It is a fifth objective of the present invention to provide methods of identifying and/or preparing specific binding partners comprising the steps of

- i) Providing a cell surface molecule identified by the methods described by the present invention
- ii) Identifying and/or preparing binding partners capable of associating with said cell surface molecules

It is furthermore an objective of the present invention to provide methods of identifying and/or preparing specific binding partners comprising the steps of

- i) Providing a cell surface molecule which preferably comprises or essentially consists of or for example is Transferrin receptor; such as type II membrane protein clone: for example is HP10481; such as type II membrane protein clone: such as HP10390; for example is PG40; such as TRC8 ; for example is TR2-11; such as OA3 antigenic surface determinant; for example is integrin alpha 6, For example GPIIb; such as vitronectin receptor alpha subunit; for example is

integrin alpha-7; such as integrin alpha E precursor; for example is
 integrin alpha 6B; such as integrin alpha 5 subunit; for example is
 integrin beta-5 subunit; such as integrin alpha-3 chain; for example is
 RYK; such as amyloid precursor protein-binding protein 1; for
 5 example is putative transmembrane GTPase; such as membrane
 cofactor protein; FOR EXAMPLE GLVR1; for example is Mr 110,000
 antigen; for example is syndecan-1; such as putative seven
 transmembrane domain protein; for example is LCA-homolog/ LAR
 protein; such as M6 antigen; for example is Me491/CD63 antigen;
 10 such as multispinning membrane protein; for example is DDR; such
 as autocrine motility factor receptor; for example is insulin receptor
 precursor; such as IGF1R, for example is insulin-like growth factor II
 receptor; such as SAS; for example is TAPA-1; such as MICB; for
 example is MHC class II HLA-DR7-associated glycoprotein beta-
 15 chain; such as HLA-DP; for example is bone small proteoglycan I
 biglycan; such as CAR; for example is MEA11; such as interferon-
 gamma receptor alpha chain; for example is Polymeric
 immunoglobulin receptor; such as metabotropic glutamate receptor
 type 4; for example is metabotropic glutamate receptor 8; such as
 20 CLPTM1; for example is MAGE-4b; such as MAGE5a; for example is
 MAGE-3; such as MAGE-1; for example is MAGE6; such as MAGE-9;
 for example is MAGE11; such as CD24; for example is CD59; such
 as CD44; for example is low density lipoprotein receptor; such as very
 low density lipoprotein receptor; for example is N-CAM; such as lamin
 25 B receptor homolog TM7SF2; for example is putative T1/ST2 receptor
 binding protein precursor; such as NTR2 receptor; for example is
 RAGE-4; such as HLA-G1; for example is MOAT-C; such as alpha 2
 delta calcium channel subunit isoform I; for example is LFA-3; such
 as L1-CAM; for example is AVPR2; such as C1 p115 C1; for example
 30 is TE2; such as RbP; for example is HCF1; such as IRAK; for
 example is CD151; such as surface antigen; for example is MAG;
 such as GPR19; for example is pcta-1; such as PRAME; for example
 is vasopressin activated calcium mobilizing receptor-like protein; such
 as serotonin receptor 5-HT4B; for example is serotonin 1D receptor
 35 (5-HT1D~); such as CD9; for example is LDL receptor member LR3;

- such as ER6; for example is tumor necrosis factor receptor; such as HG38; for example is urokinase-type plasminogen receptor; such as FGF receptor; for example is nerve growth factor receptor; such as cystine/glutamate transporter; for example is CB1 cannabinoid receptor (CNR1); such as PSG; for example is PSG13; such as CPE-receptor; for example is CRH2R; such as OCI5; for example is TRAIL receptor 2; such as HNMP-1; for example is kidney alpha-2-adrenergic receptor; such as erythropoietin receptor; for example is chondroitin sulphate proteoglycan versican V1; for example is mGluR1beta; such as CD97; for example is L6; such as NY-ESO-1; for example is T-cell receptor alpha delta; such as ror1; for example is ror2; such as SSTR2; for example is VESPR; such as IgG Fc receptor; for example is glutamate receptor subunit GluRC; such as HEK2; for example is PVR; such as CEA; for example is CC-chemokine-binding receptor JAB61; such as HER2; for example is HER3; such as hypothetical protein FLJ22357 similar to Epidermal growth factor receptor-related protein; for example is putative endothelin receptor type B-like protein; such as GLVR2; for example is P2X4 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clearance receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B receptor; for example is GFRA3; such as GRPR; for example is CDH1; such as CDH2; for example is TGFB1; such as TGFB2; for example is TGFB3; such as precursor of epidermal growth factor receptor.
- 25 ii) Identifying and/or preparing binding partners capable of associating with said cell surface molecules.

A further objective of the present invention is to provide isolated and/or purified specific binding partners capable of associating with cell surface molecules, which are expressed at a different level in malignant cells compared with normal cells, identified by the methods provided by the present invention. The present invention also provides isolated and/or purified specific binding partners capable of associating with a cell surface molecule which preferably comprises or essentially consists of or for example is GRIA2, such as LPR8, for example is CHRNA5, such as TMEFF, for example is NPTXR, such as Transferrin receptor; such as type II

membrane protein clone; for example is HP10481; such as type II membrane protein clone; such as HP10390; for example is PG40; such as TRC8; for example is TR2-11; such as OA3 antigenic surface determinant; for example is integrin alpha 6; For example GPIIb; such as vitronectin receptor alpha subunit; for example is integrin alpha-7; such as integrin alpha E precursor; for example is integrin alpha 6B; such as integrin alpha 5 subunit; for example is integrin beta-5 subunit; such as integrin alpha-3 chain; for example is RYK; such as amyloid precursor protein-binding protein 1; for example is putative transmembrane GTPase; such as membrane cofactor protein; FOR EXAMPLE GLVR1; for example is Mr 110,000 antigen; for example is syndecan-1; such as putative seven transmembrane domain protein; for example is LCA-homolog/ LAR protein; such as M6 antigen; for example is Me491/CD63 antigen; such as multispinning membrane protein; for example is DDR; such as autocrine motility factor receptor; for example is insulin receptor precursor; such as IGF1R, for example is insulin-like growth factor II receptor; such as SAS; for example is TAPA-1; such as MICB; for example is MHC class II HLA-DR7-associated glycoprotein beta-chain; such as HLA-DP; for example is bone small proteoglycan I biglycan; such as CAR; for example is MEA11; such as interferon-gamma receptor alpha chain; for example is Polymeric immunoglobulin receptor; such as metabotropic glutamate receptor type 4; for example is metabotropic glutamate receptor 8; such as CLPTM1; for example is MAGE-4b; such as MAGE5a; for example is MAGE-3; such as MAGE-1; for example is MAGE6; such as MAGE-9; for example is MAGE11; such as CD24; for example is CD59; such as CD44; for example is low density lipoprotein receptor; such as very low density lipoprotein receptor; for example is N-CAM; such as lamin B receptor homolog TM7SF2; for example is putative T1/ST2 receptor binding protein precursor; such as NTR2 receptor; for example is RAGE-4; such as HLA-G1; for example is MOAT-C; such as alpha 2 delta calcium channel subunit isoform I; for example is LFA-3; such as L1-CAM; for example is AVPR2; such as C1 p115 C1; for example is TE2; such as RbP; for example is HCF1; such as IRAK; for example is CD151; such as surface antigen; for example is MAG; such as GPR19; for example is pcta-1; such as PRAME; for example is vasopressin activated calcium mobilizing receptor-like protein; such as serotonin receptor 5-HT4B; for example is serotonin 1D receptor (5-HT1D~); such as CD9; for example is LDL receptor member LR3; such as DR6; for example is tumor necrosis factor receptor; such as HG38; for example is urokinase-type plasminogen receptor; such as FGF receptor;

for example is nerve growth factor receptor; such as cystine/glutamate transporter; for example is CB1 cannabinoid receptor (CNR1); such as PSG; for example is PSG13; such as CPE-receptor; for example is CRH2R; such as OC15; for example is TRAIL receptor 2; such as HNMP-1; for example is kidney alpha-2-adrenergic receptor; such as erythropoietin receptor; for example is chondroitin sulphate proteoglycan versican V1; for example is mGluR1beta; such as CD97; for example is L6; such as NY-ESO-1; for example is T-cell receptor alpha delta; such as ror1; for example is ror2; such as SSTR2; for example is VESPR; such as IgG Fc receptor; for example is glutamate receptor subunit GluRC; such as HEK2; for example is PVR; such as CEA; for example is CC-chemokine-binding receptor JAB61; such as HER2; for example is HER3; such as hypothetical protein FLJ22357 similar to Epidermal growth factor receptor-related protein; for example is putative endothelin receptor type B-like protein; such as GLVR2; for example is P2X4 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clearance receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B receptor; for example is GFRA3; such as GRPR; for example is CDH1; such as CDH2; for example is TGFR1; such as TGFR2; for example is TGFR3; such as precursor of epidermal growth factor receptor.

It is also an objective of the present invention to provide methods of identifying novel drug targets, comprising the steps of

- i) Providing a binding partner as described in the present invention
- ii) Identifying potential drug targets capable of associating with said binding partner

It is yet another objective of the present invention to provide drug targets identified by the methods described by the present invention.

Furthermore, it is an objective of the present invention to provide targeting complexes comprising:

- i) A binding partner as described by the present invention; and
- ii) A bioreactive species

wherein the targeting complex is capable of binding a cell surface molecule identified according to the methods described by the present invention and capable of being internalised into cells bearing said cell surface molecule.

- 5 The present invention also provides uses of binding partners as describes by the invention for the preparation of targeting complexes according to the invention.

10 It is yet a further objective of the present invention to provide pharmaceutical compositions comprising of the targeting complexes described by the present invention together with a pharmaceutically acceptable carrier.

15 It is even a further objective of the present invention to provide methods of treatment of a premalignant and/or malignant conditions in an individual in need thereof, comprising administering to said individual a pharmaceutically effective amount of the targeting complexes described by the present invention.

20 Furthermore, it is an objective of the present invention to provide uses of the targeting complex described by the present invention for the preparation of a medicament for the treatment of a premalignant and/or malignant conditions in an individual in need thereof.

Legend to figures

25 Fig. 1 illustrates the principle of targeted gene therapy.

Fig. 2 illustrates a comparison between gene expression measured by Chips analysis and RT-PCR. The figure shows a quality test of cDNA used for RT-PCR validation of Chips analysis by RT-PCR of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

30 Fig. 3 illustrates a comparison between gene expression measured by Chips analysis and RT-PCR for Pro 221 (IA-1).

Fig. 4. illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of Pro 30 (KIA0042).

5 Fig. 5. illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of Pro 41 (MAD2).

Fig. 6. illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of Pro 210 (lamin B1).

10 Fig. 7 illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of Pro 71 (CDKN2A).

Fig. 8 illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of cell surface molecule DR6.

15 Fig. 9. illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of cell surface molecule LRP8.

20 Fig. 10. illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of cell surface molecule NTPXR.

Fig. 11. illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of cell surface molecule NCAM1.

25 Fig. 12A illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of cell surface molecule GluR2 (GRIA2).

Fig. 12B illustrates a comparison between gene expression measured by Chips analysis and RT-PCR of cell surface molecule ITGAV.

30 Fig. 13 illustrates a comparison between gene expression measured by Chips analysis and western blotting of mGluR8.

35 Fig. 14. illustrates a comparison between gene expression measured by Chips analysis and western blot analysis for NPTXR.

Fig. 15. illustrates a comparison between gene expression measured by Chips analysis and western blot analysis for NCAM1.

5 Fig. 16. illustrates a comparison between gene expression measured by Chips analysis and western blot analysis for GluR2 (GRIA2).

Fig. 17. illustrates a comparison between gene expression measured by Chips analysis and western blot analysis for ITGAE.

10

Detailed description of the invention

Definitions

15 Binding partner: See "cell surface molecule binding partner".

Bioreactive species: Any molecule, which can directly or indirectly exert a biological influence on a target cell.

20 Bp: Base pair

Cell surface molecules: Molecules naturally associated with the cell surface.

25 Cell surface molecule binding partner: Any molecule that can associate specifically with a cell surface molecule. Throughout the text the terms "Cell surface molecule binding partner" and the shorter term "binding partner" are used interchangeably and both terms are equivalent to one another throughout the text.

30 Enhancer: Nucleic acid sequence, which can enhance the transcription of a second nucleic acid sequence operably linked thereto.

First nucleic acid sequences: Nucleic acid sequences, which are capable of directing expression of second nucleic acid sequences operably linked thereto.

Normal cells: Non-malignant cells that are of non-malignant origin.

Normal tissue: Non-malignant tissue

5

Promoter: First nucleic acid sequences, which are capable of directing expression of second nucleic acid sequences operably linked thereto.

10

Second nucleic acid sequences: Nucleic acid sequences, which are capable of being expressed, such as mRNA may be transcribed from such nucleic acid sequences, when they are operably linked to first nucleic acid sequences.

15

Silencer: A nucleic acid sequence, which is capable of repressing the transcription of a second nucleic acid sequence operably linked thereto.

Targeting complex: Complex which comprises at least one binding partner and a bioreactive species and which is capable of be internalised into cells.

Embodiments of the invention

20

It is becoming increasingly obvious, that if gene therapy of cancer is to become an effective, alternative or adjuvant treatment of cancer, in particular of disseminated disease, several requirements must be resolved. These include for example i) targeting of the complex to be efficient and cancer specific; ii) expression of the therapeutic gene to be efficient and cancer specific and iii) that the molecular conjugate is non-immunogenic, has a high stability after systemic administration and is able to cross capillary barriers.

25

30

In one preferred embodiment, the present invention relates to the use of novel, high throughput screening methods for identification of genes specifically expressed by cancer cells and their application for double-targeted gene transfer and expression of therapeutic genes for treatment of cancer. An example of the principle of double-targeted gene transfer is outlined in figure 1. The screening methods according to the present invention enable the identification of novel molecules expressed by the cancer cells.

35

In one embodiment the method will be applied on identification of gene expression of suitable molecules expressed by small cell lung cancer (SCLC) cells. Small cell lung cancer is a highly aggressive neoplasm, comprising of approximately 25% of all lung cancer cases. The disease is almost always disseminated at the time of diagnosis. SCLC is treated with different chemotherapeutic drugs alone or in combination with radiation therapy. Despite intensive attempts to improve treatment, and regardless of the fact that most patients respond well to the treatment in the beginning, the mortality rate is high. Existing cancer treatments are able to cure only 5-7% of these patients and the 5-year survival rate is extremely poor (5-15%). SCLC patients therefore are in great need of the development of new therapies.

The molecular phenotype of the disease has been thoroughly characterised and the aberrant expression of oncogenes (particularly of the *myc*-family) in addition to the loss of function of several tumour suppressor genes (such as p53 and Rb) have been found for more than 80% of SCLC tumours. These phenotypes are also found most cell lines deriving from SCLC tumours (reviewed in Frederiksen et al., 1999), allowing the cell lines to be used as an experimental tool for *in vitro* testing of potential anticancer drugs. In addition, these cell lines can be propagated *in vivo* in nude mice, thus allowing testing of developed drugs in an *in vivo* situation. Therefore cell lines derived from SCLC will be used for the initial screening of gene expression for identification of cancer specific (or highly expressed) surface molecules and regions with particular transcriptional activity (promoters) in SCLC cells.

It is preferred that a variety of different SCLC cell lines established by different laboratories and from different patients are used with the present invention, in order to identify genes expressed in a large number of SCLCs. Furthermore, it is preferred that expression in these SCLC cell lines is compared with expression in a variety of normal tissues, which preferably is representative of different tissues of endodermal, ectodermal and mesodermal origin.

It is possible within the present invention to apply a biphasic strategy, however in certain embodiments of the present invention other strategies may be applied. A biphasic strategy according to the present invention may for example be a gene therapy drug that via systemic administration can target cancer cells effectively through binding to functional, transport-competent receptors on the surface and which subsequently allows expression of the gene effectively in the cancer cells by a promoter, which is specifically active or hyperactive in the cancer cells.

Amino acids and nucleic acids

Throughout the description and claims either the one letter code or the three letter
5 code for natural amino acids are used. Where the L or D form has not been specified it is to be understood that the amino acid in question has the natural L form, cf. Pure & Appl. Chem. Vol. (56(5) pp 595-624 (1984) or the D form, so that the peptides formed may be constituted of amino acids of L form, D form, or a sequence of mixed L forms and D forms.

10

Where nothing is specified it is to be understood that the C-terminal amino acid of a polypeptide of the invention exists as the free carboxylic acid, this may also be specified as "-OH". The N-terminal amino acid of a polypeptide comprise a free amino-group, this may also be specified as "H-".

15

Where nothing else is specified amino acid can be selected from any amino acid, whether naturally occurring or not, such as alpha amino acids, beta amino acids, and/or gamma amino acids. Accordingly, the group comprises but are not limited to: Ala, Val, Leu, Ile, Pro, Phe, Trp, Met, Gly, Ser, Thr, Cys, Tyr, Asn, Gln, Asp, Glu,
20 Lys, Arg, His, Aib, Nal, Sar, Orn, Lysine analogues DAP and DAPA.

The term "nucleic acid" is meant to encompass DNA and RNA as well as derivatives thereof such as peptide nucleic acids (PNA) or locked nucleic acids (LNA) throughout the description.

25

Methods to identify cell surface molecules and promoters

The methods used to identify cell surface molecules and/or first nucleic acid sequences, which are capable of directing expression of second nucleic acid
30 sequences operably linked thereto according to the present invention preferably involve the comparison of levels of mRNA found in malignant cell lines with the levels of mRNA found in normal tissues.

Preferably, the malignant cell lines according to the present invention are mammalian cell lines, more preferably human cell lines. Yet more preferably, the cell lines are derived from small cell lung carcinomas (SCLC). Even more preferably, the cell lines are selected from the group consisting of CPH 54 A, CPH 54 B, GLC 2, GLC 3, GLC 14, GLC 16, GLC 19, GLC 26, GLC 28, DMS 53, DMS 79, DMS 92, DMS 114, DMS 153, DMS 273, DMS 406, DMS 456, NCI H69, NCI N417, MAR H24 and MAR 86 MI, SHP-77, NCI-H2171, NCI-H2195, NCI-H2196, NCI-H2198, NCI-H2227, NCI-H2286, NCI-H2330, NCI-H735, NCI-H1339, NCI-H1963, NCI-H2107, NCI-H2108, NCI-H1304, NCI-H1341, NCI-H1417, NCI-H1436, NCI-H1522, NCI-H1618, NCI-H1672, NCI-H1694, NCI-H1836, NCI-H1870, NCI-H1876, NCI-H1882, NCI-H1926, NCI-H1930, NCI-H1994, NCI-H2029, NCI-H2059, NCI-H2066, NCI-H2081, NCI-H2141, NCI-H211, NCI-H220, NCI-H250, NCI-H524, NCI-H592, NCI-H711, NCI-H719, NCI-H740, NCI-H748, NCI-H774, NCI-H841, NCI-H847, NCI-H865, NCI-H1048, NCI-H1059, NCI-H1092, NCI-H1105, NCI-H1184, NCI-H1238, NCI-H1284, NCI-H1688, NCI-H187, NCI-H378, NCI-H526, NCI-H660, NCI-H889, NCI-H60, NCI-H196, NCI-H446, NCI-H209, NCI-H146, NCI-H82, NCI-H460, NCI-H345, NCI-H510A, NCI-128, NCI-44 and SW 1271. More preferably, the cell lines are selected from the group consisting of CPH 54 A, CPH 54 B, GLC 2, GLC 3, GLC 14, GLC 16, GLC 19, GLC 26, GLC 28, DMS 53, DMS 79, DMS 92, DMS 114, DMS 153, DMS 273, DMS 406, DMS 456, NCI H69, NCI N417, MAR H24 and MAR 86 MI.

Yet even more preferably the cell lines are selected from the group consisting of CPH 54A, CPH 54 B, CHP 136A, GLC 2, GLC 3, GLC 14, GLC 16, GLC 19, GLC 26, GLC 28, DMS 53, DMS 79, DMS 92, DMS 114, DMS 153, DMS 273, DMS 406, DMS 456, NCI-H69, NCI-N417, MAR H24 and MAR 86MI.

Most preferably, the cell lines are selected from the group consisting of DMS 53, DMS 70, DMS 92, DMS 114, DMS 153, DMS 273, NCI 417 and NCI H69.

Preferred cell lines according to the present invention are listed in table 1 together with their accession numbers.

Table 1

5

Deposit Accession numbers of small cell lung cancer cell lines

SCLC cell line	Culture Collection	(Provisional) Accession no.	Depositor
CPH 54A	ECACC	01061905	ODIN Medical A/S
CPH 54B	ECACC	01061906	
GLC 2	ECACC	01061907	
GLC 3	ECACC	01061908	
GLC 14	ECACC	01061909	
GLC 16	ECACC	01061910	
GLC 19	ECACC	01061911	
GLC 26	ECACC	01061912	
GLC 28	ECACC	01061913	
DMS 406	ECACC	01061914	
DMS 456	ECACC	01061915	
MAR H 24	ECACC	01061916	
MAR 86 MI	ECACC	01061917	
DMS 53	ATTC	CRL-2062	O.S Pettengill; G.Sorensen
	ecacc	95062823	
DMS 79	ATTC	CRL-2049	
	ecacc	95062824	
DMS 92	ecacc	950662825	
DMS 114	ATTC	CRL-2066	
DMS 153	ATTC	CRL-2064	
	ecacc	95062827	
DMS 273	ecacc	95062830	
SHP-77	Ecacc	98110201	A.M. Koros
	ATTC	CRL-2195	

NCI-H2171	ATTC	CRL-5929	A.F.Gazda
NCI-H2195		CRL-5931	Minna
NCI N417		CRL-5809	
NCI-H2196		CRL-5932	
NCI-H2198		CRL-5933	
NCI-H2227		CRL-5934	
NCI-H2286		CRL-5938	
NCI-H2330		CRL-5940	
NCI-H735		CRL-5978	
NCI-H1339		CRL-5979	
NCI-H1963		CRL-5982	
NCI-H2107		CRL-5983	
NCI-H2108		CRL-5984	
NCI-H1304		CRL-5862	
NCI-H1341		CRL-5864	
NCI-H1417		CRL-5869	
NCI-H1436		CRL-5871	
NCI-H1522		CRL-5874	
NCI-H1618		CRL-5879	
NCI-H1672		CRL-5886	
NCI-H1694		CRL-5888	
NCI-H1836		CRL-5989	
NCI-H1870		CRL-5901	
NCI-H1876		CRL-5902	
NCI-H1882		CRL-5903	
NCI-H1926		CRL-5905	
NCI-H1930		CRL-5906	
NCI-H1994		CRL-5910	
NCI-H2029		CRL-5913	
NCI-H2059		CRL-5916	
NCI-H2066		CRL-5917	
NCI-H2081		CRL-5920	
NCI-H2141		CRL-5927	
NCI-H211		CRL-5824	
NCI-H220		CRL-5825	
NCI-H250		CRL-5828	

NCI-H524		CRL-5831	
NCI-H592		CRL-5832	
NCI-H711		CRL-5836	
NCI-H719		CRL-5837	
NCI-H740		CRL-5840	
NCI-H748		CRL-5841	
NCI-H774		CRL-5842	
NCI-H841		CRL-5845	
NCI-H847		CRL-5846	
NCI-H865		CRL-5849	
NCI-H1048		CRL-5853	
NCI-H1059		CRL-5854	
NCI-H1092		CRL-5855	
NCI-H1105		CRL-5856	
NCI-H1184		CRL-5858	
NCI-H1238		CRL-5859	
NCI-H1284		CRL-5861	
NCI-H1688		CCL-257	
NCI-H187		CRL-5804	
NCI-H378		CRL-5808	
NCI-H526		CRL-5811	
NCI-H660		CRL-5813	
NCI-H889		CRL-5817	
NCI-H60		CRL-5821	
NCI-H196		CRL-5823	
NCI-H446		HTB-171	
NCI-H209		HTB-172	
NCI-H146		HTB-173	
NCI-H82		HTB-175	
NCI-H460		HTB-177	
NCI-H345		HTB-180	
NCI-H510A		HTB-184	
NCI-128		HTB-120	A.F.Gazdar
NCI-446		HTB-171	
NCI H 69		HTB-119	
SW 1271		CRL-2177	W. McCombs

The methods for example involve at least 4, such as at least 5, for example at least 6, such as at least 8, for example at least 10, such as at least 12, for example at least 14, such as at least 16, for example at least 18, such as at least 20, for example 21, such as at least 25, for example at least 30, such as at least 40, for example at least 50, such as at least 60, for example at least 70, such as around 79 malignant cell lines selected from the group consisting of CPH 54 A, CPH 54 B, GLC 2, GLC 3, GLC 14, GLC 16, GLC 19, GLC 26, GLC 28, DMS 53, DMS 79, DMS 92, DMS 114, DMS 153, DMS 273, DMS 406, DMS 456, NCI H69, NCI N417, MAR H24 and MAR 86 MI, SHP-77, NCI-H2171, NCI-H2195, NCI-H2196, NCI-H2198, NCI-H2227, NCI-H2286, NCI-H2330, NCI-H735, NCI-H1339, NCI-H1963, NCI-H2107, NCI-H2108, NCI-H1304, NCI-H1341, NCI-H1417, NCI-H1436, NCI-H1522, NCI-H1618, NCI-H1672, NCI-H1694, NCI-H1836, NCI-H1870, NCI-H1876, NCI-H1882, NCI-H1926, NCI-H1930, NCI-H1994, NCI-H2029, NCI-H2059, NCI-H2066, NCI-H2081, NCI-H2141, NCI-H211, NCI-H220, NCI-H250, NCI-H524, NCI-H592, NCI-H711, NCI-H719, NCI-H740, NCI-H748, NCI-H774, NCI-H841, NCI-H847, NCI-H865, NCI-H1048, NCI-H1059, NCI-H1092, NCI-H1105, NCI-H1184, NCI-H1238, NCI-H1284, NCI-H1688, NCI-H187, NCI-H378, NCI-H526, NCI-H660, NCI-H889, NCI-H60, NCI-H196, NCI-H446, NCI-H209, NCI-H146, NCI-H82, NCI-H460, NCI-H345, NCI-H510A, NCI-128, NCI-446 and SW 1271.

20

In one preferred embodiment of the invention the method involve all of the cell lines DMS 53, DMS 70, DMS 92, DMS 114, DMS 153, DMS 273, NCI 417 and NCI H69.

25

The cell lines may be cultured by any suitable means, for example the cell lines may be cultured in an in vitro cell culture under suitable conditions known to the person skilled in the art. In one embodiment of the present invention, one or more cell lines are cultured in vivo in an animal as a xenograft. The animal may be any suitable animal, preferably a mammal, more preferably a rodent, most preferably a mouse. An example of how cell lines may be cultured in vivo as a xenograft is given in example 1.

30

It is also comprised within the present invention that the same cell line may cultured in an in vitro cell culture and may be cultured in vivo.

In general, in vivo culture conditions i.e. culturing as a xenograft in an animal more closely resembles a natural occurring tumour or cancer and hence it is usually preferred that at least one, such as at least 2, for example at least 3, such as at least 4, for example at least 5, such as at least 6, for example at least 7, such as at least 8 cell lines are cultured in vivo. More preferably, in the range of 1 to 79, such as 2 to 70, for example 3 to 60, such as 4 to 50, for example 5 to 40, such as 6 to 30, for example 7 to 20 cell lines are cultured in vivo. Even more preferably around 8 cell lines are cultured in vivo.

10 Preferably, the cell lines cultured in vivo are selected from the group of cell lines mentioned in table 1, even more preferably, the cell lines cultured in vivo are selected from the group consisting of CPH 54A, CHP 136A, GLC 3, GLC 14, DMS 273, NCI-H69, NCI-N417 and MAR H24.

15 Normal tissues are tissues, which are non-malignant. Preferably, such tissue is derived from an individual, which do not suffer from a premalignant and/or malignant condition. More preferably, the normal tissues are mammalian tissues, even more preferably, the tissues are human tissues. Yet more preferably, the tissues are selected from the group consisting of liver, heart, kidney, lung, adrenal gland, colon, 20 pancreas, small intestine, spleen, skeletal muscle, trachea, prostate, placenta, salivary gland, testes, leucocytes, leucocytes, brain, adipose tissue, bladder, breast, cervix, esophagus, larynx, ovary, rectum, skin, spinal cord, stomach, thymus, thyroid and uterus. Even more preferably, the tissues are selected from the group consisting of brain, adrenal gland, lung, kidney, heart, trachea, prostate, salivary gland, 25 thyroid, liver, pancreas, spleen, small intestine, skeletal muscle, colon, stomach and testes. Most preferably the tissues are selected from the group consisting of lung, liver, heart and kidney.

30 Preferably, the method involves at least 3, for example at least 4, such as at least 5, for example at least 6, such as at least 8, for example at least 10 total RNA samples.

The method may be any method suitable to compare the level of mRNA found in malignant cell lines with the levels of mRNA found in normal tissues known to the 35 person skilled in the art. In general such method involves purification of either

mRNA or total RNA. Purification of RNA may be performed according to any standard method known to the person skilled in the art as for example described in Sambrook et al, 1989 or herein below in the examples.

5 The RNA samples may be compared by a number of different techniques. Any suitable technique may be applied with the present invention. For example the RNA samples can be compared by differential display or by subtractive hybridisation. Furthermore, techniques involving hybridisation of labelled RNA or cDNA pools with known nucleic acid sequences are suitable with this invention. The known nucleic
10 acids may for example be immobilised on a solid support prior to hybridisation for example on a membrane, such as a nitrocellulose membrane, or the solid support may be of plastic or of glass.

The labelled RNA or cDNA may be labelled with any directly or indirectly detectable
15 label for example an enzyme, a radioactive isotope, chromophore, a fluorescent group or a heavy metal. Furthermore, the label may be one part of a pair of binding partners, wherein the second part is detectable, either directly or indirectly. For detection of an indirectly detectable label, it is possible to use a "sandwich" system, such as be one part of a pair of binding partners is recognised by the second part,
20 which is in turn recognised by the first part, which may again be recognised by the second part. In every step the first and/or second part may be labelled. Examples of pairs of binding partners are antigen/antibodies or biotin/streptavidin. However, any other suitable pair can also be employed with the present invention.

25 In one embodiment of the present invention the method comprises the steps of:

- i) Isolating RNA comprising mRNA from the malignant cell lines
- ii) Preparing cDNA populations from said RNA, wherein one cDNA population is prepared from RNA isolated from one cell line or one
30 tissue sample
- iii) Labelling each cDNA population with a detectable label
- iv) Providing solid supports on which an array of known nucleic acid sequences has been immobilised
- v) Incubating each cDNA population with a solid support under
35 conditions which allows for hybridisation

vi) Detecting said detectable label on the solid support

Preferably said detectable label is an indirectly detectable label, more preferably the label is one part of a pair of binding partners, wherein the second part is detectable, either directly or indirectly. Most preferably the label is biotin. The biotin can be detected with a labelled streptavidin species, preferably a fluorescently labelled streptavidin. More preferably, the streptavidin may furthermore associate with an anti-streptavidin antibody labelled with biotin, which in turn may be detected by labelled streptavidin, preferably fluorescently labelled. The fluorescent label may for example be phycoerythrin or any other suitable fluorescent label.

In one preferred embodiment the solid support is a glass plate. Preferably, at least 1000, such as at least 5000, for example at least 10,000, such as at least 50,000, such as at least 100,000, for example at least 150,000, such as at least 200,000, for example around 240,000 different known nucleic acid sequences are immobilised on the solid support. These nucleic acid sequences may all be derived from different genes, however, more preferably, each gene is represented by more than one, such as more than 2, for example more than 4, such as more than 7, for example more than 10, such as more than 15, for example more than 20, preferably around 20 different nucleic acid sequences.

In one embodiment of the present invention the RNA samples may be compared by a CHIPS analysis or a GeneChips analysis. The terms CHIPS analysis and GeneChips analysis are used interchangeably throughout the description. An example of how to perform a CHIPS analysis is given in example 1.

Suitable cell surface molecules are selected according to several criteria. Preferably, there is a difference between the amount of mRNA expressed in one or more cell lines used in the method according to the present invention and the amount of mRNA expressed in one or more tissues according to the present invention. Preferably the difference is at least 1.1 fold, such as 1.2 fold, such as 1.5-fold, such as 1.75 fold, such as 2-fold, such as 2.5 fold, such as at least 3-fold, for example at least 4-fold, such as at least 5-fold, for example at least 7.5 fold, such as at least 10 fold difference in mRNA expression. In one preferred embodiment the difference is an in principle unlimited number of fold, such as there is no detectable mRNA expressed

in one or more cell lines and mRNA is detectable in one or more normal tissues, or there is no detectable mRNA expressed in one or more normal tissues and mRNA is detectable in one or more cell lines.

5 Furthermore, there is preferably essentially no difference in the amount of mRNA expressed in at least two, such as at least 3, for example at least 4, such as at least 5, for example at least 6, such as at least 8, for example at least 10, such as at least 12, for example at least 14, such as at least 16, for example at least 18, such at
10 least 20, for example 21, such at least 25, for example at least 30, such as at least 40, for example at least 50, such as at least 60, for example at least 70, such as around 79 malignant cell lines used in the method according to the present invention.

15 Additionally, there is preferably essentially no difference in the amount of mRNA expressed in at least two, such as at least 3, for example at least 4, such as at least 5, for example at least 6, such as at least 8, for example at least 10 tissue samples, from which total RNA was used according to the methods of the present invention.

20 Nucleic acid sequences encoding for potential cell surface molecules are selected from nucleic acid sequences that full fill the above criteria. In one particular preferred embodiment the potential cell surface molecules are identified as outlined in example 1 and selected according to the criteria described in that example.

25 To determine what nucleic acid sequences encode potential cell surface molecules different strategies may be employed. For example potential cell surface molecules may be selected according to information available in commonly accessible databases. Such databases may for example be selected from the group consisting of PubMed (NCBI), Nucleotide (NCBI), Protein (NCBI), Structure (NCBI), OMIM (NCBI) and LocusLink (NCBI). NCBI is the abbreviation for National Center for Biotechnol-
30 ogy Information. Furthermore, potential cell surface molecules may be selected based on the presence of one or more of selected terms in name of the potential cell surface molecules. For example said terms may be selected from the group consisting of receptor, membrane, adhesion, integrin, surface, antigen, syndecan, transport, channel, hormone, binding, glycoprotein, matrix, CAM, desmosome, gap
35 junction, delta, immunoglobulin, MHC, CD, HSPG, CSPG, integral and notch.

Alternatively, nucleic acid sequences encoding for potential cell surface molecules are selected according to sequence homology with known cell surface molecules. Nucleic acid sequences encoding potential cell surface molecules should have at least 20%, for example at least 22.5%, such as at least 25%, for example at 27.5%, such as at least 30% sequence identify with nucleic acid sequences encoding known cell surface molecules.

The nucleic acid sequences encoding potential cell surface molecules may also be selected based on sequence homology with domains comprised within known cell surface molecules. Preferably, there is at least 20%, for example at least 22.5%, such as at least 25%, for example at 27.5%, such as at least 30%, for example at least 32.5%, such as at least 35%, for example at least 37.5%, such as at least 40%, for example at least 42.5%, such as at least 45%, for example at least 47.5%, such as at least 50% sequence identify between domains of the nucleic acids encoding potential cell surface molecules and nucleic acid sequences encoding domains of known cell surface molecules.

Nucleic acid sequences encoding potential cell surface molecules may also be selected based on that the potential cell surface molecules comprise a domain, which is often associated with the cell surface. Such a domain may for example be selected from the group consisting of hydrophobic regions and potential glycosylation sites.

In one embodiment of the present invention candidate cell surface molecules have been identified by a Chips analysis. Suitable cell surface molecules may then be selected based on several criteria. For example cell surface molecules, which scored present (P) in the absolute call and with an Average difference of for example >10, such as >20, for example >40, such as >50 may be included.

Furthermore, it is possible to make a point system to identify suitable cell surface molecules. For example a gene encoding a cell surface molecule may be set to score a number of points, such as one point for each cell line or tissue expressing the gene. The total scores for each gene may be summarised for normal tissue and the SCLC cell lines, respectively. Genes may then be selected, which were scored present in at least 3, such as 4, for example 5, such as 6, for example 7, such as 8,

for example 9, such as 10, for example more than 10 of the SCLC cells. A preferred method of selecting cell surface molecules is described in example 1.

5 The present invention also provides methods for identifying first nucleic acid sequences, which are capable of directing expression of second nucleic acid sequences operably linked thereto. These methods involves identifying second nucleic acid sequences, which are expressed at a level, which is different in malignant cells compared with normal cells.

10 Accordingly, there is preferably a difference between the amount of second nucleic acid sequence mRNA expressed in one or more cell lines and the amount of second nucleic acid sequence mRNA expressed in one or more tissues. More preferably, the difference is at least 1.1 fold, such as 1.2 fold, such as 1.5-fold, such as 1.75 fold, such as 2-fold, such as 2.5 fold, such as at least 3-fold, for example at least 4-
15 fold, such as least 5-fold, for example at least 7.5 fold, such as least 10 fold difference in mRNA expression.

In one preferred embodiment the difference is an in principle unlimited number of fold, such as there is no detectable second nucleic sequence mRNA expressed in
20 one or more cell lines and said mRNA is detectable in one or more normal tissues, or there is no detectable second nucleic acid sequence mRNA expressed in one or more normal tissues and said mRNA is detectable in one or more cell lines.

Furthermore, there is preferably essentially no difference in the amount of second
25 nucleic acid sequence mRNA expressed in at least two, such as at least 3, for example at least 4, such as at least 5, for example at least 6, such as at least 8, for example at least 10, such as at least 12, for example at least 14, such as at least 16, for example at least 18, such at least 20, for example 21, such at least 25, for example at least 30, such as at least 40, for example at least 50, such as at least
30 60, for example at least 70, such as around 79 malignant cell lines used with the methods of the present invention.

Additionally, there is preferably essentially no difference in the amount of second nucleic acid sequence mRNA expressed in at least two, such as at least 3, for

example at least 4, such as at least 5, for example at least 6, such as at least 8, for example at least 10 normal tissue samples.

5 In one particularly preferred embodiment the second nucleic acid sequences are identified according to the method described in example 1. Most preferably, the criteria outlined in that example are applied to select useful second nucleic acid sequences.

10 In one embodiment of the present invention candidate promoters have been identified by a Chips analysis. Suitable promoters may then be selected based on several criteria based on expression level of the gene which the promoter controls. For example only genes, which scored present (P) in the absolute call and with an Average difference of >10, such as >20, for example >30, such as >40, for example >50 (level of expression) may be included included. A point scoring system as
15 described herein above may be used. Genes that scored present in for example at least 3, such as at least 4, for example at least 5, such as at least 6, for example at least 7, such as at least 8, for example at least 9, such as at least 10, for example at least 11, such as at least 12 SCLC lines may for example be selected. If a gene scores present in one or more normal tissues, the median Average difference value
20 of the SCLC cell lines should preferably be 4 times or more above the median Average difference value of the normal tissue. Preferably promoters with an Average differences of expression for normal tissues <50 and for SCLC>100 are selected. More preferably, promoters with an Average differences of expression for normal tissues <50 and for SCLC>200. Most preferably, promoters with an Average
25 differences of expression for normal tissues <50 and for SCLC>400. Alternatively, promoters with an Average differences of expression in SCLC > 8 times higher than for normal tissue may be selected. . A preferred method of selecting cell surface molecules is described in example 1.

30 Once second nucleic acid sequences have been identified according to the above mentioned criteria, it is possible to identify first nucleic acid sequences operably linked to the second nucleotide sequences. This can be done according to any standard method known to the person skilled in the art. For example it is possible to take advantage of known human genome sequences.

Cell surface molecules

A cell surface molecule according to the present invention is any molecule naturally associated with the cell surface. Cell surface molecules may not be associated with the cell surface throughout their life time, but may be associated with the cell surface only at specific times. Cell surface molecules within the scope of the present invention may be any kind of molecule associated with the cell surface, however the cell surface molecules according to the present invention preferably comprise a polypeptide.

10

In one embodiment of the present invention cell surface molecules are not associated with the cell surface, but rather are intracellular receptor. Intracellular receptors for example include nuclear steroid hormone receptors.

15

However, in other preferred embodiments of the invention, cell surface molecules include for example molecules that are associated directly with the cell surface for example via a transmembrane domain, a membrane anchoring domain or a covalently linked group, which can associate with the membrane such as for example a lipophilic group. A lipophilic group may for example be a glycosyl-phosphatidylinositol group (GPI). However, it also includes molecules which are indirectly associated with the cell surface for example molecules that can associate with other cell surface molecules which are either directly or indirectly associated with the cell surface.

20

25

In general a cell surface molecule comprise at least one extracellular domain, however a cell surface molecule may comprise more than one extracellular domain such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10, for example more than 10 extracellular domains.

30

Frequently, cell surface molecules are glycosylated polypeptides.

35

In one preferred embodiment of the present invention, cell surface molecules are capable of associating with specific binding partners, and capable of internalising said specific binding partners upon association, i.e. after association between binding partner and cell surface molecule, the binding partner is transferred to the inte-

rior of the cell expressing the cell surface molecule. Frequently, the binding partner will be internalised by receptor mediated endocytosis, but other mechanisms are also possible and within the scope of the present invention. Cell surface molecules capable of internalising a binding partner may for example be useful for radio-, toxin-
5 or gene therapy or cancer vaccines.

In another preferred embodiment of the present invention, cell surface molecules are capable of associating with specific binding partners at the cell surface, but are not capable of internalising said specific binding partners. Non-internalising cell
10 surface molecules may for example be useful for radio-therapy and cancer vaccines.

Accession numbers from GenBank and names of preferred cell surface molecules are given in table 2.

Table 2

Accession	Cell surface molecule	Gene name	SEQ ID (cDNA/DNA)	SEQ ID (protein)
M11507	Transferrin receptor	Human transferrin receptor mRNA, complete cds.	1	2
X01060	Transferrin receptor	Human mRNA for transferrin receptor.	3	4
AB015633	HP10481	Homo sapiens mRNA for type II membrane protein, complete cds clone:HP10481.	5	6
M14219	PG40	Human chondroitin/dermatan sulfate proteoglycan (PG40) core protein mRNA, complete cds.	7	8
AF064801	TRC8	Homo sapiens multiple membrane spanning receptor TRC8 (TRC8) mRNA, complete cd	9	10
M29960	TR2-11	Human steroid receptor (TR2-11) mRNA, complete cds.	11	12
X69398	OA3 antigenic surface determinant	H.sapiens mRNA for OA3 antigenic surface determinant	13	14
X53586	Integrin alpha 6	Human mRNA for integrin alpha 6.	15	16
M34480	GPIIb	Human platelet glycoprotein .IIb (GPIIb) mRNA, complete cds	17	18
M14648	Vitronectin receptor alpha subunit; also designated ITGAV	Human cell adhesion protein (vitronectin) receptor alpha subunit; ITGAV mRNA, complete cds.	19	20
AF032108	Integrin alpha-7	Homo sapiens integrin alpha-7 mRNA,	21	22

		complete cds.		
M35011	Integrin beta- 5 subunit	Human integrin beta-5 subunit mRNA, complete cds.	23	24
X53002		Human mRNA for integrin beta-5 subunit.	25	26
L25851	Integrin alpha E precursor; also designated ITGAE	Homo sapiens integrin alpha E precursor; ITGAE, mRNA, complete cds.	27	28
S66213	Integrin alpha 6B	Integrin alpha 6B [human, mRNA Partial, 528 nt].	29	30
X06256	Integrin alpha 5 subunit	Human mRNA for integrin alpha 5 subunit.	31	32
M59911	Integrin alpha-3 chain	Human integrin alpha-3 chain mRNA, complete cds.	33	34
S59184	RYK	RYK=related to receptor tyrosine kinase [human, hepatoma, mRNA, 3068 nt].	35	36
U50939	Amyloid precursor protein-binding protein 1	Human amyloid precursor protein-binding protein 1 mRNA, complete cds.	37	38
U95822	Putative transmembrane GTPase	Human putative transmembrane GTPase mRNA, partial cds.	39	40
X59408	Membrane cofactor protein	H.sapiens, gene for Membrane cofactor protein.	41	
L20859	GLVR1	Human leukemia virus receptor 1 (GLVR1) mRNA, complete cds.	42	43
D64154	Mr 110,000 antigen	Human mRNA for Mr 110,000 antigen, complete cds.	44	45

		Inter-Alpha-Trypsin Inhibitor Heavy Chain LIKE gene		47
Z48199	Syndecan-1	H.sapiens syndecan-1 gene (exons 2-5).	48	49
Y18007	Putative seven trans-membrane domain protein	Homo sapiens mRNA for putative seven transmembrane domain protein	50	51
Y00815	LCA-homolog/LAR protein	Human mRNA for LCA-homolog. LAR protein (leukocyte antigen related)	52	53
X64364	M6 antigen	H.sapiens mRNA for M6 antigen.	54	55
X62654	Me491/CD63 antigen	H.sapiens gene for Me491/CD63 antigen.	56	57
U94831	Multispanning membrane protein	Homo sapiens multispanning membrane protein mRNA, complete cds.	58	59
U48705	DDR	Human receptor tyrosine kinase DDR gene, complete cds.	60	61
M63175	Autocrine motility factor receptor	Human autocrine motility factor receptor mRNA.	62	63
AB015631	Type II membrane protein clone	Homo sapiens mRNA for type II membrane protein, complete cds, clone:HP10390.	64	65
Y00285	Insuline-like growth factor II receptor	Human mRNA for insuline-like growth factor II receptor.	66	67

U01160	SAS	Human transmembrane 4 superfamily protein (SAS) mRNA, complete cds	68	69
M33680	TAPA-1	Human 26-kDa cell surface protein TAPA-1 mRNA, complete cds	70	71
M16941	MHC class II HLA-DR7-associated glycoprotein beta-chain	Human MHC class II HLA-DR7-associated glycoprotein beta-chain mRNA complete cds.	72	73
J04599	Bone small proteoglycan I biglycan	Human hPGI mRNA encoding bone small proteoglycan I biglycan), complete cds	74	75
Y07593	CAR	H.sapiens mRNA for 46 kDa coxsackievirus and adenovirus receptor (CAR) protein.	76	77
U73682	MEA11	Human meningioma-expressed antigen 11 (MEA11) mRNA, partiel cds.	78	79
U19247	Interferon-gamma receptor alpha chain	Homo sapiens interferon-gamma receptor alpha chain gene, exon 7 and complete cds.	80	81
X73079	Polymeric immunoglobulin receptor	Homo sapiens encoding Polymeric immunoglobulin receptor	82	83
X80818	Metabotropic glutamate receptor type 4	H.sapiens mRNA for metabotropic glutamate receptor type 4.	84	85
AF037339	CLPTM1	Homo sapiens cleft lip and palate transmembrane protein 1 (CLPTM1) mRNA, complete cds.	86	87
U10689	MAGE5a	Human MAGE-5a antigen (MAGE5a)	88	89

		gene, complete cds.		
U03735	MAGE-3	Human MAGE-3 antigen (MAGE-3) gene, complete cds.	90	91
M77481	MAGE-1	Human antigen (MAGE-1) gene, complete cds.	92	93
U10691	MAGE6	Human MAGE-6 antigen (MAGE6) gene, complete cds.	94	95
L33930	CD24	Homo sapiens CD24 signal transducer mRNA, complete cds and 3'region	96	97
M84349	CD59	Human transmembrane protein (CD59) gene, exon 4.	98	99
L00352	Low density lipoprotein receptor	Human low density lipoprotein receptor gene, exon 18.	100	101
AF023676	Lamin B receptor homolog TM7SF2	Homo sapiens lamin B receptor homolog TM7SF2 (TM7SF2) mRNA complete cds.	102	103
U41804	T1/ST2 receptor binding protein precursor	Human putative T1/ST2 receptor binding protein precursor mRNA, complete cds.	104	105
Y10148	NTR2 receptor	H.sapiens mRNA for NTR2 receptor.	106	107
U46194	RAGE-4	Human renal cell carcinoma antigen RAGE-4 mRNA, complete putative cds.	108	109
M90683	HLA-G1	Human lymphocyte antigen (HLA-G1) mRNA, complete cds.	110	111
AF104942	MOAT-C	Homo sapiens ABC transporter MOAT-C (MOAT-C) mRNA, complete cds.	112	113

AF042792	Alpha 2 delta calcium channel subunit isoform I	Homo sapiens alpha 2 delta calcium channel subunit isoform I mRNA, compl.cds.	114	115
Y00636	LFA-3	Human mRNA for lymphocyte function associated antigen-3 (LFA-3).	116	117
X59847	L1-CAM	H.sapiens mRNA for neural cell adhesion molecule L1 (HSNCAML1)	118	119
XM010168	AVPR2	Arginine-vasopressin receptor (AVPR2)		120
	C1 p115 C1	C1 p115		121
	TE2	ARD1 N-acetyl transferase related protein		122
	RbP	Renin binding protein		123
	HCF-1	Host cell factor 1		124
	IRAK	Interleukin-1-receptor associated kinase		125
D29963	CD151	Homo sapiens mRNA for CD151, complete cds.	126	127
M60922	Surface antigen	Human surface antigen mRNA, complete cds.	128	129
M29273	MAG	Human myelin-associated glycoprotein (MAG) mRNA, complete cds.	130	131
U64871	GPR19	Human putative G protein-coupled receptor (GPR19) gene, complete cds.	132	133
L78132	Pcta-1	Human prostate carcinoma tumor antigen (pcta-1) mRNA, complete cds.	134	135
U65011	PRAME	Human preferentially expressed antigen of melanoma (PRAME) mRNA, compl.cds.	136	137
X81882	Vasopressin activated calcium mobilizing receptor-like protein	H.sapiens mRNA for vasopressin activated calcium mobilizing receptor-like protein.	138	139
U65416	MICB	Human MHC class I molecule (MICB) gene, complete cds.	140	141
Y12505	Serotonin receptor 5-HT4B	H.sapiens mRNA for serotonin receptor 5-HT4B, splice variant	142	143

M38690	CD9	Human CD9 antigen mRNA, complete cds.	144	145
AF077820	LDL receptor member LR3	Homo sapiens LDL receptor member LR3 mRNA, complete cds.	146	147
U10688	MAGE-4b	Human MAGE-4b antigen (MAGE4b) gene, complete cds.	148	149
AF068868	DR6	Homo sapiens TNFR-related death receptor-6 (DR6) mRNA, complete cds.	150	151
D16532	Very low density lipoprotein receptor	Human gene for very low density lipoprotein receptor, exon 19	152	153
M81590	Serotonin 1D receptor (5-HT1D~)	Homo sapiens serotonin 1D receptor (5-HT1D~) mRNA, complete cds	154	155
M58286	Tumour necrosis factor receptor	Homo sapiens tumor necrosis factor receptor mRNA, complete cds.	156	157
AF062006	HG38	Homo sapiens orphan G protein-coupled receptor HG38 mRNA, complete cds	158	159
U09937	Urokinase-type plasminogen receptor	Human urokinase-type plasminogen receptor, exon 7.	160	161
M22092	N-CAM; also designated NCAM1	Human neural cell adhesion molecule (N-CAM) gene, exon SEC and partial cds.	162	163
M34641	FGF receptor	Human fibroblast growth factor (FGF) receptor-1 mRNA, complete cds.	164	165
M14764	Nerve growth factor receptor	Human nerve growth factor receptor mRNA, complete cds.	166	167
U10694	MAGE-9	Human MAGE-9 antigen (MAGE9) gene, complete cds.	168	169
AB026891	Cystine/glutamate transporter	Homo sapiens mRNA for cystine/glutamate transporter, complete cds.	170	171
U73304	CB1 cannabinoid receptor (CNR1)	Human CB1 cannabinoid receptor (CNR1) gene, complete cds.	172	173
M69245	PSG	Human pregnancy-specific beta-1 glycoprotein (PSG) mRNA, complete cds	174	175
AB000712	CPE receptor	Homo sapiens hCPE-R mRNA for CPE-receptor, complete cds.	176	177
AF011406	CRH2R	Homo sapiens corticotropin releasing hormone receptor type 2 beta isoform (CRH2R) mRNA, complete cds.	178	179
U50410	OCI5	Human heparan sulphate proteoglycan (OCI5) mRNA, complete cds	180	181
AF016266	TRAIL receptor 2	Homo sapiens TRAIL receptor 2 mRNA, complete cds.	182	183

U87947	HNMP-1	Human hematopoietic neural membrane protein (HNMP-1) mRNA, complete cds.	184	185
J03853	Kidney alpha-2-adrenergic receptor	Human kidney alpha-2-adrenergic receptor mRNA, complete cds.	186	187
U10686	MAGE11	Human MAGE-11 antigen (MAGE11) gene, complete cds.	188	189
U25988	PSG13'	Human pregnancy-specific glycoprotein 13 (PSG13') mRNA, complete cds	190	191
M60459	Erythropoietin receptor	Human erythropoietin receptor mRNA, complete cds.	192	193
X15998	Chondroitin sulphate proteoglycan versican V1	H.sapiens mRNA for the chondroitin sulphate proteoglycan versican V1 splice-variant; precursor peptide.	194	195
U31216	mGlu1beta	Human metabotropic glutamate receptor 1 beta (mGluR1beta) mRNA, complete cds.	196	197
X94630	CD97	H.sapiens CD97 gene exon 1 (and joined CDS).	198	199
M90657	L6	Human tumor antigen (L6) mRNA, complete cds.	200	201
U87459	NY-ESO-1	Human autoimmunogenic cancer/testis antigen NY-ESO-1 mRNA, complete cds.	202	203
S71824	N-CAM; also designated NCAM1	N-CAM=145 kda neural cell adhesion molecule [human, small cell lung cancer cell line OS2-R, mRNA, 2960 nt].	204	205
AE000659	T-cell receptor alpha delta	Homo sapiens T-cell receptor alpha delta locus from bases 250472 to 501670 (section 2 of 5) of the Complete Nucleotide Sequence.	206	207 208 209 210 211 212 213 214 215 216 217 218 219 220 221

				222
M97639	Ror2	Human transmembrane receptor (ror2) mRNA, complete cds.	223	224
M81830	SSTR2	Human somatostatin receptor isoform 2 (SSTR2) gene, complete cds	225	226
AF030339	VESPR	Homo sapiens receptor for viral semaphorin protein (VESPR) mRNA, complete cds.	227	228
X02160	Insulin receptor precursor	Human mRNA for insulin receptor precursor.	229	230
U12255	IgG Fc receptor	Human IgG Fc receptor hFcRn mRNA, complete cds.	231	232
X82068	Glutamate receptor subunit GluRC	H.sapiens mRNA for glutamate receptor subunit GluRC.	233	234
X75208	HEK2	H.sapiens HEK2 mRNA for protein tyrosine kinase receptor.	235	236
X64116	PVR	H.sapiens PVR gene for poliovirus receptor (exon 1),	237	
		poliovirus receptor γ		238
		poliovirus receptor β		239
		poliovirus receptor α		240
M29540	CEA	Human carcinoembryonic antigen mRNA (CEA), complete cds.	241	242
U94888	CC-chemokine-binding receptor JAB61	Homo sapiens CC-chemokine-binding receptor JAB61 mRNA, complete cds.	243	244
M97675	Ror1	Human transmembrane receptor (ror1) mRNA, complete cds.	245	246
M12036	HER2	Human tyrosine kinase-type receptor (HER2) gene, partial cds.	247	248
U87460	Putative endothelin receptor type B-like protein	Human putative endothelin receptor type B-like protein mRNA, complete cds.	249	250
L20852	GLVR2	Human leukemia virus receptor 2 (GLVR2) mRNA, complete cds.	251	252
L05424		Human cell surface glycoprotein CD44 (CD44) gene, 3' end of long tailed isoform	253	254
M59040	CD44	Human cell adhesion molecule (CD44) mRNA, complete cds	255	256

U83993	P2X4 purinoreceptor	Human P2X4 purinoreceptor mRNA, complete cds.	257	258
XM_015664	FLJ22357 similar to epidermal growth factor-related protein	Homo sapiens hypothetical protein FLJ22357 similar to Epidermal growth factor receptor-related protein (FLJ22357) mRNA.	261	262
NM_022450		Homo sapiens hypothetical protein FLJ22357 similar to Epidermal growth factor receptor-related protein (FLJ22357) mRNA.	259	260
M84562	FPRL1	Human formyl peptide receptor-like receptor (FPRL1) mRNA, complete cds	263	264
M34309	HER3	Human epidermal growth factor receptor (HER3) mRNA, complete cds.	265	266
M83664	HLA-DP	Human MHC class II lymphocyte antigen (HLA-DP) beta chain mRNA, compl.cds.	267	268
AF025998	Atrial natriuretic peptide clearance receptor	Homo sapiens atrial natriuretic peptide clearance receptor (ANPRC) mRNA, complete cds.	269	270
XM_006034	Gastrin/CCK-B receptor	Homo sapiens cholecystokinin B receptor (CCKBR), mRNA.	271	272
M73482	Neuromedin B receptor	Human neuromedin B receptor (NMB-R) mRNA, complete cds.	273	274
NM_001496	GFRA3	Homo sapiens GDNF family receptor alpha 3 (GFRA3), mRNA.	275	276
XM_010317	GRPR	Homo sapiens gastrin-releasing peptide receptor (GRPR), mRNA.	277	278
U92459	Metabotropic glutamate receptor 8; also designated GRM8 or GluR8	Human metabotropic glutamate receptor 8 (GluR8) mRNA, complete cds.; GRM8	279	280
XM_007840	CDH1	Homo sapiens cadherin 1, type 1, E-cadherin (epithelial)(CDH1),mRNA.	281	282
XM_016157	CDH2	Homo sapiens cadherin 2, type 1, N-cadherin (neuronal)(CDH2),mRNA.	283	284
XM_005591	TGFBR1	Homo sapiens transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD) (TGFBR1), mRNA.	285	286
XM_003094	TGFBR2	Homo sapiens transforming growth factor, beta receptor II (70-80kD) (TGFBR2), mRNA.	287	288
XM_001924	TGFBR3	Homo sapiens transforming growth factor, beta receptor III (betaglycan, 300kD)(TGFBR3), mRNA.	289	290
NM_000875	IGF1R	Homo sapiens insulin-like growth factor 1 receptor (IGF1R), mRNA.	291	292

X00588	Precursor of epidermal growth factor receptor	Human mRNA for precursor of epidermal growth factor receptor.	293	294
Z75190	LRP8	Homo sapiens apolipoprotein E receptor 2 (APOER2), also designated LRP8; mRNA	295	296
U62434	CHRNA 5	Nicotinic acetylcholine receptor alpha5 subunit (CHRNA 5); mRNA	297	298
U19878	TMEFF1	Transmembrane protein with EGF-like and two follastatin-like domains 1 (TMEFF1); mRNA	299	300
L20814	GRIA2; also designated GluR2	Human glutamate receptor 2 (HBGR2); also designated GluR2 or GRIA2; complete coding sequence	301	302
AL008583	NPTXR	Neuronal pentraxin receptor (NPTXR); DNA sequence	303	304

Even more preferred cell surface molecules according to the present invention are
5 receptors which belong to one of the following groups:

- Members of receptor tyrosine kinases
- Members of the integrin family
- Members of the immunoglobulin superfamily adhesion molecules
- 10 Members of the heparan sulfate proteoglycan family
- Members of the chondroitin sulfate proteoglycan family
- Members of the MAGE family
- Members of the RAGE family
- Members of the low density lipoprotein receptor family
- 15 Members of the cadherin adhesion molecules
- Members of the metabotropic glutamate receptors
- Members of the steroid hormone families
- Members of the seven transmembrane receptor family
- Atrial natriuretic peptide clearance receptor
- 20 GFRA3
- Transferrin receptor
- Members of the serine/threonine kinase receptors

Yet more preferred cell surface molecules according to the present invention are cell
25 surface molecules selected from the group consisting of NCAM1, NPTXR, LRP8,

CHRNA5, GRIA2, GRM8, ITGAV, ITGAE, TNFRSF12, L1CAM, GPR9 and TMEFF1.

5 In one preferred embodiment of the present invention, cell surface molecules are capable of internalising specific binding partners upon association (see herein above). Preferred cell surface molecules according to the present invention capable of internalising a binding partner may be selected from the group consisting of NCAM1, NPTXR, LRP8 and CHRNA5.

10 In another preferred embodiment of the present invention, cell surface molecules are not capable of internalising their specific binding partners. Preferred cell surface molecules according to the present invention not capable of internalising binding partner(s) may be selected from the group consisting of GRIA2, GRM8, ITGAV and ITGAE

15 One especially preferred cell surface molecule according to the present invention is NCAM1 (NCAM, neural cell adhesion molecule, N-CAM, CD56). NCAM1 is highly expressed in most SCLC. The expression of NCAM1 has been shown by for example CHIPS analysis, RT-PCR and western blotting (see example 1, figure 11 and
20 figure 15). NCAM1 is capable of internalising binding partners. Binding partners capable of associating with NCAM1 are described herein below. NCAM1 has been shown to be internalised in astrocytes (Minana *et al.*, 2001) and has been demonstrated capable of very efficient internalisation of a very large molecule complex consisting of: anti-NCAM1 antibody-Protein A-Streptavidine-Biotin- β -galactosidase
25 enzyme (Yu *et al.*, 2000).

Another preferred cell surface molecule according to the present invention is NPTXR (Neuronal pentraxin receptor, NPR). NPTXR is expressed in most SCLC. The expression of NPTXR has been demonstrated by for example CHIPS analysis,
30 RT-PCR and western blotting (see example 1, figure 10 and figure 14). NPTXR is a highly internalising receptor. Binding partners capable of associating with NPTXR are described herein below.

Yet another preferred cell surface molecule according to the present invention is
35 LRP8 (low density lipoprotein receptor related protein, apolipoprotein E receptor 2).

LRP8 is expressed in all tested SCLC. The expression of LRP8 has been demonstrated by for example CHIPS analysis and RT-PCR (see example 1 and figure 9). LRP8 is a highly internalising receptor. Binding partners capable of associating with LRP8 are described herein below.

5

Yet another preferred cell surface molecule according to the present invention is CHRNA5 (nicotinic acetylcholine receptor alpha5 subunit). Binding partners capable of associating with CHRNA5 are described herein below.

10 Yet another cell surface molecule that may be used with the present invention is L1CAM (neural cell adhesion molecule L1). L1 is known to be able to internalise binding partners. Binding partners capable of associating with L1CAM are described herein below.

15 Yet another preferred cell surface molecule according to the present invention is TNFRSF12 (DR6, tumor necrosis factor receptor superfamily member 21). TNFRSF12 is expressed in most SCLC. The expression of TNFRSF12 has been demonstrated by for example CHIPS analysis and RT-PCR (see example 1 and figure 8). Other members of the family to which TNFRSF12 belong are capable of
20 internalising binding partners.

An especially preferred cell surface molecule according to the present invention is GRIA2 (Ionotropic glutamate receptor 2, GLUR2, GLURB, HBGR2, AMPA 2). GRIA2 is expressed in all tested SCLC and in the brain. GRIA2 is a highly specific
25 SCLC receptor outside the brain. Expression of GRIA2 has for example been demonstrated by Chips analysis, RT-PCR and Western blotting (see example 1, figure 12A and figure 16).

Another preferred cell surface molecule according to the present invention is GRM8
30 (metabotropic glutamate 8 receptor, GLUR8, mGlu8, GPRC1H). GRM8 is highly specifically expressed in SCLC except for the brain and is expressed in most SCLC. The expression of GRM8 has been demonstrated by for example Chips analysis, RT-PCR and western blotting (see example 1 and figure 13). Binding partners capable of associating with GRM8 are described herein below.

35

Yet another preferred cell surface molecule according to the invention is ITGAV (Integrin subunit α_v , vitronectin receptor, CD 51). ITGAV is highly expressed by SCLC. Expression has been demonstrated by for example CHIPS analysis and RT-PCR (see example 1 and figure 12B)

5

Yet another preferred cell surface molecule according to the present invention is ITGAE (integrin α_E subunit-precursor, human mucosal lymphocyte-1'antigen, CD 103). ITGAE is expressed by all SCLC tested and ITGAE is highly specifically expressed in SCLC. Expression has been demonstrated by for example CHIPS analysis and western blotting (see example 1 and figure 17).

10

Yet another preferred cell surface molecule according to the present invention is GPR49 (orphan G protein-coupled receptor 67, GPR67, HG38).

15 Yet another preferred cell surface molecule according to the present invention is TMEFF1 (transmembrane protein with EGF-like and two follastatin-like domains).

However, the present invention is also directed towards cell surface molecules which comprises fragments, which are encoded by fragments of the nucleotide sequences given in table 2. In one preferred embodiment, the present invention is directed towards cell surface molecules encoded by splice variants of these sequences, which are encoded by the same gene. Splice variants of cell surface molecules outlined in table 2 may encode a polypeptide sequence which share fragments with said cell surface molecules; however splice variants may take advantage of an alternative reading frame, so that although the products of the two splice variants are encoded by nucleotide sequences that share common fragments, the polypeptide sequences may not be related.

20

25

Furthermore, the present invention is directed to fragments of the nucleotide sequences encoding cell surface molecules according to table 2. In particular, binding partners according to the present invention (see herein below) may associate with products of only one or more fragments of a cell surface molecule according to the present invention, but preferably not with all fragments of a cell surface molecule. Accordingly, it is possible to use fragments of the cell surface molecules to identify potential binding partners (see herein below).

30

35

For example such fragments comprise the 5' half of the sequence or the 3' half of the sequences. Furthermore, the fragments may comprise part of the 5' half or part of the 3' half of the sequences. Preferably, such fragments are shorter than 5000
5 bp, such as shorter than 4000 bp, for example shorter than 3000 bp, such as shorter than 2500 bp, for example shorter than 2000 bp, such as shorter than 1750 bp, such as shorter than 1500 bp, for example shorter than 1250 bp, such as shorter than 1000 bp, for example shorter than 900 bp, such as shorter than 800 bp, for example shorter than 700 bp, such as shorter than 600 bp, for example shorter than 500 bp,
10 such as shorter than 400 bp, for example shorter than 300 bp, such as shorter than 200 bp, for example shorter than 100 bp, such as shorter than 75 bp, for example shorter than 50 bp, such as shorter than 40 bp, for example shorter than 30 bp, such as shorter than 25 bp, for example shorter than 20 bp, such as shorter than 18 bp.

15 Such fragments may be internal fragments or they may be comprise the 5' or the 3' terminal.

In one preferred embodiment of the present invention the fragments comprise a plurality of building blocks of a predetermined length and wherein the building blocks
20 are linked so that the fragments are identical to part of a native gene sequence, preferably the sequences outlined in table 2. Accordingly, fragments may comprise a plurality of building blocks of the predetermined length and a predetermined starting point.

25 Building blocks are nucleic acid sequences, which have a predetermined length and starting point, so that the first building block starts at a given position in the nucleic acid sequence and the subsequent building blocks starts at the position following the position where the previous building block stops.

30 Preferably, the building blocks are derived from any of the sequences SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9, SEQ ID NO. 11, SEQ ID NO. 13, SEQ ID NO. 15, SEQ ID NO. 17, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 23, SEQ ID NO. 25, SEQ ID NO. 27, 29, SEQ ID NO. 31, SEQ ID NO. 33, SEQ ID NO. 35, SEQ ID NO. 37, SEQ ID NO. 39, SEQ ID NO. 41, SEQ ID NO.
35 42, SEQ ID NO. 44, SEQ ID NO. 48, SEQ ID NO. 50, SEQ ID NO. 52, SEQ ID NO.

54, SEQ ID NO. 56, SEQ ID NO. 58, SEQ ID NO. 60, SEQ ID NO. 62, SEQ ID NO. 64, SEQ ID NO. 66, SEQ ID NO. 68, SEQ ID NO. 70, SEQ ID NO. 72, SEQ ID NO. 74, SEQ ID NO. 76, SEQ ID NO. 78, SEQ ID NO. 80, SEQ ID NO. 82, SEQ ID NO. 84, SEQ ID NO. 86, SEQ ID NO. 88, SEQ ID NO. 90, SEQ ID NO. 92, SEQ ID NO. 94, SEQ ID NO. 96, SEQ ID NO. 98, SEQ ID NO. 100, SEQ ID NO. 102, SEQ ID NO. 104, SEQ ID NO. 106, SEQ ID NO. 108, SEQ ID NO. 110, SEQ ID NO. 112, SEQ ID NO. 114, SEQ ID NO. 116, SEQ ID NO. 118, SEQ ID NO. 126, SEQ ID NO. 128, SEQ ID NO. 130, SEQ ID NO. 132, SEQ ID NO. 134, SEQ ID NO. 136, SEQ ID NO. 138, SEQ ID NO. 140, SEQ ID NO. 142, SEQ ID NO. 144, SEQ ID NO. 146, SEQ ID NO. 148, SEQ ID NO. 150, SEQ ID NO. 152, SEQ ID NO. 154, SEQ ID NO. 156, SEQ ID NO. 158, SEQ ID NO. 160, SEQ ID NO. 162, SEQ ID NO. 164, SEQ ID NO. 166, SEQ ID NO. 168, SEQ ID NO. 170, SEQ ID NO. 172, SEQ ID NO. 174, SEQ ID NO. 176, SEQ ID NO. 178, SEQ ID NO. 180, SEQ ID NO. 182, SEQ ID NO. 184, SEQ ID NO. 186, SEQ ID NO. 188, SEQ ID NO. 190, SEQ ID NO. 192, SEQ ID NO. 194, SEQ ID NO. 196, SEQ ID NO. 198, SEQ ID NO. 200, SEQ ID NO. 202, SEQ ID NO. 204, SEQ ID NO. 206, SEQ ID NO. 223, SEQ ID NO. 225, SEQ ID NO. 227, SEQ ID NO. 229, SEQ ID NO. 231, SEQ ID NO. 233, SEQ ID NO. 235, SEQ ID NO. 237, SEQ ID NO. 241, SEQ ID NO. 243, SEQ ID NO. 245, SEQ ID NO. 247, SEQ ID NO. 249, SEQ ID NO. 251, SEQ ID NO. 253, SEQ ID NO. 255, SEQ ID NO. 257, SEQ ID NO. 261, SEQ ID NO. 259, SEQ ID NO. 263, SEQ ID NO. 265, SEQ ID NO. 267, SEQ ID NO. 269, SEQ ID NO. 271, SEQ ID NO. 273, SEQ ID NO. 275, SEQ ID NO. 277, SEQ ID NO. 279, SEQ ID NO. 281, SEQ ID NO. 283, SEQ ID NO. 285, SEQ ID NO. 287, SEQ ID NO. 289, SEQ ID NO. 291, SEQ ID NO. 293, SEQ ID NO. 295, SEQ ID NO. 297, SEQ ID NO. 299, SEQ ID NO. 301 and SEQ ID NO. 303.

Each building block is preferably shorter than 1000 bp, for example shorter than 900 bp, such as shorter than 800 bp, for example shorter than 700 bp, such as shorter than 600 bp, for example shorter than 500 bp, such as shorter than 400 bp, for example shorter than 300 bp, such as shorter than 200 bp, for example shorter than 100 bp, such as shorter than 75 bp, for example shorter than 50 bp, such as shorter than 40 bp, for example shorter than 30 bp, such as shorter than 25 bp, for example shorter than 20 bp, such as shorter than 18 bp. In one embodiment the building block is around 18 bp.

The building blocks may start at position 1, such as position 2, for example position 3, such as position 4, for example position 5, such as position 6, for example position 7, such as position 8, for example position 9, such as position 10, for example position 11, such as position 12, for example position 13, such as position 14, for example position 15, such as position 16, for example position 17, such as position 18, for example position 19, such as position 20, such as any of the positions 20 to 100, for example any of the position 100 of any of the sequences outlined in table 2.

The fragments preferably comprise a plurality of building blocks, such as 2, for example 3, such as 4, for example 5, such as from 5 to 10, for example from 10 to 20, such as from 20 to 30, for example from 30 to 40, such as from 40 to 50, for example from 50 to 75, such as from 75 to 100, for example more than 100 building blocks.

In one embodiment the fragments comprise building blocks which are 100 base pairs long and which start at position 1.

Furthermore, fragments of cell surface molecules according to the present invention may be chimeric fragments, such chimeric fragments comprise more than one fragments which are not associated with each other according to the sequences outlined in table 2. Such chimeric fragments may comprise fragments from the same cell surface molecule or they may contain fragments from more than one cell surface molecule according to the invention.

Furthermore, the present invention is directed to fragments of the polypeptides sequences of cell surface molecules according to table 2. In particular, binding partners according to the present invention (see herein below) may associate with only one or more fragments of a cell surface molecule according to the present invention, but preferably not with all fragments of a cell surface molecule. Accordingly, it is possible to use fragments of the cell surface molecules to identify potential binding partners (see herein below).

Fragments of polypeptide sequences may be shorter than 3000 amino acids, such as shorter than 2500 amino acids, for example shorter than 2000 amino acids, such as shorter than 1750 amino acids, such as shorter than 1500 amino acids, for ex-

ample shorter than 12 amino acids, such as shorter than 1000 amino acids, for example shorter than 900 amino acids, such as shorter than 800 amino acids, for example shorter than 700 amino acids, such as shorter than 600 amino acids, for example shorter than 500 amino acids, such as shorter than 400 amino acids, for example shorter than 300 amino acids, such as shorter than 200 amino acids, for example shorter than 100 amino acids, such as shorter than 75 amino acids, for example shorter than 50 amino acids, such as shorter than 40 amino acids, for example shorter than 30 amino acids, such as shorter than 25 amino acids, for example shorter than 20 amino acids, such as shorter than 15 amino acids, for example shorter than 10 amino acids.

Preferably, the fragments are fragments of polypeptide sequences SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 8, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 14, SEQ ID NO. 16, SEQ ID NO. 18, SEQ ID NO. 20, SEQ ID NO. 22, SEQ ID NO. 24, SEQ ID NO. 26, SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 34, SEQ ID NO. 36, SEQ ID NO. 38, SEQ ID NO. 40, SEQ ID NO. 43, SEQ ID NO. 45, SEQ ID NO. 47, SEQ ID NO. 49, SEQ ID NO. 51, SEQ ID NO. 53, SEQ ID NO. 55, SEQ ID NO. 57, SEQ ID NO. 59, SEQ ID NO. 61, SEQ ID NO. 63, SEQ ID NO. 65, SEQ ID NO. 67, SEQ ID NO. 69, SEQ ID NO. 71, SEQ ID NO. 73, SEQ ID NO. 75, SEQ ID NO. 77, SEQ ID NO. 79, SEQ ID NO. 81, SEQ ID NO. 83, SEQ ID NO. 85, SEQ ID NO. 87, SEQ ID NO. 89, SEQ ID NO. 91, SEQ ID NO. 93, SEQ ID NO. 95, SEQ ID NO. 97, SEQ ID NO. 99, SEQ ID NO. 101, SEQ ID NO. 103, SEQ ID NO. 105, SEQ ID NO. 107, SEQ ID NO. 109, SEQ ID NO. 111, SEQ ID NO. 113, SEQ ID NO. 115, SEQ ID NO. 117, SEQ ID NO. 119, SEQ ID NO. 120, SEQ ID NO. 121, SEQ ID NO. 122, SEQ ID NO. 123, SEQ ID NO. 124, SEQ ID NO. 125, SEQ ID NO. 126, SEQ ID NO. 127, SEQ ID NO. 129, SEQ ID NO. 131, SEQ ID NO. 133, SEQ ID NO. 135, SEQ ID NO. 137, SEQ ID NO. 139, SEQ ID NO. 141, SEQ ID NO. 143, SEQ ID NO. 145, SEQ ID NO. 147, SEQ ID NO. 149, SEQ ID NO. 151, SEQ ID NO. 153, SEQ ID NO. 155, SEQ ID NO. 157, SEQ ID NO. 159, SEQ ID NO. 161, SEQ ID NO. 163, SEQ ID NO. 165, SEQ ID NO. 167, SEQ ID NO. 169, SEQ ID NO. 171, SEQ ID NO. 173, SEQ ID NO. 175, SEQ ID NO. 177, SEQ ID NO. 179, SEQ ID NO. 181, SEQ ID NO. 183, SEQ ID NO. 185, SEQ ID NO. 187, SEQ ID NO. 189, SEQ ID NO. 191, SEQ ID NO. 193, SEQ ID NO. 195, SEQ ID NO. 197, SEQ ID NO. 199, SEQ ID NO. 201, SEQ ID NO. 203, SEQ ID NO. 205, SEQ ID NO. 207, SEQ ID NO. 208, SEQ ID NO. 209, SEQ ID NO. 210, SEQ ID NO. 211, SEQ

ID NO. 212, SEQ ID NO. 213, SEQ ID NO. 214, SEQ ID NO. 215, SEQ ID NO. 216, SEQ ID NO. 217, SEQ ID NO. 218, SEQ ID NO. 219, SEQ ID NO. 220, SEQ ID NO. 221, SEQ ID NO. 222, SEQ ID NO. 224, SEQ ID NO. 226, SEQ ID NO. 228, SEQ ID NO. 230, SEQ ID NO. 232, SEQ ID NO. 234, SEQ ID NO. 236, SEQ ID NO. 238, SEQ ID NO. 240, SEQ ID NO. 242 and SEQ ID NO. 244, SEQ ID NO. 246, SEQ ID NO. 248, SEQ ID NO. 250, SEQ ID NO. 252, SEQ ID NO. 254, SEQ ID NO. 256, SEQ ID NO. 258, SEQ ID NO. 260, SEQ ID NO. 262, SEQ ID NO. 264, SEQ ID NO. 266, SEQ ID NO. 268, SEQ ID NO. 270, SEQ ID NO. 272, SEQ ID NO. 274, SEQ ID NO. 276, SEQ ID NO. 278, SEQ ID NO. 280, SEQ ID NO. 282, SEQ ID NO. 284, SEQ ID NO. 286, SEQ ID NO. 288, SEQ ID NO. 290, SEQ ID NO. 292, SEQ ID NO. 294, SEQ ID NO. 296, SEQ ID NO. 298, SEQ ID NO. 300, SEQ ID NO. 302 and SEQ ID NO. 304. Furthermore, functional homologues of the fragments of the polypeptide sequences may also be comprised within cell surface molecules of the present invention, or the cell surface molecules may consist of functional homologues of the fragments of the polypeptide sequences. Functional homologues are defined herein below.

Particularly preferred fragments of the cell surface molecules according to the present invention are fragments that comprises one or more extracellular domains of the cell surface molecules. Additionally, fragments which comprise parts of extracellular domains are also preferred fragments within the scope of the present invention. Most preferably, the fragments of the cell surface molecules according to the present invention are fragments that comprise one or more extracellular domains and which are capable of internalising a binding partner having affinity for said fragment.

In one embodiment the fragments comprise an extracellular domain or fragments thereof or derivatives thereof, wherein said extracellular domain may be selected from the group consisting of polypeptide sequences, which are encoded by the nucleotide sequences SEQ ID NO 3 nucleotide 1014 to 2450, SEQ ID NO 15 nucleotide 216 to 3179, SEQ ID NO. 31 nucleotide 147 to 2999, SEQ ID NO 52 nucleotide 419 to 4120, SEQ ID NO 66 nucleotide 268 to 7059, SEQ ID NO 82 nucleotide 235 to 2094, SEQ ID NO 104 nucleotide 160 to 663, SEQ ID NO 204 nucleotide 301 to 2250, SEQ ID NO 229 nucleotide 130 to 2880, SEQ ID NO 281 nucleotide 569 to 2152, SEQ ID NO 283 nucleotide 585 to 1901, SEQ ID NO 291 nucleotide 121 to 2836 and SEQ ID NO 293 nucleotide 259 to 2127.

The cell surface molecule and the fragments of cell surface molecules as outlined herein above, may furthermore comprise posttranslational modifications. Examples of posttranslational modifications are phosphorylations, glycosylation, acetylations, methylation, sulfatation, polysialylation, farnesylation, myristoylation or palmitylation.

Functional homologues of the cell surface molecules outlined in table 2 are also contained within the present invention. SEQ ID NO of polypeptide sequences encoding preferred cell surface molecules according to the present invention are also given in table 2. Functional homologues of cell surface molecules according to the present invention are cell surface molecules which can associate with the binding partners according to the present invention and which preferably can internalise said binding partners.

Promoters

Promoters within the scope of the present invention are first nucleic acid sequences, which are capable of directing expression of second nucleic acid sequences operably linked thereto. Such first nucleic acid sequences are normally found upstream on the chromosome of nucleic acid sequences that may be transcribed.

In one embodiment, preferably a first nucleic acid sequence operably linked to a second nucleic acid sequence comprise at least 15,000 base pairs upstream of the translation start codon of said second nucleic acid sequence on the chromosome. However, the first nucleic acid sequence operably linked to a second nucleic acid sequence may also comprise at least 12.500, such as at least 10.000, for example at least 8,000, such as at least 6,000, such as at least 5,000, such as at least 4,000, such as at least 3,000, for example at least 2,500, such as at least 2,000, such as at least 1,500, such as at least 1,000, for example at least 500, such as at least 400, for example at least 300, such as at least 200, for example at least 150, such as at least 100, for example at least 50, such as at least 25, for example at least 10 base pairs upstream of the translation start codon of said second nucleic acid sequence on the chromosome, or a fragment of any such sequences capable of directing gene expression.

Furthermore, in another embodiment the first nucleic acid sequence operably linked to a second nucleic acid sequence preferably comprises up to 10, such as up to 100, such as up to 500, for example up to 1000, such as up to 2500, for example up to 5000 base pairs upstream of the translation start codon of said second nucleic acid sequence on the chromosome, or a fragment thereof capable of directing gene expression.

It is also within the scope of the present invention, that the first nucleic acid sequence operably linked to a second nucleic acid sequence may comprise one or more intron sequences or fragments thereof found upstream of the translation start codon of said second nucleic acid sequence on the chromosome. Furthermore, the first nucleic acid sequence operably linked to a second nucleic acid sequence may comprise one or more intron sequences or fragments thereof found downstream of the translation start codon of said second nucleic acid sequence on the chromosome.

The first nucleic acid sequence operably linked to a second nucleic acid sequence may furthermore comprise an enhancer sequence located more than 15,000 base pairs upstream or downstream from the translation start codon of said second nucleic acid sequence on the chromosome.

The above mentioned first nucleic acid sequence operably linked to a second nucleic acid sequence may also comprise deletions and/or additions of nucleic acids. Deletions and/or additions may be internal or they may be at the end of the nucleic acid sequence.

Accordingly, from a first nucleic acid sequence, which for example comprise up to 1000, such as up to 2500, for example up to 5000, such as up to 7500, such as up to 10,000, for example up to 15,000, such as up to 20,000 base pairs upstream from the translation start codon of a second nucleic acid sequence on the chromosome, at least 10 internal bp, such as at least 25 internal bp, for example at least 50 internal bp, such as at least 100 internal bp, for example 200 internal bp, such as at least 300 internal bp, for example at least 400 internal bp, such as at least 500

internal bp, for example at least 750 internal bp, such as at least 1000 internal bp, for example at least 1250, such as at least 1500, for example at least 1750, such as at least 2000, for example at least 2500, such as at least 3000, for example at least 3500, such as at least 4000, for example at least 4500 internal base pairs may be deleted.

Specific nucleic acid sequences may be more favourable to delete than others. For example sequences that suppress expression or sequences that do not alter expression of second nucleic acid sequences operably linked thereto may be deleted. Accordingly, the present invention also encompass first nucleic acid sequence operably linked to a second nucleic acid sequence comprising up to 1000, such as up to 2500, for example up to 5000, such as up to 7500, such as up to 10,000, for example up to 15,000, such as up to 20,000 base pairs upstream from the translation start codon of a second nucleic acid sequence on the chromosome, from which at least one silencer has been deleted.

It is also possible that the first nucleic acid sequence comprises more than one deletion, such as 2, for example 3, such as 4, for example 5, such as more than 5 deletions.

Furthermore, from a first nucleic acid sequence, which for example comprise up to 20,000, for example up to 15,000, such as up to 10,000, for example up to 7500, for example up to 5000, such as up to 2500, for example up to 1000 base pairs upstream from the translation start codon of a second nucleic acid sequence on the chromosome, at least 10, such as at least 25, for example at least 50, such as at least 100, for example 200, such as at least 300, for example at least 400, such as at least 500, for example at least 750, such as at least 1000, for example at least 1250, such as at least 1500, for example at least 1750, such as at least 2000, for example at least 2500, such as at least 3000, for example at least 3500, such as at least 4000, for example at least 4500 base pairs may be deleted from either one or the other end.

Additions of nucleic acid sequences may be done at the end or internally. First nucleic acid sequences may comprise more than one addition, for example 2, such as 3, for example 4, such as 5, for example more than 5 additions. It may be

addition of at least 10, such as at least 25, for example at least 50, such as at least 100, for example 200, such as at least 300, for example at least 400, such as at least 500, for example at least 750, such as at least 1000, for example at least 1250, such as at least 1500, for example at least 1750, such as at least 2000, for example at least 2500, such as at least 3000, for example at least 3500, such as at least 4000, for example at least 4500, such as more than 4500 base pairs.

For example it is possible to add nucleic acid sequences that alter the function of the first nucleic acid sequence. For example nucleic acid sequences which are recognised by specific transcription factors may be added. For example nucleic acid sequences that are recognised by nuclear steroid hormone receptors

Examples of preferred first nucleic acid sequences are given in table 3 and 4. Functional homologues as described herein below of these nucleic acid sequences as well as deletion and/or addition mutants as described herein above are also comprised with in the present invention.

Table 3 First nucleic acid sequences indicating accession no. in the Blast database Version: May 10, 2001

(<http://www.ncbi.nlm.nih.gov/genome/seq/page.cgi?F=HsBlast.html&&ORG=Hs>)

No	Acc. No.	Chromosome	Region	Bases
pro4	J05614	20	NT_011387.3 -	4.073.925-4.125.777
pro12	AF059531	11	NT_009107.3 +	16.582.000-16.639.000
pro17	AA913812	1	NT_004705.3 +	145.236.000-145.282.000
pro18	W25866	1	NT_004705.3 +	145.240.856-145.281.103
pro28	W74442	15	NT_010356.3 -	87.186.215-87.226.899
pro37	U63743	1	NT_004808.3 -	73.601.528-73.642.295

pro49	AA203476	4	<u>NT 006291.3</u> +	46.964.000-47.005.368
		8	<u>NT 008166.3</u> +	66.825.152-66.865.799
pro53	M15205	17	<u>NT 024874.3</u> ?	78.209.000-78.266.000
pro55	Z95118	6	<u>NT 007577</u>	
pro62	AL050306	X	<u>NT 011553</u>	
		11	<u>NT 025842</u>	
pro73	U18271	12	<u>NT 009681.3</u> +	103.894.000-103.940.000
pro74	U03735	X	<u>NT 011534.1</u> +	138.253.000-138.770.000
pro76	U89387	2	<u>NT 005409.3</u> -	130.026.000-130.083.000
pro77	U10689	X	<u>NT 011726.3</u> ?	137.038.000-137.108.000
pro83	AI553745	5	<u>NT 023270.3</u> -	177.081.000-177.128.000
pro86	L18877	X	<u>NT 011534.1</u> +	138.233.000-138.771.000
pro87	U10691	X	<u>NT 011534.1</u> +	138.233.000-138.770.000
pro89	L18920	X	<u>NT 011534.1</u> +	138.233.000-138.770.000
pro91	N23137	12	<u>NT 009464.3</u> +	132.284.168-132.324.678
pro93	W28479	13	<u>NT 024495.3</u> +	87.871.068-87.891.259
pro97	AF053305	6	<u>NT 007592.3</u> +	37.167.152-37.207.246
		12	<u>NT 009782.3</u> +	53.429.369-53.469.399
pro103	U77949	17	<u>NT 024901.3</u> -	40.905.000-40.968.000
pro112	AL021546	12	<u>NT 009775</u>	

pro120	M31315	5	<u>NT 023188.3</u> ?	176.642.000-176.692.000
pro121	D26488	1	<u>NT 004680.3</u> +	214.431.387-214.471.483
pro122	AL021366	6	<u>NT 007592.3</u> +	31.000.000-38.000.000
pro123	N58115	2	<u>NT 005343.3</u> -	184.162.000-184.223.000
pro129	AL031427	1	<u>NT 004424</u>	
pro139	Y13115	8	<u>NT 008176.3</u> -	39.029.000-39.073.000
pro142	AA151922	17	<u>NT 010711.3</u> -	73.365.739-73.406.421
pro153	U07563	9	<u>NT 008338</u>	
pro154	W26762	1	<u>NT 019273.3</u> -	115.514.000-115.557.000
pro156	AI950382	17	<u>NT 010641.3</u> +	77.160.000-77.208.000
pro161	M21259	1	<u>NT 004662.3</u> +	175.106.661-175.147.391
pro163	U75285	17	<u>NT 024874</u>	
pro166	AA926957	5	<u>NT 016864.3</u> +	52.120.104-52.140.918
		17	<u>NT 010692.3</u> +	1.029.000-1.077.000
pro171	M90354	13	<u>NT 024495.3</u> +	89.323.836-89.365.575
pro172	AA143321	18	<u>NT 010934.3</u> -	35.186.000-35.241.000
pro176	AA181196	13	<u>NT 009799.3</u> +	49.703.000-49.752.000
pro178	AB002359	15	<u>NT 010364.3</u> -	19.619.949-19.660.316
pro183	U13695	2	<u>NT 022197.3</u> -	197.599.000-197.820.000

pro184	U65011	22	<u>NT 011520.5</u> +	18.956.000-19.011.000
pro194	AF091754	1	<u>NT 004734.3</u> +	233.039.886-233.081.072
pro198	AL049842	13	<u>NT 009910</u>	
pro202	AA810792	12	<u>NT 009464.3</u> +	132.288.241-132.328.844
pro210	L37747	5	<u>NT 023326.1</u> -	122.981.845-123.022.988
pro212	Z36714	2	<u>NT 005370.3</u> -	212.774.647-212.814.782
pro216	X06745	X	<u>NT 011821.1</u> ?	21.110.482-21.151.898
pro225	T75292	4	<u>NT 006088.3</u> +	82.210.258-82.250.894
pro228	U38979	1	<u>NT 021930.3</u> +	97.904.873-97.945.550
pro229	AL031778	6	<u>NT 016968</u>	
pro230	AA044787	5	<u>NT 006964.3</u> -	154.054.000-154.122.000
pro232	M77481	X	<u>NT 011534.1</u> +	138.236.000-138.766.000
pro234	AL021397	1	<u>NT 004668</u>	
pro239	AA595596	1	<u>NT 004668</u>	
pro240	W25874	4	<u>NT 006088.3</u> +	82.210.000-82.256.000
pro241	AC004774	7	<u>NT 007816</u>	
Pro245	AF006010	8	<u>NT 007978.3</u> -	104.966.000-105.280.000

pro254	AA733050	1	<u>NT 004662.3</u> +	175.107.000-175.116.000
pro260	AF094481	3	<u>NT 005791.3</u> -	84.866.000-84.938.000
pro268	L16991	5	<u>NT 023126.3</u> -	20.814.448-20.854.499
pro273	AC004770	11	<u>NT 004686; 11q12</u>	64224936-64225035
pro280	AI985964	21	<u>NT 011514.4</u> -	43.166.000-43.211.000
pro284	AA926959	5	<u>NT 006687.3</u> -	48.821.840-48.862.512
pro292	U28386	4	<u>NT 006109.2</u> -	: 89.638.000-89.682.000
pro299	AI087268	6	<u>NT 007193.3</u> +	38.723.000-38.783.000
pro302	AF014837	14	<u>NT 019583.3</u> +	18.376.000-18.432.000
pro303	AI570572	22	<u>NT 011520.5</u> +	33.485.000-33.531.000
pro304	L17131	2	<u>NT 005428.3</u> -	76.252.000-76.295.000
pro306	AI740522	6	<u>NT 007234.3</u> -	128.840.581-128.881.528
pro328	M15796	X	<u>NT 011568.3</u> -	33.655.000-33.706.000
		20	<u>NT 011387.3</u> -	4.068.000-4.115.000
pro329	D00596	18	<u>NT 011005.3</u> +	849.000.000-872.000.000
pro331	W27939	12	<u>NT 009785.3</u> ?	49.701.000-49.745.000
pro338	AA768912	10	<u>NT 008609.3</u> -	26.001.705-26.042.334
pro341	AA877215	1	<u>NT 019273.3</u> -	114.182.965-114.223.575

		13	<u>NT 009952.3</u> +	98.753.071-98.793.770
pro344	X16277	2	<u>NT 005380.3</u> +	10.809.000-10.860.000
pro347	AI032612	1	<u>NT 019269.3</u> -	41.189.000-41.265.000
pro348	AI032612	12	<u>NT 024394.3</u> -	101.992.000-102.107.000
pro352	AI525633	12	<u>NT 009785.3</u> ?	49.699.479-49.740.007
pro358	N95406	7	<u>NT 007816.3</u> ?	96.997.000-97.064.000
pro361	AA255502	6	<u>NT 007592.3</u> +	28.000.000-32.000.000

Table 4 First nucleic acid sequences indicating accession no. in the human genome browser, 12 Dec 2000 draft assembly of the human genome Human genome browser

5

No	Acc. No.	Chromosome	Band	Bases
pro1	M87338	7	7q11.22	67380990-67396543
pro2	U73379	20	20q13.11	46319851-46338917
pro3	X05360	10	10q21.2	64194062-64211044
pro5	M25753	5	5q23.2	137604120-137622654
		5	5q22.2	121662724-121679510
		5	5q13.1	73649568-73666303
pro6	M74558	1	1p33	52577823-52592535
pro7	D38073	6	6p12.2	56968405-56986831
pro8	AF015254	17	17p12	9089031-9106502
pro9	J03626	3	3q21.2	135784683-135799798
pro10	U74612	12	12p13.33	3074066-3089514
pro13	D63880	12	12p13.31	6903002-6917288
pro14	D14657	15	15q22.2	60215632-60231472
pro15	AB024704	20	20q11.21	31872458-31887490

pro16	AI375915 (J04088)	17	17q21.2	42673095-42689004
pro19	U37426	10	10q23.33	99600001-99623479
pro20	AF098162	12	12q13.3	58470993-58506578
pro21	X74330	12	12q13.3	58801599-58817157
pro22	L47276	17	17q21.2	42703746-42719695
pro23	L25876	14	14q22.2	50958791-50974988
pro24	U65410	4	4q26	126153161-126168416
pro25	X13293	20	20q12	44147604-44164046
pro26	X51688	4	4q26	128042847-128058218
pro27	AL080146	15	15q22.1	55104198-55120101
pro29	D88357	10	10q21.2	64199199-64214445
pro30	D26361	1	1q32.1	224035414-224051265
pro31	D14678	6	6p21.31	36374334-36389597
pro32	AF011468	20	20q13.2	36644429-36659811
				58763968-58779170
pro34	AB019987	3	3q25.33	175620714-175635845
pro36	AF053306	15	15q15.1	35625667-35641196
pro38	AF032862	5	5q34	178469476-178486752
pro39	U01038	16	16p21.1	28930379-28945875
pro40	D13633	14	14q22.3	29043898-29059035
				51960394-51975921
pro41	AJ000186	4	4q26	126153146-126168525
pro42	D26018	11	11q13.4	79445361-79460511
pro43	X02308	18	18p11.32	931580-947280
pro44	AF016371	1	1p34.1	47366616-47382271
pro45	U05340	1	1p34.1	48138801-48153800
pro46	D80008	20	20p11.21	27258467-27274295
pro47	AB000449	14	14q32.2	96123633-96139456
pro48	AF017790	18	18p11.32	2615001-2630207
pro50	X51688	4	4q26	128041767-128057590
pro51	AF081280	10	10q24.32	109292185-109308954
pro52	M86699	6	6q14.1	85882001-85897200
pro54	X74794	8	8q11.22	50261007-50276309
pro56	AB006624	12	12q13.3	59174501-59189500
pro57	L38933	17	17q21.2	45056497-45072182
pro58	AB018334	5	5p13.2	40319301-40338000
pro59	AF091433	8	8q22.1	98382913-98396920
pro60	Z29066	1	1q32.3	237405001-237420000
pro61	D79988	12	12q24.31	133269001-133284000
				133230501-133245500

pro63	AL05015	8	8q24.3	14393088-8952036
pro64	D79997	9	9p13.2	39124660-39148000
pro65	L07541	13	13q13.1	32415001-32433000
pro66	U37139	1	1p31.3	71792205-71807237
pro67	Y00272	10	10q21.2	64194599-64211207
pro68	D90070	18	18q21.32	62061499-62077998
pro69	U14518	2	2p23.3	26821351-26836883
pro70	X87843	14	14q23.1	57525402-57541401
pro71	U26727	9	9p21.3	23824001-23840000
pro72	X52142	1	1q42.12	251569001-251584900
pro75	L48692	2	2p13.3	69512098-69527598
pro78	L31801	1	1p13.2	124826201-124843002
				124490069-124506743
pro79	U15552	1	1p22.1	105019659-105034740
pro80	AF039652	17	17p11.2	20094899-20110488
pro81	U79266	11	11q13.2	67334001-67349000
pro82	X92106	17	17q11.2	31700001-31715000
pro84	L07540	12	12q24.23	126266001-126283000
pro85	U76638	2	2q35	219994976-220010675
pro88	L34600	2	2p16.1	56591445-56606916
pro90	D83781	11	11p11.2	48298842-48316506
pro92	X59618	X	Xp11.3	41625001-41640000
pro94	U73704	1	1p22.1	102963001-102978500
pro95	D50923	1	1q42.13	256927030-256942117
pro96	M85085	X	Xq22.1	100331001-100346000
pro98	AF025840	14	14q21.3	46340081-46355371
pro99	AF029670	17	17q23.2	63449001-63464000
pro100	AF070559	13	13q33.1	106141001-106156500
pro101	S78085	6	6q27	180902275-180917523
pro104	U39817	15	15q26.1	87983001-87998000
pro105	L23959	13	13q34	116658001-116673000
pro106	X77743	2	2q24.1	160044918-160062017
pro107	U10564	11	11p15.3	9127192-9142201
pro108	AB028069	7	7q21.12	88435001-88450000
pro109	AF053977	5	5q31.1	150402501-150422204
pro110	U09087	12	12q23.1	104568858-104585221
pro111	AF073362	11	11q21	101407914-101423315
pro113	L49054	3	3q25.32	173904528-173934748
pro114	X04327	7	7q33	139307570-139325937
pro115	AF074723	14	14q24.2	68654211-68669417
pro116	AF091092	1	1p32.3	58583305-58598434

pro117	AF05891	19	19q13.43	7003730-052300
pro118	AF025441	15	15q15.1	36875108-36890661
pro119	AJ006591	4	4q31.1	148771298-148786657
pro124	L36529	18	18p11.32	254219-270019
pro125	X65550	10	10q26.2	138240294-138255077
pro126	M34065	5	5q31.2	150756331-150771379
pro127	L02547	20	20q13.2	58756755-58772000
pro128	U00238	4	4q12	59266501-59283500
pro130	L42450	2	2q31.1	176199115-176214588
pro131	X98253	X	Xq24	122031634-122047863
pro133	U58970	20	20q12	45447501-45463000
pro134	AF077953	18	18q21.1	47833501-47849000
pro135	J00140	5	5q14.1	86483185-86498573
		18	18q11.2	25676581-25692180
pro136	M74093	19	19q12	34192227-34207465
pro137	AF029669	17	17q23.1	63211106-63252789
pro138	AL050019	1	1p36.33	52302-67336
pro140	M68520	12	12q13.2	57983277-57998212
pro141	Y13467	17	17q12	41583543-41598142
pro143	U64805	17	17q21.31	45619001-45639000
pro144	U78082	14	14q24.2	68653184-68668183
pro145	Y15164	X	Xp22.22	13061501-13076500
pro146	AF008442	6	6p21.1	47871392-47886807
pro147	X16901	13	13q14.13	43972520-43990027
pro148	U06632	17	17q23.1	61863000-61878839
pro149	D26069	3	3q29	215253329-215270320
pro150	AF027150	14	14q21.1	35344279-35359894
pro152	D13413	3	3q29	211580067-211591811
pro155	L20320	5	5q13.1	73642669-73657817
pro157	AJ223728	22	22q11.21	16393966-16409005
pro158	AB023215	14	14q24.3	74118287-74135032
pro159	D32002	9	9q22.33	98867915-98884079
pro160	Y18046	6	6q27	177044740-177060727
pro162	U27459	2	2q33.2	206003518-206019965
pro164	D86322	4	4q31.1	147998675-148013849
pro165	Z46376	2	2p12	75788712-75806284
pro167	AF003540	11	11p15.5	2576355-2591604
pro168	D38553	2	2q11.1	94745291-94760990
pro169	M60725	17	17q23.2	64866487-64881241
pro173	L34673	3	3q24	162499055-162515000
pro174	U93867	1	1q21.1	162966980-162983139

pro175	U44754	14	14q23.1	5856775-582473
pro177	AL050405	X	Xq26.1	132444071-132459420
pro179	U18937	5	5q31.3	153395323-153411137
pro180	X76388	4	4q31.21	152639006-152654005
pro181	AF038662	3	3q13.32	129394716-129409918
pro182	AF042169	10	10q22.1	74034210-74049959
pro185	U07804	20	20q12	41507121-41523513
pro187	M97388	1	1p22.1	104042438-104058335
pro189	L35546	1	1p22.1	104986774-105006727
pro191	AB007962	1	1q21.3	170103257-170119230
pro193	AF006259	12	12p13.22	4781441-4796771
pro195	X78627	2	2q14.3	123494635-123511228
pro196	M62810	10	10q21.1	61677452-61693234
pro197	AL080116	6	6q15	94998657-95013656
pro199	U79256	10	10q24.1	104501013-104516982
pro201	AL080088	16	16p13.2	11860550-11875029
pro203	M27878	12	12q24.33	144471103-144484312
pro204	AF091090	1	1p22.2	99597586-99612101
pro205	AF067656	10	10q21.1	59448924-59463923
pro206	U03911	2	2p16.3	48415852-48431851
pro207	U61145	7	7q36.1	155082360-155098279
pro208	D78335	1	1q23.3	187227102-187243552
pro209	U30872	1	1q41	240503771-240519770
pro211	U97188	7	7p15.3	23230613-23248257
		6	6q27	176760451-176776177
pro213	D38550	6	6p22.3	22232782-22247803
pro215	X15331	X	Xq22.3	108009046-108024961
pro217	D87448	3	3q22.1	146018136-146033999
pro219	U31556	8	8q21.3	88467142-88482808
pro220	X66113	1	1p36.22	11562849-11578096
pro221	M93119	20	20p11.23	21882614-21898000
pro222	AB020670	18	18q23	83636442-83651891
pro223	AF000430	12	12p11.21	33646020-33661381
pro224	U73960	7	7p21.3	11968001-11983000
pro226	X76029	4	4q12	58426181-58442374
pro227	AF063020	9	9p22.3	16919890-16934979
pro231	AJ132440	1	1q32.1	226438005-226453537
pro233	AB024401	13	13q34	113595323-113611692
pro235	AL049266	2	2q32.1	190196543-190212071
pro236	AB014550	18	18p11.32	2784040-2799481
pro237	X78932	7	7q11.21	64013301-64028356

pro238	U22377	1	1p34.2	4468392-599429
pro242	L16782	10	10q23.31	96533196-96548690
pro243	AJ001810	16	16q12.2	63707495-63722576
pro244	U16028	2	2q31.1	178830447-178845919
pro246	L08424	12	12q23.2	109949544-109964900
pro247	U07559	5	5q11.2	53964473-53980257
pro248	Y10043	X	Xq28	155144719-155160264
pro249	S74445	15	15q24.2	74840231-74855495
pro250	U25165	3	3q26.33	196934501-196950372
pro251	U63336	6	6p21.33	33662019-33677856
pro253	U13022	7	7q35	149686107-149702331
pro255	AB019494	5	5p13.2	39907204-39922203
pro256	L07919	2	2q31.1	175756788-175772636
pro257	AB029006	2	2p22.3	32520144-32540169
pro258	AB028995	17	17q23.2	63475124-63497063
pro259	U62325	2	2q35	223126524-223141423
pro262	X54942	9	9q22.1	87899001-87915976
pro263	U10860	4	4p16.1	9058241-9073583
pro264	M87339	3	3q27.3	204899461-204915188
pro267	X59543	11	11p15.5	3340168-3358000
pro269	M76180	7	7p12.2	51709937-51727010
pro270	M92299	17	17q21.32	52711008-52726713
pro271	AB028021	20	20p11.21	25363017-25378980
pro272	Y16752	6	6p22.2	27692102-27707775
pro275	U96131	5	5p15.33	1133261-1148076
pro277	X84194	14	14q24.3	73530456-73545798
pro278	D82345	X	Xq22.1	102209954-102227610
pro279	L36818	11	11q13.4	76825241-76843255
pro282	V00568	8	8q24.13	130952716-130971510
pro283	U87459	X	Xq28	157900553-157917852
pro285	X16396	2	2p12	74933738-74953722
pro286	AF007140	19	19p13.2	10684785-10702574
pro287	AF053641	20	20q13.13	50999953-51020590
pro289	X55110	11	11p11.2	47010261-47026357
pro290	U84573	3	3q24	159499984-159525599
		X	Xq26.2	137568108-137581997
pro291	M97856	1	1p34.1	50925640-50946744
pro293	AB011173	1	1p36.12	25196653-25221848
pro294	U34994	3	3p24.3	25352447-25367957
pro295	Y18004	X	Xp22.13	18909706-18961865
pro296	D78611	7	7q32.2	133415266-133433462

pro297	D55718	7	7q22.1	1016566-1674644
pro298	L19183	17	17q11.2	29841430-29862449
pro300	X00737	14	14q11.2	16658977-16678611
pro301	X14850	9	9q21.12	73041595-73057571
pro305	M63180	5	5p13.3	32613067-32631841
pro307	AB014458	1	1p31.3	70502659-70519495
pro308	L07493	7	7p22.1	6711371-6728698
pro309	AF041474	3	3q26.33	198844404-198867622
pro310	Y18418	3	3q21.3	139858490-139872261
pro311	M94362	NA_random		1360953-1386439
pro312	U50939	16	16q22.1	75154638-75172659
pro313	D64110	21	21q11.2	15926421-15943327
pro315	M91670	17	17p11.2	17349263-17365467
		10	10p11.21	38991035-39007459
pro316	X64229	6	6p22.3	19889797-19909681
pro317	X53793	4	4q12	59189280-59209671
pro318	AL080119	1	1p31.2	76612579-76631294
pro319	D28423	6	6p21.31	40691099-40706383
pro320	U35451	17	17q21.32	52107808-52124651
pro321	U94319	9	9p22.3	16952805-16970295
pro322	M30938	2	2q35	221329992-221351121
pro323	AF047473	10	10q26.12	132970590-132988540
pro324	L33930	6	6q21	114313634-114328131
pro326	X62534	4	4q34.1	182348719-182364558
pro327	D84557	2	2q22.1	138697866-138715350
pro330	D21063	3	3q21.3	139528312-139551423
pro332	U90426	19	19p13.13	15547854-15568398
pro333	D00762	14	14q23.1	55012125-55034336
pro334	U72066	18	18q11.2	22625608-22643453
pro335	M86737	11	11q12.1	57630355-57653499
pro336	D13627	21	21q21.3	27298411-27317280
pro337	X01060	3	3q29	216708325-216729920
pro339	AF039022	20	20q11.22	34329184-34345180
pro340	L27706	7	7p11.2	57350245-57365971
pro346	AF035316	6	6p25.2	3491115-3506631
pro349	U25182	X	Xp22.12	22338422-22357291
pro353	X74262	1	1p35.1	35716074-35777340
pro354	J02645	14	14q23.3	64971951-64997045
pro355	M37583	4	4q24	104191912-104207386
pro356	U37689	3	3q27.2	202022093-202041189
pro359	U09510	7	7p14.3	30543349-30559412

Pro362	X04741	4	4p4	3992685	927127
--------	--------	---	-----	---------	--------

Preferably, the first nucleic acid sequences are selected from the group consisting of
 pro1, pro2, pro3, pro4, pro5, pro6, pro7, pro8, pro9, pro10, pro12, pro13, pro14,
 5 pro15, pro16, pro17, pro18, pro19, pro20, pro21, pro22, pro23, pro24, pro25, pro26,
 pro27, pro28, pro29, pro30, pro31, pro32, pro34, pro36, pro37, pro38, pro39, pro40,
 pro41, pro42, pro43, pro44, pro45, pro46, pro47, pro48, pro49, pro50, pro51, pro52,
 pro53, pro54, pro55, pro56, pro57, pro58, pro59, pro60, pro61, pro62, pro63, pro64,
 pro65, pro66, pro67, pro68, pro69, pro70, pro71, pro72, pro73, pro74, pro75, pro76,
 10 pro77, pro78, pro79, pro80, pro81, pro82, pro83, pro84, pro85, pro86, pro87, pro88,
 pro89, pro90, pro91, pro92, pro93, pro94, pro95, pro96, pro97, pro98, pro99,
 pro100, pro101, pro103, pro104, pro105, pro106, pro107, pro108, pro109, pro110,
 pro111, pro112, pro113, pro114, pro115, pro116, pro117, pro118, pro119, pro120,
 pro121, pro122, pro123, pro124, pro125, pro126, pro127, pro128, pro129, pro130,
 15 pro131, pro133, pro134, pro135, pro136, pro137, pro138, pro139, pro140, pro141,
 pro142, pro143, pro144, pro145, pro146, pro147, pro148, pro149, pro150, pro152,
 pro153, pro154, pro155, pro156, pro157, pro158, pro159, pro160, pro161, pro162,
 pro163, pro164, pro165, pro166, pro167, pro168, pro169, pro171, pro172, pro173,
 pro174, pro175, pro176, pro177, pro178, pro179, pro180, pro181, pro182, pro183,
 20 pro184, pro185, pro187, pro189, pro191, pro193, pro194, pro195, pro196, pro197,
 pro198, pro199, pro201, pro202, pro203, pro204, pro205, pro206, pro207, pro208,
 pro209, pro210, pro211, pro212, pro213, pro215, pro216, pro217, pro219, pro220,
 pro221, pro222, pro223, pro224, pro225, pro226, pro227, pro228, pro229, pro230,
 pro231, pro232, pro233, pro234, pro235, pro236, pro237, pro238, pro239, pro240,
 25 pro241, pro242, pro243, pro244, pro245, pro246, pro247, pro248, pro249, pro250,
 pro251, pro253, pro254, pro255, pro256, pro257, pro258, pro259, pro260, pro262,
 pro263, pro264, pro267, pro268, pro269, pro270, pro271, pro272, pro273, pro275,
 pro277, pro278, pro279, pro280, pro282, pro283, pro284, pro285, pro286, pro287,
 pro289, pro290, pro291, pro292, pro293, pro294, pro295, pro296, pro297, pro298,
 30 pro299, pro300, pro301, pro302, pro303, pro304, pro305, pro306, pro307, pro308,
 pro309, pro310, pro311, pro312, pro313, pro315, pro316, pro317, pro318, pro319,
 pro320, pro321, pro322, pro323, pro324, pro326, pro327, pro328, pro329, pro330,
 pro331, pro332, pro333, pro334, pro335, pro336, pro337, pro338, pro339, pro340,

pro341, pro344, pro346, pro347, pro348, pro349, pro352, pro353, pro354, pro355, pro356, pro358, pro359 and pro361.

5 More preferably, the first nucleic acid sequence is selected from the group consisting of pro1, pro2, pro3, pro4, pro5, pro6, pro7, pro8, pro9, pro10, pro12, pro13, pro14, pro15, pro16, pro17, pro18, pro19, pro21, pro22, pro23, pro24, pro25, pro26, pro27, pro28, pro29, pro30, pro31, pro32, pro34, pro36, pro37, pro38, pro39, pro40, pro41, pro42, pro43, pro44, pro45, pro46, pro47, pro48, pro49, pro50, pro51, pro52, pro53, pro54, pro56, pro58, pro59, pro62, pro64, pro65, pro66, pro68, pro69, pro70, 10 pro71, pro72, pro73, pro74, pro75, pro77, pro78, pro81, pro82, pro85, pro86, pro87, pro89, pro90, pro92, pro98, pro103, pro105, pro108, pro120, pro125, pro128, pro130, pro133, pro135, pro136, pro137, pro157, pro184, pro205, pro206, pro207, pro209, pro210, pro211, pro212, pro216, pro217, pro219, pro221, pro227, pro231, pro233, pro241, pro246, pro248, pro249, pro253 and pro256.

15 Yet more preferably, the first nucleic acid sequences are selected from the group consisting of pro1, pro2, pro3, pro4, pro5, pro7, pro8, pro14, pro15, pro16, pro22, pro23, pro24, pro26, pro27, pro29, pro34, pro37, pro38, pro39, pro40, pro45, pro46, pro48, pro49, pro50, pro52, pro59, pro69, pro71, pro74, pro77, pro86, pro87, pro89, 20 pro184, pro205, pro206, pro207, pro209, pro210, pro211, pro221, pro241, pro246, pro248 and pro256.

Even more preferably, the first nucleic acid sequences are selected from the group consisting of pro2, pro4, pro8, pro14, pro15, pro16, pro22, pro49, pro74, pro86, 25 pro87, pro89, pro205, pro221, pro246,

Most preferably, the first nucleic acid sequences are selected from the group consisting of pro221, pro210, pro71, pro41, pro30, pro2, pro209, pro14, pro4, pro8, pro246, pro16, pro27, pro5, pro49, pro19, pro140, pro139, pro207, pro81, pro273 30 and pro362.

In another preferred embodiment the first nucleic acid sequences are selected from the group consisting of pro1, pro2, pro3, pro4, pro5, pro6, pro7, pro8, pro9, pro10, pro12, pro13, pro14, pro15, pro16, pro17, pro18, pro19, pro20, pro21, pro22, pro23, 35 pro24, pro25, pro26, pro27, pro28, pro29, pro30, pro31, pro32, pro34, pro36, pro37,

pro38, pro39, pro40, pro41, pro42, pro43, pro44, pro45, pro46, pro47, pro48, pro49,
pro50, pro51, pro52, pro53, pro54, pro55, pro56, pro57, pro58, pro59, pro60, pro61,
pro62, pro63, pro64, pro65, pro66, pro67, pro68, pro69, pro70, pro71, pro72, pro73,
pro74, pro75, pro76, pro77, pro78, pro79, pro80, pro81, pro82, pro83, pro84, pro85,
5 pro86, pro87, pro88, pro89, pro90, pro91, pro92, pro93, pro94, pro95, pro96, pro97,
pro98, pro99, pro100, pro101, pro103, pro104, pro105, pro106, pro107, pro108,
pro109, pro110, pro111, pro112, pro113, pro114, pro115, pro116, pro117, pro118,
pro119, pro120, pro121, pro122, pro123, pro124, pro125, pro126, pro127, pro128,
pro129, pro130, pro131, pro133, pro134, pro135, pro136, pro137, pro138, pro139,
10 pro140, pro141, pro142, pro143, pro144, pro145, pro146, pro147, pro148, pro149,
pro150, pro152, pro153, pro154, pro155, pro156, pro157, pro158, pro159, pro160,
pro161, pro162, pro163, pro164, pro165, pro166, pro167, pro168, pro169, pro171,
pro172, pro173, pro174, pro175, pro176, pro177, pro178, pro179, pro180, pro181,
pro182, pro183, pro184, pro185, pro187, pro189, pro191, pro193, pro194, pro195,
15 pro196, pro197, pro198, pro199, pro201, pro202, pro203, pro204, pro205, pro206,
pro207, pro209, pro210, pro211, pro212, pro213, pro216, pro217, pro219, pro220,
pro221, pro222, pro223, pro224, pro225, pro227, pro228, pro229, pro230, pro231,
pro233, pro234, pro235, pro236, pro237, pro238, pro239, pro240, pro241, pro242,
pro243, pro244, pro245, pro246, pro248, pro249, pro250, pro251, pro253, pro254,
20 pro255, pro256, pro257, pro258, pro259, pro260, pro269, pro278, pro282, pro283,
pro284, pro285, pro297, pro315, pro326, pro327, pro328 and pro329.

In one especially preferred embodiment of the present invention, the first nucleic
acid sequence is pro 221 or a fragment thereof or a functional homologue thereof.
25 Pro221 is the promoter of the gene encoding Insulinoma-associated antigen, IA-1,
INSM1. Insulinoma-associated antigen mRNA is expressed at very high levels by all
SCLC tested and only expressed at very low levels in brain and adrenal gland. Ex-
pression has been demonstrated by for example CHIPS analysis and RT-PCR (see
example 1 and figure 3).

30

In another preferred embodiment of the present invention the first nucleic acid se-
quence is pro210 or a fragment thereof or a functional homologue thereof. Pro210 is
the promoter of the gene encoding lamin B, LMNB1. LMNB1 mRNA is expressed at
very high levels by all tested SCLC and is only expressed at very low levels in

spleen, colon and lung. Expression of LMNB1 has been demonstrated by for example CHIPS analysis and RT-PCR (see example 1 and figure 6).

5 In another preferred embodiment of the present invention the first nucleic acid sequence is pro71 or a fragment thereof or a functional homologue thereof. Pro71 is the promoter of the gene encoding p16INK4/MTS1, MTS1, cyclin-dependent kinase inhibitor 2A, CDKN2A. p16INK4/MTS1 mRNA is expressed at very high levels by most SCLC and is only expressed at very low levels or not at all in normal tissues. Expression of LMNB1 has been demonstrated by for example CHIPS analysis and
10 RT-PCR (see example 1 and figure 7).

In another preferred embodiment of the present invention the first nucleic acid sequence is pro41 or a fragment thereof or a functional homologue thereof. Pro41 is the promoter of the gene encoding human MAD2L1, mitotic arrest deficient, yeast
15 homolog-like 1. MAD2L1 mRNA is expressed at very high levels in SCLC and expressed at high levels in testes, but only at low levels in other normal tissues. Expression of MAD2L1 has been demonstrated by for example CHIPS analysis and RT-PCR (see example 1 and figure 5).

20 In another preferred embodiment of the present invention the first nucleic acid sequence is pro30 or a fragment thereof or a functional homologue thereof. Pro30 is the promoter of the human *KIAA0042* gene. *KIAA0042* RNA is expressed at very high levels in most SCLC and in normal tissues it is only expressed at low levels in testes. Expression of *KIAA0042* has been demonstrated by for example CHIPS
25 analysis and RT-PCR (see example 1 and figure 4).

In another preferred embodiment of the present invention the first nucleic acid sequence is pro2 or a fragment thereof or a functional homologue thereof. Pro2 is the promoter of the human gene encoding Human cyclin-selective ubiquitin carrier protein, UBE2C. UBE2C mRNA is expressed at very high levels in most SCLC and in
30 normal tissues it is expressed at low levels in spleen and testes. Expression of UBE2C has been demonstrated by for example CHIPS analysis (see example 1).

In another preferred embodiment of the present invention the first nucleic acid sequence is pro209 or a fragment thereof or a functional homologue thereof. Pro209 is
35

the promoter of the human gene encoding mitotin, CENPF, centromere protein F. CENPF mRNA is expressed at high levels in most SCLC and in normal tissues it is expressed at low levels in testes. Expression of CENPF has been demonstrated by for example CHIPS analysis (see example 1).

5

In another preferred embodiment of the present invention the first nucleic acid sequence is pro14 or a fragment thereof or a functional homologue thereof. Pro14 is the promoter of the human KIAA0101 gene. KIAA0101 RNA is expressed at high levels in most SCLC and in normal tissues it is expressed at low levels in 7 tissues. Expression of KIAA0101 has been demonstrated by for example CHIPS analysis (see example 1).

10

15

In another preferred embodiment of the present invention the first nucleic acid sequence is pro4 or a fragment thereof or a functional homologue thereof. Pro4 is the promoter of the human gene encoding Cyclin protein gene, Proliferating cell nuclear antigen (PCNA). PCNA mRNA is expressed at high levels in most SCLC and in normal tissues it is expressed at low levels in colon, spleen and testes. Expression of PCNA has been demonstrated by for example CHIPS analysis (see example 1).

20

In another preferred embodiment of the present invention the first nucleic acid sequence is pro8 or a fragment thereof or a functional homologue thereof. Pro8 is the promoter of the human gene encoding serine/threonine kinase, STK-1, STK12, fms-related tyrosine kinase 3. STK-1mRNA is expressed at high levels in SCLC and in normal tissues it is expressed at low levels in colon, spleen and testes. Expression of STK-1 has been demonstrated by for example CHIPS analysis (see example 1).

25

30

In another preferred embodiment of the present invention the first nucleic acid sequence is pro246 or a fragment thereof or a functional homologue thereof. Pro246 is the promoter of the human gene encoding Achaete scute homologous protein, ASH1, ASCL1. ASH1 mRNA is expressed at high levels in many SCLC and in normal tissues it is expressed at low levels in brain. Expression of ASH1 has been demonstrated by for example CHIPS analysis (see example 1).

35

In another preferred embodiment of the present invention the first nucleic acid sequence is pro16 or a fragment thereof or a functional homologue thereof. Pro16 is

the promoter of the human gene encoding DNA topoisomerase II α (170 kD), TOP2A. TOP2A mRNA is expressed at high levels in SCLC and in normal tissues it is expressed at low levels in 9 tissues and at high levels in testes. Expression of TOP2A has been demonstrated by for example CHIPS analysis (see example 1).

5

In another preferred embodiment of the present invention the first nucleic acid sequence is pro27 or a fragment thereof or a functional homologue thereof. Pro27 is the promoter of the human gene encoding Cyclin B2, CCNB2. Cyclin B2 mRNA is expressed at high levels in SCLC and in normal tissues it is expressed at low levels in spleen and trachea and at high levels in testes. Expression of Cyclin B2 has been demonstrated by for example CHIPS analysis (see example 1).

10

In another preferred embodiment of the present invention the first nucleic acid sequence is pro5 or a fragment thereof or a functional homologue thereof. Pro5 is the promoter of the human gene encoding Cyclin B1, CCNB1. Cyclin B1 mRNA is expressed at high levels in SCLC and in normal tissues it is expressed at low levels in colon, spleen and trachea and at high levels in testes. Expression of Cyclin B1 has been demonstrated by for example CHIPS analysis (see example 1).

15

In another preferred embodiment of the present invention the first nucleic acid sequence is pro49 or a fragment thereof or a functional homologue thereof. Pro49 is the promoter of the human gene encoding Pituitary tumor-transforming 1, PTTG1. PTTG1 mRNA is expressed at high levels in SCLC and in normal tissues it is expressed at low levels in thyroid, spleen and trachea and at high levels in testes. Expression of PTTG1 has been demonstrated by for example CHIPS analysis (see example 1).

20

25

In another preferred embodiment of the present invention the first nucleic acid sequence is pro19 or a fragment thereof or a functional homologue thereof. Pro19 is the promoter of the human gene encoding Kinesin-like spindle protein HKSP, KNSL1. KNSL1mRNA is expressed at high levels in SCLC and in normal tissues it is expressed at low levels in colon, small intestine and testes. Expression of KNSL1 has been demonstrated by for example CHIPS analysis (see example 1).

30

In another preferred embodiment of the present invention the first nucleic acid sequence is pro140 or a fragment thereof or a functional homologue thereof. Pro140 is the promoter of the human gene encoding cdc2-related protein kinase, CDK2. CDK2 mRNA is expressed at high levels in SCLC and in normal tissues it is expressed at high levels in spleen. Expression of CDK2 has been demonstrated by for example CHIPS analysis (see example 1).

In another preferred embodiment of the present invention the first nucleic acid sequence is pro139 or a fragment thereof or a functional homologue thereof. Pro139 is the promoter of the human gene encoding Serine/threonine protein kinase SAK. SAK mRNA is expressed at high levels in most SCLC and in normal tissues it is expressed at high levels in testes. Expression of SAK has been demonstrated by for example CHIPS analysis (see example 1).

In another preferred embodiment of the present invention the first nucleic acid sequence is pro207 or a fragment thereof or a functional homologue thereof. Pro207 is the promoter of the human gene encoding Enhancer of zeste homolog 2 (EZH2). EZH2 mRNA is expressed at high levels in SCLC and in normal tissues it is expressed at high levels in testes. Expression of EZH2 has been demonstrated by for example CHIPS analysis (see example 1).

In another preferred embodiment of the present invention the first nucleic acid sequence is pro81 or a fragment thereof or a functional homologue thereof. Pro81 is the promoter of the human *HSU79266* gene. *HSU79266* RNA is expressed at high levels in most SCLC and in normal tissues it is expressed in testes and spleen. Expression of *HSU79266* has been demonstrated by for example CHIPS analysis (see example 1).

In another preferred embodiment of the present invention the first nucleic acid sequence is pro273 or a fragment thereof or a functional homologue thereof. Pro273 is the promoter of the human gene encoding Rad2, flap structure-specific endonuclease 1, FEN1. Rad2 mRNA is expressed at high levels in most SCLC and in normal tissues it is at low levels in 12 tissues. Expression of Rad2 has been demonstrated by for example CHIPS analysis (see example 1).

In another preferred embodiment of the present invention the first amino acid sequence is pro362 or a fragment thereof or a functional homologue thereof. Pro362 is the promoter of the human gene encoding Protein gene product PGP, ubiquitin carboxyl-terminal esterase L1, ubiquitin thiolesterase. PGP mRNA is expressed at high levels in most SCLC and in normal tissues it is expressed at low levels in kidney and high levels in brain. Expression of PGP has been demonstrated by for example CHIPS analysis (see example 1).

Functional homologues

10

Functional homologues of polypeptides according to the present invention is meant to comprise any polypeptide sequence which comprise the same function. For example functional homologues of cell surface molecules are molecules associated with the cell surface which can associate with a binding partner and preferably is capable of internalising the binding partner. Functional homologues of binding partners are molecules which can associate with the cell surface molecule and which preferably is capable of being internalised into cells expressing the cell surface molecule.

20

Functional homologues according to the present invention comprise polypeptides with an amino acid sequence, which are sharing at least some homology with the predetermined polypeptide sequences as outlined herein above. For example such polypeptides are at least about 40 percent, such as at least about 50 percent homologous, for example at least about 60 percent homologous, such as at least about 70 percent homologous, for example at least about 75 percent homologous, such as at least about 80 percent homologous, for example at least about 85 percent homologous, such as at least about 90 percent homologous, for example at least 92 percent homologous, such as at least 94 percent homologous, for example at least 95 percent homologous, such as at least 96 percent homologous, for example at least 97 percent homologous, such as at least 98 percent homologous, for example at least 99 percent homologous with any of the predetermined polypeptide sequences as outlined herein.

30

The homology between amino acid sequences may be calculated using well known algorithms such as for example any one of BLOSUM 30, BLOSUM 40, BLOSUM 45, BLOSUM 50, BLOSUM 55, BLOSUM 60, BLOSUM 62, BLOSUM 65, BLOSUM 70, BLOSUM 75, BLOSUM 80, BLOSUM 85, and BLOSUM 90.

5

Functional homologues may comprise an amino acid sequence that comprises at least one substitution of one amino acid for any other amino acid. For example such a substitution may be a conservative amino acid substitution or it may be a non-conservative substitution.

10

A conservative amino acid substitution is a substitution of one amino acid within a predetermined group of amino acids for another amino acid within the same group, wherein the amino acids within a predetermined groups exhibit similar or substantially similar characteristics. Within the meaning of the term "conservative amino acid substitution" as applied herein, one amino acid may be substituted for another within groups of amino acids characterised by having

15

i) polar side chains (Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, and Cys,)

20

ii) non-polar side chains (Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, and Met)

iii) aliphatic side chains (Gly, Ala Val, Leu, Ile)

iv) cyclic side chains (Phe, Tyr, Trp, His, Pro)

25

v) aromatic side chains (Phe, Tyr, Trp)

vi) acidic side chains (Asp, Glu)

30

vii) basic side chains (Lys, Arg, His)

viii) amide side chains (Asn, Gln)

ix) hydroxy side chains (Ser, Thr)

35

- x) sulphur-containing side chains (Cys, Met), and
- xi) amino acids being monoamino-dicarboxylic acids or monoamino-monocarboxylic-monoamidocarboxylic acids (Asp, Glu, Asn, Gln).

5

Non-conservative substitutions are any other substitutions. A non-conservative substitution leading to the formation of a functional homologue would for example i) differ substantially in hydrophobicity, for example a hydrophobic residue (Val, Ile, Leu, Phe or Met) substituted for a hydrophilic residue such as Arg, Lys, Trp or Asn, or a hydrophilic residue such as Thr, Ser, His, Gln, Asn, Lys, Asp, Glu or Trp substituted for a hydrophobic residue; and/or ii) differ substantially in its effect on polypeptide backbone orientation such as substitution of or for Pro or Gly by another residue; and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having a minor side chain, e.g. Ala, Gly or Ser (and vice versa).

10

15

20

25

Functional homologues according to the present invention may comprise more than one such substitution, such as e.g. two amino acid substitutions, for example three or four amino acid substitutions, such as five or six amino acid substitutions, for example seven or eight amino acid substitutions, such as from 10 to 15 amino acid substitutions, for example from 15 to 25 amino acid substitution, such as from 25 to 30 amino acid substitutions, for example from 30 to 40 amino acid substitution, such as from 40 to 50 amino acid substitutions, for example from 50 to 75 amino acid substitution, such as from 75 to 100 amino acid substitutions, for example more than 100 amino acid substitutions.

30

The addition or deletion of an amino acid may be an addition or deletion of from 2 to 5 amino acids, such as from 5 to 10 amino acids, for example from 10 to 20 amino acids, such as from 20 to 50 amino acids. However, additions or deletions of more than 50 amino acids, such as additions from 50 to 200 amino acids, are also comprised within the present invention.

The polypeptides according to the present invention, including variants and functional homologues thereof, may in one embodiment comprise more than 5 amino acid residues, such as more than 10 amino acid residues, for example more than 20 amino acid residues, such as more than 25 amino acid residues, for example more than 50 amino acid residues, such as more than 75 amino acid residues, for example more than 100 amino acid residues, such as more than 150 amino acid residues, for example more than 200 amino acid residues.

Additional factors may be taken into consideration when determining functional homologues according to the meaning used herein. For example functional homologues may be capable of associating with antisera which are specific for the polypeptides according to the present invention.

In a further embodiment the present invention relates to functional equivalents which comprise substituted amino acids having hydrophilic or hydrophobic indices that are within ± 2.5 , for example within ± 2.3 , such as within ± 2.1 , for example within ± 2.0 , such as within ± 1.8 , for example within ± 1.6 , such as within ± 1.5 , for example within ± 1.4 , such as within ± 1.3 for example within ± 1.2 , such as within ± 1.1 , for example within ± 1.0 , such as within ± 0.9 , for example within ± 0.8 , such as within ± 0.7 , for example within ± 0.6 , such as within ± 0.5 , for example within ± 0.4 , such as within ± 0.3 , for example within ± 0.25 , such as within ± 0.2 of the value of the amino acid it has substituted.

The importance of the hydrophilic and hydrophobic amino acid indices in conferring interactive biologic function on a protein is well understood in the art (Kyte & Doolittle, 1982 and Hopp, U.S. Pat. No. 4,554,101, each incorporated herein by reference).

The amino acid hydrophobic index values as used herein are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5) (Kyte & Doolittle, 1982).

The amino acid hydrophobicity values are: arginine (+3.0); lysine (+3.0); aspartate (+3.0+-.1); glutamate (+3.0+-.1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5+-.1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4) (U.S. 4,554,101).

Substitution of amino acids can therefore in one embodiment be made based upon their hydrophobicity and hydrophilicity values and the relative similarity of the amino acid side-chain substituents, including charge, size, and the like. Exemplary amino acid substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

In addition to the polypeptide compounds described herein, sterically similar compounds may be formulated to mimic the key portions of the peptide structure and that such compounds may also be used in the same manner as the peptides of the invention. This may be achieved by techniques of modelling and chemical designing known to those of skill in the art. For example, esterification and other alkylations may be employed to modify the amino terminus of, e.g., a di-arginine peptide backbone, to mimic a tetra peptide structure. It will be understood that all such sterically similar constructs fall within the scope of the present invention.

Peptides with N-terminal alkylations and C-terminal esterifications are also encompassed within the present invention. Functional equivalents also comprise glycosylated and covalent or aggregative conjugates, including dimers or unrelated chemical moieties. Such functional equivalents are prepared by linkage of functionalities to groups which are found in fragment including at any one or both of the N- and C-termini, by means known in the art.

Functional equivalents may thus comprise fragments conjugated to aliphatic or acyl esters or amides of the carboxyl terminus, alkylamines or residues containing carboxyl side chains, e.g., conjugates to alkylamines at aspartic acid residues; O-acyl derivatives of hydroxyl group-containing residues and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g. conjugates with

Met-Leu-Phe. Derivatives of the acyl groups are selected from the group of alkyl-moieties (including C3 to C10 normal alkyl), thereby forming alkanoyl species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The reactive groups preferably are difunctional compounds known per se for use in cross-linking proteins to insoluble matrices through reactive side groups:

Homologues of nucleic acid sequences within the scope of the present invention are nucleic acid sequences, which

- 10 i) encodes an RNA and/or a protein with similar biological function;
 or
 ii) is capable of exerting a similar biological influence;

and which is

- 15 a) at least 50% identical, such as at least 60% identical, for example at least 70% identical, such as at least 75% identical, for example at least 80% identical, such as at least 85% identical, for example at least 90% identical, such as at least 95% identical
- 20 b) or able to hybridise to the complementary strand of said nucleic acid sequence under stringent conditions.

A similar biological influence within this context may for example be that the nucleic acid sequence is capable influencing transcription of second nucleic acid sequences operably linked thereto in a fashion similar to functional homologous thereof.

Stringent conditions as used herein shall denote stringency as normally applied in connection with Southern blotting and hybridisation as described e.g. by Southern E. M., 1975, J. Mol. Biol. 98:503-517. For such purposes it is routine practise to include steps of prehybridization and hybridization. Such steps are normally performed using solutions containing 6x SSPE, 5% Denhardt's, 0.5% SDS, 50% formamide, 100 µg/ml denaturated salmon testis DNA (incubation for 18 hrs at 42°C), followed by washings with 2x SSC and 0.5% SDS (at room temperature and at 37°C), and a washing with 0.1x SSC and 0.5% SDS (incubation at 68°C for 30 min), as described

by Sambrook et al., 1989, in "Molecular Cloning/A Laboratory Manual", Cold Spring Harbor), which is incorporated herein by reference.

5 Homologous of nucleic acid sequences also encompass nucleic acid sequences which comprise additions and/or deletions. Such additions and/or deletions may be internal or at the end. Additions and/or deletions may be of 1-5 nucleotides, such as 5 to 10 nucleotide, for example 10 to 50 nucleotides, such as 50 to 100 nucleotides, for example at least 100 nucleotides.

10 Vaccine

In one embodiment of the present invention the cell surface molecules may be used for the preparation of a vaccine. Preferably such a vaccine is capable of raising an immune response against the cell surface molecule. Such an immune response
15 preferably results in specific killing of cells expressing said cell surface molecule. Most preferably, the cells expressing the cell surface molecule are malignant cells, such as the vaccine results in specific killing of malignant cells.

Accordingly, the vaccine is preferably suitable for ameliorating and/or curative
20 and/or prophylactic treatment of a premalignant and/or malignant condition. Hence, the vaccine preferably should be administrated to an individual suffering from a premalignant and/or malignant conditions, preferably cancer. The individual may be any animal, however preferably the individual is a human being.

25 It is possible to use either the cell surface molecule or fragments thereof or derivatives thereof as well as nucleic acids encoding the cell surface molecule or fragments thereof or derivatives thereof. Preferred cell surface molecules to use with such a vaccine are cell surface molecules which are expressed at a higher level in malignant cells in vivo and/or malignant cell lines than in normal tissues. For
30 example such a cell surface molecule may be identified according to the methods outlined herein above. However, other suitable cell surface molecules may also be employed.

Preferably, the cell surface molecule comprises or essentially consists of or for example is GRIA2, such as LPR8, for example is CHRNA5, such as TMEFF, for example is NPTXR, such as Transferrin receptor; such as type II membrane protein clone: for example is HP10481; such as type II membrane protein clone: such as HP10390; for example is PG40; such as TRC8 ; for example is TR2-11; such as OA3 antigenic surface determinant; for example is integrin alpha 6, For example GPIIb; such as vitronectin receptor alpha subunit; for example is integrin alpha-7; such as integrin alpha E precursor; for example is integrin alpha 6B; such as integrin alpha 5 subunit; for example is integrin beta-5 subunit; such as integrin alpha-3 chain; for example is RYK; such as amyloid precursor protein-binding protein 1; for example is putative transmembrane GTPase; such as membrane cofactor protein; FOR EXAMPLE GLVR1; for example is Mr 110,000 antigen; for example is syndecan-1; such as putative seven transmembrane domain protein; for example is LCA-homolog/ LAR protein; such as M6 antigen; for example is Me491/CD63 antigen; such as multispinning membrane protein; for example is DDR; such as autocrine motility factor receptor; for example is insulin receptor precursor; such as IGF1R, for example is insulin-like growth factor II receptor; such as SAS; for example is TAPA-1; such as MICB; for example is MHC class II HLA-DR7-associated glycoprotein beta-chain; such as HLA-DP; for example is bone small proteoglycan I biglycan; such as CAR; for example is MEA11; such as interferon-gamma receptor alpha chain; for example is Polymeric immunoglobulin receptor; such as metabotropic glutamate receptor type 4; for example is metabotropic glutamate receptor 8; such as CLPTM1; for example is MAGE-4b; such as MAGE5a; for example is MAGE-3; such as MAGE-1; for example is MAGE6; such as MAGE-9; for example is MAGE11; such as CD24; for example is CD59; such as CD44; for example is low density lipoprotein receptor; such as very low density lipoprotein receptor; for example is N-CAM; such as lamin B receptor homolog TM7SF2; for example is putative T1/ST2 receptor binding protein precursor; such as NTR2 receptor; for example is RAGE-4; such as HLA-G1; for example is MOAT-C; such as alpha 2 delta calcium channel subunit isoform I; for example is LFA-3; such as L1-CAM; for example is AVPR2; such as C1 p115 C1; for example is TE2; such as RbP; for example is HCF1; such as IRAK; for example is CD151; such as surface antigen; for example is MAG; such as GPR19; for example is pcta-1; such as PRAME; for example is vasopressin activated calcium mobilizing receptor-like protein; such as serotonin receptor 5-HT4B; for example is serotonin 1D receptor (5-

HT1D~); such as CD9; for example is LDL receptor member LR3; for example is DR6; for example is tumor necrosis factor receptor; such as HG38; for example is urokinase-type plasminogen receptor; such as FGF receptor; for example is nerve growth factor receptor; such as cystine/glutamate transporter; for example is CB1
5 cannabinoid receptor (CNR1); such as PSG; for example is PSG13'; such as CPE-receptor; for example is CRH2R; such as OC15; for example is TRAIL receptor 2; such as HNMP-1; for example is kidney alpha-2-adrenergic receptor; such as erythropoietin receptor; for example is chondroitin sulphate proteoglycan versican V1; for example is mGluR1beta; such as CD97; for example is L6; such as NY-ESO-
10 1; for example is T-cell receptor alpha delta; such as ror1; for example is ror2; such as SSTR2; for example is VESPR; such as IgG Fc receptor; for example is glutamate receptor subunit GluRC; such as HEK2; for example is PVR; such as CEA; for example is CC-chemokine-binding receptor JAB61; such as HER2; for example is HER3; such as hypothetical protein FLJ22357 similar to Epidermal
15 growth factor receptor-related protein; for example is putative endothelin receptor type B-like protein; such as GLVR2; for example is P2X4 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clearance receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B receptor; for example is GFRA3; such as GRPR; for example is CDH1; such as CDH2; for example is TGFBR1; such
20 as TGFBR2; for example is TGFBR3; such as precursor of epidermal growth factor receptor.

More preferably, the cell surface molecule is selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, GRIA2, GRM8, ITGAV, ITGAE, TNFRSF12,
25 L1CAM, GPR49 and TMEFF1.

In one preferred embodiment the vaccine furthermore comprise a non-self antigen covalently linked to said cell surface molecule. Alternatively, when nucleic acid sequences encoding cell surface molecules are used, the vaccine may comprise
30 second nucleic acid sequences encoding a non-self antigen linked to the nucleic acid sequences.

Examples of non-self antigens which may be used with the present invention are invention are T-cell epitopes, preferably polypeptides or peptide.

It is also possible that the vaccine comprises more than one antigen such as 2, for example 3, such as 4, for example 5, such as more than 5 different antigens. The antigens may be self antigens or non-self antigens.

- 5 The vaccine according to the present invention may furthermore comprise an adjuvant and /or a carrier. The carrier or adjuvant could be any carrier or adjuvant known in the art including functional equivalents thereof. Functionally equivalent carriers are capable of presenting the same antigen in essentially the same steric conformation when used under similar conditions. Functionally equivalent adjuvants
- 10 are capable of providing similar increases in the efficacy of the composition when used under similar conditions.
- Preferably, said compositions comprise potent, nontoxic adjuvants that will enhance and/or modulate the immunogenicity of immunogenic determinants including anti-
- 15 genic determinants including haptenic determinants represent one group of preferred adjuvants. In addition, such adjuvants preferably also elicit an earlier, more potent, or more prolonged immune response. Such an adjuvant would also be useful in cases where an antigen supply is limited or is costly to produce.
- 20 Adjuvants pertaining to the present invention may be grouped according to their origin, be it mineral, bacterial, plant, synthetic, or host product. The first group under this classification is the mineral adjuvants, such as aluminum compounds. Antigens precipitated with aluminum salts or antigens mixed with or adsorbed to performed aluminum compounds have been used extensively to augment immune responses
- 25 in animals and humans. Aluminium particles have been demonstrated in regional lymph nodes of rabbits seven days following immunisation, and it may be that another significant function is to direct antigen to T cell containing areas in the nodes themselves. Adjuvant potency has been shown to correlate with intimation of the draining lymph nodes. While many studies have confirmed that antigens administered with aluminium salts lead to increased humoral immunity, cell mediated immunity appears to be only slightly increased, as measured by delayed-type hypersensi-
- 30 tivity. Aluminium hydroxide has also been described as activating the complement pathway. This mechanism may play a role in the local inflammatory response as well as immunoglobulin production and B cell memory. Furthermore, aluminium hydroxide can protect the antigen from rapid catabolism. Primarily because of their
- 35

excellent record of safety, aluminum compounds are presently only adjuvants used in humans.

Another large group of adjuvants is those of bacterial origin. Adjuvants with bacterial origins can be purified and synthesised (e.g. muramyl dipeptides, lipid A) and host mediators have been cloned (Interleukin 1 and 2). The last decade has brought significant progress in the chemical purification of several adjuvants of active components of bacterial origin: Bordetella pertussis, Mycobacterium tuberculosis, lipopolysaccharide, Freund's Complete Adjuvant (FCA) and Freund's Incomplete Adjuvant (Difco Laboratories, Detroit, Mich.) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.). Additionally suitable adjuvants in accordance with the present invention are e.g. Titermax Classical adjuvant (SIGMA-ALDRICH), ISCOMS, Quil A, ALUN, see US 58767 and 5,554,372, Lipid A derivatives, cholera toxin derivatives, HSP derivatives, LPS derivatives, synthetic peptide matrixes, GMDP, and other as well as combined with immunostimulants (US 5,876,735).

B. pertussis is of interest as an adjuvant in the context of the present invention due to its ability to modulate cell-mediated immunity through action on T-lymphocyte populations. For lipopolysaccharide and Freund's Complete Adjuvant, adjuvant active moieties have been identified and synthesised which permit study of structure-function relationships. These are also considered for inclusion in immunogenic compositions according to the present invention.

Lipopolysaccharide and its various derivatives, including lipid A, have been found to be powerful adjuvants in combination with liposomes or other lipid emulsions. It is not yet certain whether derivatives with sufficiently low toxicity for general use in humans can be produced. Freund's Complete Adjuvant is the standard in most experimental studies.

Mineral oil may be added to vaccine formulation in order to protect the antigen from rapid catabolism.

Many other types of materials can be used as adjuvants in immunogenic compositions according to the present invention. They include plant products such as saponin, animal products such as chitin and numerous synthetic chemicals.

Adjuvants according to the present invention can also be categorised by their proposed mechanisms of action. This type of classification is necessarily somewhat arbitrary because most adjuvants appear to function by more than one mechanism.

5 Adjuvants may act through antigen localisation and delivery, or by direct effects on cells making up the immune system, such as macrophages and lymphocytes. Another mechanism by which adjuvants according to the invention enhance the immune response is by creation of an antigen depot. This appears to contribute to the adjuvant activity of aluminum compounds, oil emulsions, liposomes, and synthetic
10 polymers. The adjuvant activity of lipopolysaccharides and muramyl dipeptides appears to be mainly mediated through activation of the macrophage, whereas B. pertussis affects both macrophages and lymphocytes. Further examples of adjuvants that may be useful when incorporated into immunogenic compositions according to the present invention are described in US 5,554,372.

15

In one preferred embodiment, adjuvants according to the present invention are selected from the group consisting of aluminium compounds, Freund's incomplete adjuvant, Titermax classical adjuvant and oil emulsions.

20 There is also provided an embodiment of the present invention wherein the immunogenic composition further comprises a carrier. The carrier may be present independently of an adjuvant. The purpose of conjugation and/or co-immunisation of an antigen and a carrier can be e.g. to increase the molecular weight of the antigen in order to increase the activity or immunogenicity of the antigen, to confer stability to
25 the antigen, to increase the biological activity of the determinant, or to increase its serum half-life. The carrier protein may be any conventional carrier including any protein suitable for presenting antigens. Conventional carrier proteins include, but are not limited to, keyhole limpet hemocyanin, serum proteins such as transferrin, bovine serum albumin, or human serum albumin, an ovalbumin, immunoglobulins,
30 or hormones, such as insulin.

While any suitable pharmaceutical carrier known to those of ordinary skill in the art may be employed in the vaccine of this invention, the type of pharmaceutical carrier will vary depending on the mode of administration and whether a sustained release
35 administration is desired. For parenteral administration, such as subcutaneous in-

jection, the pharmaceutical carrier may e.g. comprise water, salt, alcohol, fat, a wax or a buffer. Biodegradable microspheres (e.g., polylactic galactide) may also be employed as pharmaceutical carriers for the pharmaceutical compositions of this invention.

5

In one embodiment of the present invention, the vaccine involves the use of dendritic cells. Such an embodiment preferably comprises the steps of

- i) providing dendritic cells; and
- 10 ii) transferring nucleic acid sequences encoding a cell surface molecule according to the present invention operably linked to second nucleic acid sequences directing expression thereof to the dendritic cells or transferring a cell surface molecule or a fragment thereof to the dendritic cells; and
- 15 iii) displaying said cell surface molecules or fragments thereof on the cell surface of the dendritic cells; and
- iv) transferring said dendritic cells to the individual to be treated

Preferably, the dendritic cells are cells derived from the individual to be treated, 20 however the dendritic cells may also be derived from another individual. When the dendritic cells are derived from another individual, preferably, the cells are derived from the same species as the individual to be treated. For example, if the individual to be treated is a human being, preferably, the dendritic cells are derived from a human being.

25

Preferably, the cell surface molecules are displayed on the cell surface as fragments, such as peptide fragments in the context on MHC molecules.

Drug target

30

Cell surface molecules, which are capable of binding a binding partner and internalising said binding partner into cells expressing said cell surface molecule, may also be used as drug targets. Preferably, such cell surface molecules are expressed at a different level in malignant cell lines compared with normal tissues.

More preferably, the cell surface molecules are identified according to the methods outlined in the present invention.

More preferably the cell surface molecule comprises or essentially consists of or for example is GRIA2, such as LPR8, for example is CHRNA5, such as TMEFF, for example is NPTXR, such as Transferrin receptor; such as type II membrane protein clone: for example is HP10481; such as type II membrane protein clone: such as HP10390; for example is PG40; such as TRC8 ; for example is TR2-11; such as OA3 antigenic surface determinant; for example is integrin alpha 6, For example GPIIb; such as vitronectin receptor alpha subunit; for example is integrin alpha-7; such as integrin alpha E precursor; for example is integrin alpha 6B; such as integrin alpha 5 subunit; for example is integrin beta-5 subunit; such as integrin alpha-3 chain; for example is RYK; such as amyloid precursor protein-binding protein 1; for example is putative transmembrane GTPase; such as membrane cofactor protein; FOR EXAMPLE GLVR1; for example is Mr 110,000 antigen; for example is syndecan-1; such as putative seven transmembrane domain protein; for example is LCA-homolog/ LAR protein; such as M6 antigen; for example is Me491/CD63 antigen; such as multispinning membrane protein; for example is DDR; such as autocrine motility factor receptor; for example is insulin receptor precursor; such as IGF1R, for example is insulin-like growth factor II receptor; such as SAS; for example is TAPA-1; such as MICB; for example is MHC class II HLA-DR7-associated glycoprotein beta-chain; such as HLA-DP; for example is bone small proteoglycan I biglycan; such as CAR; for example is MEA11; such as interferon-gamma receptor alpha chain; for example is Polymeric immunoglobulin receptor; such as metabotropic glutamate receptor type 4; for example is metabotropic glutamate receptor 8; such as CLPTM1; for example is MAGE-4b; such as MAGE5a; for example is MAGE-3; such as MAGE-1; for example is MAGE6; such as MAGE-9; for example is MAGE11; such as CD24; for example is CD59; such as CD44; for example is low density lipoprotein receptor; such as very low density lipoprotein receptor; for example is N-CAM; such as lamin B receptor homolog TM7SF2; for example is putative T1/ST2 receptor binding protein precursor; such as NTR2 receptor; for example is RAGE-4; such as HLA-G1; for example is MOAT-C; such as alpha 2 delta calcium channel subunit isoform I; for example is LFA-3; such as L1-CAM; for example is AVPR2; such as C1 p115 C1; for example is TE2; such as RbP; for example is HCF1; such as IRAK; for example is CD151; such as surface

antigen; for example is MAG; such as GPR19; for example is pcta such as PRAME; for example is vasopressin activated calcium mobilizing receptor-like protein; such as serotonin receptor 5-HT4B; for example is serotonin 1D receptor (5-HT1D~); such as CD9; for example is LDL receptor member LR3; such as DR6; for example is tumor necrosis factor receptor; such as HG38; for example is urokinase-type plasminogen receptor; such as FGF receptor; for example is nerve growth factor receptor; such as cystine/glutamate transporter; for example is CB1 cannabinoid receptor (CNR1); such as PSG; for example is PSG13'; such as CPE-receptor; for example is CRH2R; such as OCI5; for example is TRAIL receptor 2; such as HNMP-1; for example is kidney alpha-2-adrenergic receptor; such as erythropoietin receptor; for example is chondroitin sulphate proteoglycan versican V1; for example is mGluR1beta; such as CD97; for example is L6; such as NY-ESO-1; for example is T-cell receptor alpha delta; such as ror1; for example is ror2; such as SSTR2; for example is VESPR; such as IgG Fc receptor; for example is glutamate receptor subunit GluRC; such as HEK2; for example is PVR; such as CEA; for example is CC-chemokine-binding receptor JAB61; such as HER2; for example is HER3; such as hypothetical protein FLJ22357 similar to Epidermal growth factor receptor-related protein; for example is putative endothelin receptor type B-like protein; such as GLVR2; for example is P2X4 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clearance receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B receptor; for example is GFRA3; such as GRPR; for example is CDH1; such as CDH2; for example is TGFBR1; such as TGFBR2; for example is TGFBR3; such as precursor of epidermal growth factor receptor.

Yet more preferably, the cell surface molecule is selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, GRIA2, GRM8, ITGAV, ITGAE, TNFRSF12, L1CAM, GPR49 and TMEFF1.

A drug target within the scope of the present invention is a molecule, which can be used as a bait, to identify molecules that associates with the drug target and accordingly are potential candidates for drugs. Especially such drugs can be used in the treatment of a premalignant and/or malignant conditions, when formulated accordingly.

The present invention furthermore is concerned with methods for identifying novel drug targets, which can interact with the binding partners according to the present invention (see herein below).

5 Preferably, such a novel drug target comprise a polypeptide, which is a cell surface molecule expressed at a different level in malignant cells compared with normal cells.

10 Additionally, the present invention also is concerned with the novel drug targets identified by the above methods.

Methods to identify binding partners

15 The present invention furthermore provides methods of identifying specific binding partners. Additionally, the invention provides methods of preparing specific binding partners.

20 A specific binding partner may be identified/prepared by a number of different methods. Any suitable method known to the person skilled in the art may be used with the present invention depending of the specific embodiment.

In one embodiment of the present invention, the binding partner is prepared by standard methods for preparing specific antibodies. For example such a method may involve the following steps:

25

- i) immunising an animal with said cell surface molecule or a fragment of said cell surface molecule; and
- ii) obtaining antibodies from said animal; or
- 30 iii) obtaining cells producing antibodies from said animal and obtaining antibodies from said cells

The animal to be immunised may be any animal, preferably a mammal, more preferably the animal is selected from the group comprising rabbit, mouse, rat, donkey, goat and sheep.

The antibodies are preferably obtained from a serum of the immunised animal. They may be purified by any standard method, such as for example by affinity chromatography. Antibodies thus obtained are preferably polyclonal antibodies.

5

Cell producing antibodies are preferably obtained from the spleen of the immunised animals, preferably the cells are B-cells. The antibody producing cells may be fused with other cells subsequent to purification from the animal, in order to obtain immortal cells. The cells may be cultivated in vitro and antibodies may for example be recovered from the tissue culture supernatant by any standard method such as for example affinity chromatography, or protein A or protein G chromatography. These antibodies are often monoclonal antibodies.

10

15

Subsequently, the antibodies may be humanised by any suitable method known to the person skilled in the art.

20

Antibodies may however also be prepared or identified by other means. For example naturally occurring antibodies may be purified from any suitable animal including a human being. Antibodies may also be obtained from an expression library (see herein below).

25

In another embodiment of the present invention the binding partner consists of or comprises a polypeptide, which may be identified by screening an expression library. Any suitable expression library may be used with the present invention.

30

The library may be contained within any suitable host cells, for example the host cells may be bacterial cells, yeast cells, insect cells or mammalian cells. The library may contain nucleic acid sequences encoding polypeptides and/or oligopeptides derived from any species, for example viruses, bacteria, yeast, fungi, plants or animal. Animals may be any animal, preferably mammals, more preferably human beings. The library may also contain nucleic acid sequences encoding polypeptides and/or oligopeptides, which are synthetic and not naturally occurring. The nucleic acid sequences may be contained within any suitable vector, for example a plasmid, a virus, a virus derived vector, a phage, an artificial chromosome or a cosmid.

35

For example the binding partners may be selected from an expression library expressing polypeptides and/or oligopeptides. They may also be selected from a synthetic combinatorial library expressing polypeptides and/or oligopeptides.

- 5 The binding partner may furthermore be identified by screening a phage display library of antibodies. Preferably the phage display library is a library of human antibodies.

- 10 In yet another embodiment the binding partners are selected from a library of small chemical compounds. Such a library may comprise any number of different chemical compounds, which may be produced, by a number of different reactions. Suitable libraries such as for example combinatorial libraries are known to the person skilled in the art.

- 15 Once a specific binding partner, which can associate with a cell surface molecule or a fragment of a cell surface molecule has been identified/prepared, such a binding partner should preferably be tested for capability of being internalised. Such tests can be performed in a number of suitable ways depending on the nature of the binding partner.

- 20 For example, the binding partner may be incubated with cells expressing the cell surface molecule or fragment thereof, with which the binding partner can associate. Following incubation, the presence and/or absence of the binding partner in the cell interior may be detected. Detection may for example be performed taking advantage
- 25 of that the binding partner may have been labelled with a directly or indirectly detectable label. Alternatively, the presence of the binding partner may be determined using a first species which can interact specifically with the binding partner. Such a species may be directly or indirectly labelled or it may be detected using a second species, which can interact specifically with the first species and
- 30 which may be labelled. It is possible to use a third species, which can interact with the second, forth which can interact with the third and so forth.

Binding partners

5 The specific binding partners according to the present invention are capable of interacting with at least one cell surface molecule. However, a specific binding partner may be capable of associating with more than one different cell surface molecules.

10 In one embodiment of the present invention binding partners within are preferably binding partners, which are capable of being internalised into a cell expressing a cell surface molecule following association with the cell surface molecule.

15 The binding partners according to the present invention may be identified by any of the methods outlined herein above. However, the binding partner may also be identified by any other method known to the person skilled in the art.

20 Preferably, the binding partner according to the present invention is capable of associating with one or more cell surface molecules selected from the group consisting of receptors which belong to one of the following groups:

Members of receptor tyrosine kinases

Members of the integrin family

Members of the immunoglobulin superfamily adhesion molecules

25 Members of the heparan sulfate proteoglycan family

Members of the chondroitin sulfate proteoglycan family

Members of the MAGE family

Members of the RAGE family

Members of the low density lipoprotein receptor family

30 Members of the cadherin adhesion molecules

Members of the metabotropic glutamate receptors

Members of the steroid hormone families

Members of the seven transmembrane receptor family

Atrial natriuretic peptide clearance receptor

GFRA3

Transferrin receptor

Members of the serine/threonine kinase receptors

5

More preferably, the binding partner according to the present invention is capable of associating with one or more cell surface molecules selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, GRIA2, GRM8, ITGAV, ITGAE, TNFRSF12, L1CAM, GPR49 and TMEFF1.

10

Yet more preferably, the binding partner may associate with one or more fragments of a cell surface molecule. Preferred fragments of cell surface molecules are outlined herein above. Most preferably, the fragments of the cell surface molecules are derived from the extracellular part of the cell surface molecule.

15

It is preferred that the binding partners according to the present invention may be used in pharmaceutical compositions for the treatment of a premalignant and/or malignant conditions.

20

In one embodiment of the present invention the binding partner comprises or essentially consists of a polypeptide or an oligopeptide. A polypeptide and/or an oligopeptide according to the present invention may be naturally occurring or it may be a synthetic polypeptide.

25

In one preferred embodiment the binding partner is an antibody or a fragment of an antibody. The antibody may be a polyclonal antibody or a binding fragment thereof or it may be a monoclonal antibody or a binding fragment thereof.

30

The antibody may be derived from an animal, preferably a mammal, more preferably a mammal selected from the group consisting of rat, rabbit, mouse, human, donkey, goat and sheep. In one embodiment the binding partner is a monoclonal antibody derived from a mouse or a rat, for example the binding partner is a murine monoclonal antibody.

The antibody may however also be combinatorial antibody, such as one part of the antibody is derived from one species and the other part is derived from another species. Furthermore, the antibody may be a synthetic antibody, which is not naturally produced.

5

For many purposes it is preferred that the antibody is a humanised antibody. Especially, if the binding partner should be used for the treatment of a premalignant and/or malignant conditions in a human being, it is desirable that the antibody is humanised.

10

The antibody may also be human antibody. A human antibody may be a naturally produced human antibody or it may be identified from a phage display library. Furthermore it may be a combinatorial antibody that also comprise parts derived from human antibodies, for example identified from a combinatorial library. Such an antibody need no further humanisation.

15

The antibody preferably, may interact with the extracellular part of the cell surface molecule (see herein above). The antibody may also associate with a posttranslational modification of the extracellular part of the cell surface molecule.

20

Alternatively, the antibody may interacts with any of the fragments of the cell surface molecule as outlined herein above.

25

Most preferably the antibody is capable of being internalised upon association with said cell surface molecule. Many antibodies, which associate with a cell surface molecule, are not internalised into a cell expressing the cell surface molecule upon association. Preferred antibodies within the scope of the present invention are antibodies, which may be internalised into a cell expressing the cell surface molecule following association.

30

In another embodiment of the present invention the binding partner is a naturally occurring ligand for said cell surface molecule. A naturally occurring ligand is a compound, which under natural conditions associates with the cell surface molecule. A naturally occurring ligand may for example selected from the group consisting of polypeptides, oligopeptides, hormones, lipids, saccharides, amino acids,

35

neurotransmitters, nucleotide, nucleoside and combinations thereof.

A hormone could for example be a steroid hormone. Steroid hormones may be selected from the group consisting of androgens, estrogens, progestogens and corticoids.

5

Androgens can for example be selected from the group consisting of testosterone, dihydrotestosterone, androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) and derivatives thereof.

10 Estrogens can for example be selected from the group consisting of estrion, estradiol, estriol and derivatives thereof.

A naturally occurring ligand may be purified from an animal including a human being by any conventional technique suitable for the ligand of the embodiment. However,
15 a natural ligand may also be produced in vitro by any method known to the person skilled in the art.

In one embodiment of the present invention the binding partner is a recombinantly produced ligand for said cell surface molecule. If the ligand is a polypeptide or an
20 oligopeptide, the ligand may be produced by transforming a suitable host, such as bacteria, yeast, protozoa, animals such as for example mammals, plants, animal cells or plant cells with a nucleic acid sequence encoding the ligand operably linked to nucleic acid sequences that direct transcriptions and/or translation of the nucleic acid sequence in the particular host. Transformation may be performed according to
25 any conventional technique. Subsequently the ligand may be purified according to any standard method.

In another embodiment the binding partner is a viral protein or comprise a viral protein or fragments thereof. A large number of viral proteins are capable of
30 associating with cell surface molecule. Frequently such an association results in internalisation of the virus particle, and hence viral proteins are suitable binding partners according to the present invention.

Preferably, a viral protein is a viral capsid protein, more preferably a viral capsid protein is capable of being internalised into a cell expressing the cell surface molecule.

- 5 The viral protein may be derived from any virus, preferably a virus which is capable of infecting cells which naturally expresses the cell surface molecule. The virus could for example be selected from the group consisting of adenovirus, herpes simplex virus, influenza virus and members of the lentivirus family.
- 10 The binding partner may be recombinantly produced (see herein above) and comprise viral capsid protein sequences. Preferably the viral capsid protein sequences are the sequences of the viral protein which can associate with the cell surface molecule and result in internalisation.
- 15 In yet another embodiment of the present invention the binding partner is a small chemical compound. Such a small chemical compound is usually synthetically produced. It can be produced by any process or combination of processes known to the person skilled in the art.
- 20 Preferred small chemical compounds can interact with the cell surface molecules and/or the fragments of cell surface molecules as outlined herein above. More preferably, the small chemical compounds are capable of being internalised into cells expressing said cell surface molecules.
- 25 In one embodiment the binding partner may be a polypeptide selected from the group consisting of EGF, TGF- α , TGF- β , amphiregulin, HB-EGF, epiregulin, beta-cellulin, IGF-1, IGF-2, collagen, fibronectin, vitronectin, laminin, amyloid beta-protein precursor, interferon γ , transferrin, autocrine motility factor, L1, NCAM, cadherin, bombesin, neuromedin B, TNF, erythropoietin, interleukin and cholecystokinin B.
- 30 Furthermore, the binding partner may for example be an organic compound selected from the group consisting of cannabinoid, acetylcholin, dopamine, norepinephrine, serotonin and GABA. In addition the binding partner may for example be an oligopeptide selected from the group consisting of formyl peptide and atrial natriuretic peptide. Furthermore the binding partner may for example be an amino acid, the binding
- 35 partner may be any amino acid, preferably the amino acid is selected from the group

consisting of glutamate, glycine and histamine. Additionally, the binding partner may for example be a nucleotide selected from the group consisting of ATP and GTP. Furthermore, the binding partner may be a hormone such as estrogen, a lipid or a saccharide.

5

Furthermore, the binding partner according to the present invention may be selected from the group consisting of EGF, TGF- α , heregulins, Insulin, IGF-1, PDGF, CSF-1, SCF, Flt-3L, VEGF, FGFs1-9, NGF, BDNF, NT-3, NT-4, HGF, MSP, Gas6, Angiopoietin-1, ephrinA1-5, ephrinB1-3, GDNF, PEPHC1, TGF- β , Angiotensin, Thrombin, Adenosine, Adrenalin, Serotonin, deltorphin, Dopamine, PTH, Secretin, VIP, PACAP, Glucagon, CRF, Bombesin, Bradykinin, NPY, Glutamate, Ca^{2+} , GABA, Chemokines and Opioids.

10

More preferably, the binding partner may be selected from the group consisting of L-glutamate, kainate, 5-(bromomethyl)-4-isoxazolepropionic acid (L-5-HT), analogues of glutamate, substituted quinoxaline 2,3 diones, GYKI52466, 5-I-Willardine, 5-F-Willardine, agonist and antagonist ligands to the AMPA ((RS)- α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, NBQX, CNQX, DNQX, GYKI 52466, 6-Chlorokynurenic acid, JSTX, L-APA, L-SOP, ACPT, (R,S)-PPG, CPPG, MAP4, (S)-3,4-DCPG, vitronectin, cytactin, fibronectin, fibrinogen, laminin, MMP-2, osteopontin, prothrombin, thrombospondin, von Willebrandts Factor, recombinant fragments of L1CAM, salmosin, E-cadherin and peptides thereof, including the peptide: NRDKETKV, NCAM1 domain Ig I+II, NCAM1 domain IgIII and peptides thereof, peptides C3: ASKKPKRNIKA (SEQ ID NO. 305), D3: AKKERQRKDTU (SEQ ID NO 306), D4: ARALNWGAKP (SEQ ID NO 307), monoclonal antibody 123C3, NPTX1, NPTX2, taipoxin, TCBP49, Oxyrin, ApoE2, ApoE3, ApoE4, peptides from ApoE ($\text{E}_{141-155}$; LRKLRKLLRDADDL (SEQ ID NO 308) and its tandem $\text{E}_{(141-155)2}$; LRKLRKLLRDADDL-LRKLRKLL RDADDL (tandem of SEQ ID NO 308)) reelin, nicotine, acetylcholine, α -bungarotoxin and carbachol.

15

20

25

30

The binding partner according to the present invention should be selected according to cell surface molecule employed in the specific embodiment of the invention.

35

Hence, in embodiments of the invention, wherein the cell surface molecule is capable of internalising a binding partner or a targeting complex, the binding partner is

preferably selected from the group consisting of NCAM1 domain Ig^{II}, NCAM1 domain Ig^{III} and peptides thereof, peptides C3: ASKKPKRNIKA (SEQ ID NO 305), D3: AKKERQRKDTU (SEQ ID NO 306), D4: ARALNWGAKP (SEQ ID NO 307), monoclonal antibody 123C3, NPTX1, NPTX2, taipoxin, TCBP49, Oxyrin, ApoE2, ApoE3, ApoE4, peptides from ApoE (E₁₄₁₋₁₅₅: LRKLRKRLLRDADDL (SEQ ID NO 308) and its tandem E₍₁₄₁₋₁₅₅₎₂: LRKLRKRLLRDADDL-LRKLRKRLLRDADDL (tandem of SEQ ID NO 308)) reelin, nicotine, acetylcholine, α -bungarotoxin, carbachol and specific internalising antibodies directed against said cell surface molecules.

In embodiments of the invention wherein the cell surface molecule is not capable of internalising a binding partner or a targeting complex, the binding partner is preferably selected from the group consisting of L-glutamate, kainate, 5-(bromomethyl)-4-isoxazolepropionic acid (), analogues of glutamate, substituted quinoxaline 2,3 diones, GYKI52466, 5-I-Willardine, 5-F-Willardine, agonist and antagonist ligands to the AMPA ((RS)- α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, NBQX, CNQX, DNQX, GYKI 52466, 6-Chlorokynurenic acid, JSTX, L-APA, L-SOP, ACPT, (R,S)-PPG, CPPG, MAP4, (S)-3,4-DCPG, vitronectin, cytactin, fibronectin, fibrinogen, laminin, MMP-2, osteopontin, prothrombin, thrombospondin, von Willebrandts Factor, recombinant fragments of L1CAM, salmosin, E-cadherin and peptides thereof, including the peptide: NRDKETKV (SEQ ID NO 309) and specific antibodies directed to said cell surface molecules.

In one especially preferred embodiment of the present invention the cell surface molecule is NCAM1. When the cell surface molecule is NCAM1, then the binding partner is preferably selected from the group consisting of the first and second Immunoglobulin domains (Ig) of NCAM1 (Kiselyov *et al.*, 1997), the third Ig domain of NCAM1, the adhesion molecule L1 and proteoglycans. Furthermore, the binding partner may preferably be selected from the group consisting of synthetic binding partners capable of associating with NCAMs including for example a large number of peptides (11 amino acids) identified from a combinatorial peptide library (Rønn *et al.*, 1999), including for example C3: ASKKPKRNIKA (SEQ ID NO 305), D3: AKKERQRKDTU (SEQ ID NO 306) and D4: ARALNWGAKPK (SEQ ID NO 307) (Rønn *et al.*, 1999). In addition the binding partner may preferably be selected from the group consisting of antibodies against NCAM1, preferably monoclonal antibodies against NCAM1, for example antibody (123C3) which causes internalisation.

In another preferred embodiment of the invention the cell surface molecule is NPTXR. When the cell surface molecule is NPTXR, then the binding is preferably selected from the group consisting of Neuronal pentraxin 1 (NP1, NPTX1) and Neuronal pentraxin 2 (NP2, NPTX2) (Kirkpatrick *et al.*, 2000; Dodds *et al.*, 1997). Furthermore, the binding partner may preferably be selected from the group consisting of the snake venom taipoxin and taipoxin associated calcium-binding protein 49 (TCBP49) and the taipoxin analogue, Oxynor. In addition the binding partner may preferably be selected from the group consisting of antibodies against NPTXR, preferably monoclonal antibodies against NPTXR.

In another preferred embodiment of the invention the cell surface molecule is LRP8. When the cell surface molecule is LRP8, then the binding partner is preferably selected from the group consisting of ApoE2, ApoE3 and ApoE4 and reelin. Furthermore, the binding partner may preferably be selected from the group consisting of various recombinant ApoE isoforms some of which are commercially available. However, the natural ApoE isoforms are capable of associating with several receptors. In addition, the binding partner may preferably be selected from the group consisting of peptides from ApoE, for example (E₁₄₁₋₁₅₅; LRKLRKRLRDADDL (SEQ ID NO 308) and its tandem E₍₁₄₁₋₁₅₅₎₂; LRKLRKRLRDADDL-LRKLRKRL RDADDL), both have been shown to inhibit receptor function (Riddell *et al.*, 1999). In addition the binding partner may preferably be selected from the group consisting of antibodies against LRP8, preferably monoclonal antibodies against LRP8.

In another preferred embodiment of the invention the cell surface molecule is CHRNA5. When the cell surface molecule is CHRNA5, then the binding partner is preferably selected from the group consisting of nicotine, acetylcholine and the toxin α -bungarotoxin. Furthermore, the binding partner may be selected from the group consisting of synthetic agonists of CHRNA5, for example carbachol. In addition the binding partner may preferably be selected from the group consisting of antibodies against CHRNA5, preferably monoclonal antibodies against CHRNA5.

In another preferred embodiment of the invention the cell surface molecule is L1CAM. When the cell surface molecule is L1CAM, then the binding partner may for

example comprise an adhesion molecule of the integrin family or a fragment thereof. L1CAM is known to bind several adhesion molecules of the integrin family through an RGD sequence and of the immunoglobulin family via an oligomannosidic carbohydrate. In addition the binding partner may preferably be selected from the group consisting of antibodies against L1CAM, preferably monoclonal antibodies against L1CAM.

In another preferred embodiment of the invention the cell surface molecule is TNFRSF12. When the cell surface molecule is TNFRSF12, then the binding partner may for example an antibody against TNFRSF12, preferably a monoclonal antibody against TNFRSF12, for example a monoclonal antibody to the extracellular domain of TNFRSF12.

In one especially preferred embodiment of the present invention the cell surface molecule is GRIA2. When the cell surface molecule is GRIA2, then the binding partner is preferably selected from the group consisting of L-glutamate and kainate. Furthermore, the binding partner may preferably be selected from the group consisting of synthetic ligands to GRIA2, for example agonist and antagonist ligands to the AMPA ((RS)- α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors. AMPA receptor ligands are generally either analogues of glutamate or substituted quinoxaline 2,3 diones. The antagonists are divided into competitive and modulatory site antagonists (reviewed in (Bräuner-Osborne *et al.*, 2000; Madsen *et al.*, 2001)). In addition, one AMPA antagonist, GYKI52466, has been shown to inhibit tumor cell growth (Cavalheiro and Olney, 2001) on cells expressing the GRIA2 receptor. As the receptor binding of the ligands involves binding of the major portions of the ligand, substitutions (such as halogens) can only be performed at very few sites. A bromo substituted form of AMPA (ABPA) was shown to act as a potent agonist of AMPA receptors (Krogsgaard-Larsen *et al.*, 1985). The agonist may also be a halogenated form of an agonist, for example willardiine and analogues with different AMPA receptor affinities (Jane D., 2001). Many of these show many fold higher affinity for AMPA receptors than AMPA itself. Synthesis of Willardiine and 6-azowillardiine halogenated analogues is described in detail in (Jane *et al.*, 1997). 5-I-Willardiine and 5-F-Willardiine are commercially available, also in a ^3H - forms. In addition the binding partner may be selected from the group consisting of small molecule antagonists, for example the commercially available NBQX, CNQX,

DNQX, GYKI 52466 and 6-Chlorokynurenic acid and the group of longer polyamine antagonists of AMPA receptor channels related to the spider toxin JSTX-3 (Yoneda *et al.*, 2001). In addition the binding partner may preferably be selected from the group consisting of antibodies against GRIA2, preferably monoclonal antibodies
5 against GRIA2.

In another preferred embodiment of the invention the cell surface molecule is GRM8. When the cell surface molecule is GRM8, then the binding partner may preferably be L-glutamate. Furthermore, the binding partner may preferably be selected
10 from the group consisting of agonists and antagonists, for example the commercially available L-APA, L-SOP, ACPT, (R,S)-PPG, CPPG, MAP4, (S)-3,4-DCPG and MSOP and their ³H labelled forms. One agonist, (R,S)-PPG has a 25 fold preference for GRM8 (Gasparini *et al.*, 1999) and the agonist (S)-3,4-DCPG displays more than 100 fold selectivity for GRM8 (Bruno *et al.*, 2001; Thomas *et al.*, 2001; Turner and
15 Salt, 1999). In addition the binding partner may preferably be selected from the group consisting of antibodies against GRM8, preferably monoclonal antibodies against GRM8.

In another preferred embodiment of the invention the cell surface molecule is IT-
20 GAV. When the cell surface molecule is ITGAV, then the binding partner may preferably be selected from the group consisting of vitronectin, cyactin, fibronectin, fibrinogen, laminin, MMP-2, osteopontin, prothrombin, thrombospondin von Willebrandts Factor and $\alpha v \beta 3$. $\alpha v \beta 3$ has been shown to bind recombinant fragments of the neural cell adhesion molecule L1 though the αv subunit (Montgomery *et al.*,
25 1996). The natural ligands, such as vitronectin, are also ligands for a number of other, ubiquitously expressed integrins and therefore not optimal for specific targeting. Furthermore, the binding partner may preferably be selected from the group consisting of disintegrins and ADAMs, for example salmosin or contortrostatin. Disintegrins and ADAMs (A Disintegrin and A Metalloprotease) are a large number of
30 proteins from snake venoms, which bind with different specificities to different integrins (Evans, 2001; Huang, 1998). Several disintegrins specific for $\alpha v \beta 3$ and $\alpha v \beta 5$ have been identified, including recombinantly produced salmosin (Kang *et al.*, 1999) and contortrostatin (Mercer *et al.*, 1998). In addition, the binding partner may preferably be selected from the group consisting of small cyclic peptides and non-peptide
35 compounds, which are antagonists of $\alpha v \beta 3$ binding (Boger *et al.*, 2001; Hartman and

Duggan, 2000; Kerr *et al.*, 2000; Batt *et al.*, 2000). In addition the binding partner may preferably be selected from the group consisting of antibodies against ITGAV, preferably monoclonal antibodies against ITGAV.

- 5 In another preferred embodiment of the invention the cell surface molecule is ITGAE. When the cell surface molecule is ITGAE, then the binding partner may preferably be the cell adhesion molecule E-cadherin or a fragment thereof. The heterophilic binding site on E-cadherin for $\alpha E\beta 7$ differs from the homophilic binding site of E-cadherin with another E-cadherin (Karecla *et al.*, 1996; Taraszka *et al.*, 2000).
- 10 Preferably the fragment comprises or even more preferably consists of a short peptide sequence from the first domain of E-cadherin (amino acids 27-34: NRDKETKV (SEQ ID NO 309), which are capable of interfering with the binding of $\alpha E\beta 7$ to E-cadherin. Furthermore, the binding partner may be selected from the group consisting of specific $\alpha E\beta 7$ specific peptides (Brenner and Cepek, 2001). In addition the
- 15 binding partner may preferably be selected from the group consisting of antibodies against ITGAE, preferably monoclonal antibodies against ITGAE, such as αE specific antibodies that may be used as antagonists.

Complex

20

- In one embodiment the present invention relates to a complex comprising a cell surface molecule and a binding partner. Preferably the cell surface molecule is identified by the method disclosed by the present invention. Preferably, the cell surface molecule comprises or essentially consists of or for example is GRIA2, such
- 25 as LPR8, for example is CHRNA5, such as TMEFF, for example is NPTXR, such as Transferrin receptor; such as type II membrane protein clone: for example is HP10481; such as type II membrane protein clone: such as HP10390; for example is PG40; such as TRC8; for example is TR2-11; such as OA3 antigenic surface determinant; for example is integrin alpha 6, For example GPIIb; such as vitronectin
- 30 receptor alpha subunit; for example is integrin alpha-7; such as integrin alpha E precursor; for example is integrin alpha 6B; such as integrin alpha 5 subunit; for example is integrin beta-5 subunit; such as integrin alpha-3 chain; for example is RYK; such as amyloid precursor protein-binding protein 1; for example is putative transmembrane GTPase; such as membrane cofactor protein; FOR EXAMPLE

GLVR1; for example is Mr 110,000 antigen; for example is syndecan-1; such as
 putative seven transmembrane domain protein; for example is LCA-homolog/ LAR
 protein; such as M6 antigen; for example is Me491/CD63 antigen; such as
 multispinning membrane protein; for example is DDR; such as autocrine motility
 5 factor receptor; for example is insulin receptor precursor; such as IGF1R, for
 example is insulin-like growth factor II receptor; such as SAS; for example is TAPA-
 1; such as MICB; for example is MHC class II HLA-DR7-associated glycoprotein
 beta-chain; such as HLA-DP; for example is bone small proteoglycan I biglycan;
 such as CAR; for example is MEA11; such as interferon-gamma receptor alpha
 10 chain; for example is Polymeric immunoglobulin receptor; such as metabotropic
 glutamate receptor type 4; for example is metabotropic glutamate receptor 8; such
 as CLPTM1; for example is MAGE-4b; such as MAGE5a; for example is MAGE-3;
 such as MAGE-1; for example is MAGE6; such as MAGE-9; for example is
 MAGE11; such as CD24; for example is CD59; such as CD44; for example is low
 15 density lipoprotein receptor; such as very low density lipoprotein receptor; for
 example is N-CAM; such as lamin B receptor homolog TM7SF2; for example is
 putative T1/ST2 receptor binding protein precursor; such as NTR2 receptor; for
 example is RAGE-4; such as HLA-G1; for example is MOAT-C; such as alpha 2
 delta calcium channel subunit isoform I; for example is LFA-3; such as L1-CAM; for
 20 example is AVPR2; such as C1 p115 C1; for example is TE2; such as RbP; for
 example is HCF1; such as IRAK; for example is CD151; such as surface antigen; for
 example is MAG; such as GPR19; for example is pcta-1; such as PRAME; for
 example is vasopressin activated calcium mobilizing receptor-like protein; such as
 serotonin receptor 5-HT4B; for example is serotonin 1D receptor (5-HT1D~); such
 25 as CD9; for example is LDL receptor member LR3; such as DR6; for example is
 tumor necrosis factor receptor; such as HG38; for example is urokinase-type
 plasminogen receptor; such as FGF receptor; for example is nerve growth factor
 receptor; such as cystine/glutamate transporter; for example is CB1 cannabinoid
 receptor (CNR1); such as PSG; for example is PSG13'; such as CPE-receptor; for
 30 example is CRH2R; such as OCI5; for example is TRAIL receptor 2; such as HNMP-
 1; for example is kidney alpha-2-adrenergic receptor; such as erythropoietin
 receptor; for example is chondroitin sulphate proteoglycan versican V1; for example
 is mGluR1beta; such as CD97; for example is L6; such as NY-ESO-1; for example
 is T-cell receptor alpha delta; such as ror1; for example is ror2; such as SSTR2; for
 35 example is VESPR; such as IgG Fc receptor; for example is glutamate receptor

subunit GluRC; such as HEK2; for example is PVR; such as CEA; for example is CC-chemokine-binding receptor JAB61; such as HER2; for example is HER3; such as hypothetical protein FLJ22357 similar to Epidermal growth factor receptor-related protein; for example is putative endothelin receptor type B-like protein; such as GLVR2; for example is P2X4 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clearance receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B receptor; for example is GFRA3; such as GRPR; for example is CDH1; such as CDH2; for example is TGFB1; such as TGFB2; for example is TGFB3; such as precursor of epidermal growth factor receptor.

10

More preferably the cell surface molecule may be selected from the group consisting of

Members of receptor tyrosine kinases

Members of the integrin family

15

Members of the immunoglobulin superfamily adhesion molecules

Members of the heparan sulfate proteoglycan family

Members of the chondroitin sulfate proteoglycan family

Members of the MAGE family

Members of the RAGE family

20

Members of the low density lipoprotein receptor family

Members of the cadherin adhesion molecules

Members of the metabotropic glutamate receptors

Members of the steroid hormone families

Members of the seven transmembrane receptor family

25

Atrial natriuretic peptide clearance receptor

GFRA3

Transferrin receptor

Members of the serine/threonine kinase receptors

30

More preferably, the cell surface molecule is selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, GRIA2, GRM8, ITGAV, ITGAE, TNFRSF12, L1CAM, GPR49 and TMEFF1.

The binding partner of the complex may be any specific binding partner capable of interacting with the cell surface molecule. Examples of binding partners are given herein above.

5 **Targeting complex**

The present invention provides targeting complexes, which comprise a binding partner and a bioreactive species. The binding partner should be capable of associating with one or more cell surface molecules or fragments thereof as outlined
10 herein above.

In one preferred embodiment of the present invention, the cell surface molecule, which can associate with the binding partner of the targeting complex, is capable of internalising the targeting complex. However, in another preferred embodiment of
15 the present invention, the cell surface molecule is not capable of internalising the targeting complex, but merely is capable of associating with the targeting complex.

More preferably, the cell surface molecule comprises or essentially consists of or for example is Transferrin receptor; such as type II membrane protein clone: for example
20 is HP10481; such as type II membrane protein clone: such as HP10390; for example is PG40; such as TRC8 ; for example is TR2-11; such as OA3 antigenic surface determinant; for example is integrin alpha 6, For example GPIIb; such as vitronectin receptor alpha subunit; for example is integrin alpha-7; such as integrin alpha E precursor; for example is integrin alpha 6B; such as integrin alpha 5 subunit; for
25 example is integrin beta-5 subunit; such as integrin alpha-3 chain; for example is RYK; such as amyloid precursor protein-binding protein 1; for example is putative transmembrane GTPase; such as membrane cofactor protein; FOR EXAMPLE GLVR1; for example is Mr 110,000 antigen; for example is syndecan-1; such as putative seven transmembrane domain protein; for example is LCA-homolog/ LAR
30 protein; such as M6 antigen; for example is Me491/CD63 antigen; such as multi-spanning membrane protein; for example is DDR; such as autocrine motility factor receptor; for example is insulin receptor precursor; such as IGF1R, for example is insulin-like growth factor II receptor; such as SAS; for example is TAPA-1; such as MICB; for example is MHC class II HLA-DR7-associated glycoprotein beta-chain;

such as HLA-DP; for example is bone small proteoglycan I biglycan; such as CAR; for example is MEA11; such as interferon-gamma receptor alpha chain; for example is Polymeric immunoglobulin receptor; such as metabotropic glutamate receptor type 4; for example is metabotropic glutamate receptor 8; such as CLPTM1; for example is MAGE-4b; such as MAGE5a; for example is MAGE-3; such as MAGE-1; for example is MAGE6; such as MAGE-9; for example is MAGE11; such as CD24; for example is CD59; such as CD44; for example is low density lipoprotein receptor; such as very low density lipoprotein receptor; for example is N-CAM; such as lamin B receptor homolog TM7SF2; for example is putative T1/ST2 receptor binding protein precursor; such as NTR2 receptor; for example is RAGE-4; such as HLA-G1; for example is MOAT-C; such as alpha 2 delta calcium channel subunit isoform I; for example is LFA-3; such as L1-CAM; for example is AVPR2; such as C1 p115 C1; for example is TE2; such as RbP; for example is HCF1; such as IRAK; for example is CD151; such as surface antigen; for example is MAG; such as GPR19; for example is pcta-1; such as PRAME; for example is vasopressin activated calcium mobilizing receptor-like protein; such as serotonin receptor 5-HT4B; for example is serotonin 1D receptor (5-HT1D~); such as CD9; for example is LDL receptor member LR3; such as DR6; for example is tumor necrosis factor receptor; such as HG38; for example is urokinase-type plasminogen receptor; such as FGF receptor; for example is nerve growth factor receptor; such as cystine/glutamate transporter; for example is CB1 cannabinoid receptor (CNR1); such as PSG; for example is PSG13'; such as CPE-receptor; for example is CRH2R; such as OCI5; for example is TRAIL receptor 2; such as HNMP-1; for example is kidney alpha-2-adrenergic receptor; such as erythropoietin receptor; for example is chondroitin sulphate proteoglycan versican V1; for example is mGluR1beta; such as CD97; for example is L6; such as NY-ESO-1; for example is T-cell receptor alpha delta; such as ror1; for example is ror2; such as SSTR2; for example is VESPR; such as IgG Fc receptor; for example is glutamate receptor subunit GluRC; such as HEK2; for example is PVR; such as CEA; for example is CC-chemokine-binding receptor JAB61; such as HER2; for example is HER3; such as hypothetical protein FLJ22357 similar to Epidermal growth factor receptor-related protein; for example is putative endothelin receptor type B-like protein; such as GLVR2; for example is P2X4 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clearance receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B receptor; for example is GFRA3; such as GRPR; for example is CDH1; such as CDH2; for example is TGFBR1; such as

TGFB β 2; for example is TGFB β 3; such as precursor of epidermal growth factor receptor, yet more preferably the cell surface molecule is selected from the group consisting of receptors which belong to one of the following groups:

- 5 Members of receptor tyrosine kinases
- Members of the integrin family
- Members of the immunoglobulin superfamily adhesion molecules
- Members of the heparan sulfate proteoglycan family
- Members of the chondroitin sulfate proteoglycan family
- 10 Members of the MAGE family
- Members of the RAGE family
- Members of the low density lipoprotein receptor family
- Members of the cadherin adhesion molecules
- Members of the metabotropic glutamate receptors
- 15 Members of the steroid hormone families
- Members of the seven transmembrane receptor family
- Atrial natriuretic peptide clearance receptor
- GFRA3
- Transferrin receptor
- 20 Members of the serine/threonine kinase receptors

Even more preferably, the cell surface molecules selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, GRIA2, GRM8, ITGAV, ITGAE, TNFRSF12, L1CAM, GPR49 and TMEFF1.

25

- The bioreactive species according to the present invention may be any species, which can directly or indirectly exert a biological influence on a target cell, wherein the target cell, is any cell expressing the cell surface molecule and which can
- 30 internalise the targeting construct. The biological influence according to the present invention may for example be selected from the group consisting of cell cycle arrest, protection of cell against toxins and cell death.

The bioreactive species may any compound for example it may be a nucleic acid sequence, a polypeptide, an oligopeptide, a toxin, a small chemical compound or a radioactive isotope.

- 5 In one preferred embodiment the bioreactive species is a nucleic acid sequence. Preferably, the nucleic acid sequence comprises a second nucleic acid operably linked to a first nucleic acid sequence comprising an expression signal.

10 The second nucleic acid sequence may in one preferred embodiment encode a therapeutic protein (see herein below). The nucleic acid sequence encoding a therapeutic protein may comprise complementary DNA (cDNA). The term "cDNA" used here, is intended to refer to DNA prepared using messenger RNA (mRNA) as template. The advantage of using a cDNA, as opposed to genomic DNA or DNA polymerised from a genomic DNA or non- or partially-processed RNA template, is
15 that the cDNA does not contain any non-coding intron sequences but, rather comprise the uninterrupted coding region of the corresponding protein. There may be times when the full or partial genomic sequence is preferred, however, such as where the non-coding regions are required for optimal expression.

- 20 In another embodiment the second nucleic acid sequence encodes an antisense RNA or part of an antisense RNA. Alternatively, the second nucleic acid sequence may comprise or essentially consist of an antisense RNA or part of an antisense RNA.

- 25 In the context of the present invention the term "antisense RNA" is intended to encompass an RNA sequence transcribed from the non-coding DNA strand of a gene or an RNA sequence that is capable of hybridising to an mRNA or fragments thereof under stringent conditions.

- 30 Preferably, the antisense RNA within the context of the present invention is the antisense RNA of a gene encoding a protein, which promotes cell survival, cell growth and/or cell mobility. More preferably, the antisense RNA is the antisense RNA of an oncogene or a growth factor.

In another embodiment the second nucleic acid sequence encodes or comprises a ribozyme. A ribozyme within the present context is a molecule, which comprises at least one RNA, which comprises an enzymatic activity. Preferably, ribozymes according to the present invention is targeted against RNA of an oncogene or a protooncogene or growth factors.

Accordingly, in preferred embodiments of the present invention antisense RNAs or ribozymes are targeted against RNA of an oncogene or proto-oncogene or growth factors. Examples of growth factors are indicated herein below.

Oncogenes are a diverse class of genes, whose products may contribute to the development and/or advancement of cancer. Proto-oncogenes may under certain circumstances or after due to mutations contribute to the development and/or advancement of cancer. Oncogene or proto-oncogene may for example be selected from the group consisting of Ras, Raf, Myc, Syn, Pim, BMI-1, FOP, Sis, KGF, Fms, Flg, Neu, Trk, Kit, Met, Src, Fyn, Mas, Fes/Fps, Tre, Mer, ABL, BCL3, int-2, Cym, Ets, Elk, RhoA, Ski, Wnt-5a, Spi-1, Rap2, p55 and c-tyr. This is not an exhaustive list of oncogenes and proto-oncogenes, which may be used with the present invention, but merely comprises illustrative examples.

The second nucleic acid sequences may also encode a tumour suppressor gene to be introduced into the cell expressing the cell surface molecule in order to correct any endogenous mutations of said tumour suppressor within the cell. The tumour suppressor may be any tumour suppressor for example any of the tumour suppressors indicated herein below.

The first nucleic acid sequences according to the present invention preferably comprise an expression signal. Such an expression signal should preferably influence the transcription of second nucleic acid sequences operably linked thereto. Preferably, the first nucleic acids sequences according to the present invention influence transcription such as they enhance transcription under specific circumstances.

In one embodiment of the present invention the first nucleic acid sequence comprises an expression signal, which directs a lower level of expression of a

second nucleic acid sequence in malignant cells, compared with non-malignant cells. In another embodiment the first nucleic acid sequence comprises an expression signal; which directs approximately the same level of expression of a second nucleic acid sequence in malignant cells, compared with non-malignant cells.

However, in a preferred embodiment of the present invention the first nucleic acid sequences directs a higher level of expression of a second nucleic acid sequence in malignant cells compared with non-malignant cells. In particular, the first nucleic acid sequences may be selected from the group consisting of first nucleic acid sequences identified according to the methods outlined herein above.

Preferably, the first nucleic acid sequence is selected from the group consisting of pro1, pro2, pro3, pro4, pro5, pro6, pro7, pro8, pro9, pro10, pro12, pro13, pro14, pro15, pro16, pro17, pro18, pro19, pro20, pro21, pro22, pro23, pro24, pro25, pro26, pro27, pro28, pro29, pro30, pro31, pro32, pro34, pro36, pro37, pro38, pro39, pro40, pro41, pro42, pro43, pro44, pro45, pro46, pro47, pro48, pro49, pro50, pro51, pro52, pro53, pro54, pro55, pro56, pro57, pro58, pro59, pro60, pro61, pro62, pro63, pro64, pro65, pro66, pro67, pro68, pro69, pro70, pro71, pro72, pro73, pro74, pro75, pro76, pro77, pro78, pro79, pro80, pro81, pro82, pro83, pro84, pro85, pro86, pro87, pro88, pro89, pro90, pro91, pro92, pro93, pro94, pro95, pro96, pro97, pro98, pro99, pro100, pro101, pro103, pro104, pro105, pro106, pro107, pro108, pro109, pro110, pro111, pro112, pro113, pro114, pro115, pro116, pro117, pro118, pro119, pro120, pro121, pro122, pro123, pro124, pro125, pro126, pro127, pro128, pro129, pro130, pro131, pro133, pro134, pro135, pro136, pro137, pro138, pro139, pro140, pro141, pro142, pro143, pro144, pro145, pro146, pro147, pro148, pro149, pro150, pro152, pro153, pro154, pro155, pro156, pro157, pro158, pro159, pro160, pro161, pro162, pro163, pro164, pro165, pro166, pro167, pro168, pro169, pro171, pro172, pro173, pro174, pro175, pro176, pro177, pro178, pro179, pro180, pro181, pro182, pro183, pro184, pro185, pro187, pro189, pro191, pro193, pro194, pro195, pro196, pro197, pro198, pro199, pro201, pro202, pro203, pro204, pro205, pro206, pro207, pro208, pro209, pro210, pro211, pro212, pro213, pro215, pro216, pro217, pro219, pro220, pro221, pro222, pro223, pro224, pro225, pro226, pro227, pro228, pro229, pro230, pro231, pro232, pro233, pro234, pro235, pro236, pro237, pro238, pro239, pro240, pro241, pro242, pro243, pro244, pro245, pro246, pro247, pro248, pro249, pro250,

pro251, pro253, pro254, pro255, pro256, pro257, pro258, pro259, pro260, pro262,
pro263, pro264, pro267, pro268, pro269, pro270, pro271, pro272, pro273, pro275,
pro277, pro278, pro279, pro280, pro282, pro283, pro284, pro285, pro286, pro287,
pro289, pro290, pro291, pro292, pro293, pro294, pro295, pro296, pro297, pro298,
5 pro299, pro300, pro301, pro302, pro303, pro304, pro305, pro306, pro307, pro308,
pro309, pro310, pro311, pro312, pro313, pro315, pro316, pro317, pro318, pro319,
pro320, pro321, pro322, pro323, pro324, pro326, pro327, pro328, pro329, pro330,
pro331, pro332, pro333, pro334, pro335, pro336, pro337, pro338, pro339, pro340,
pro341, pro344, pro346, pro347, pro348, pro349, pro352, pro353, pro354, pro355,
10 pro356, pro358, pro359 and pro361.

The first nucleic acid sequences may furthermore comprise and/or essentially consist of fragments of nucleic acid sequences selected from the group consisting of
pro1, pro2, pro3, pro4, pro5, pro6, pro7, pro8, pro9, pro10, pro12, pro13, pro14,
15 pro15, pro16, pro17, pro18, pro19, pro20, pro21, pro22, pro23, pro24, pro25, pro26,
pro27, pro28, pro29, pro30, pro31, pro32, pro34, pro36, pro37, pro38, pro39, pro40,
pro41, pro42, pro43, pro44, pro45, pro46, pro47, pro48, pro49, pro50, pro51, pro52,
pro53, pro54, pro55, pro56, pro57, pro58, pro59, pro60, pro61, pro62, pro63, pro64,
pro65, pro66, pro67, pro68, pro69, pro70, pro71, pro72, pro73, pro74, pro75, pro76,
20 pro77, pro78, pro79, pro80, pro81, pro82, pro83, pro84, pro85, pro86, pro87, pro88,
pro89, pro90, pro91, pro92, pro93, pro94, pro95, pro96, pro97, pro98, pro99,
pro100, pro101, pro103, pro104, pro105, pro106, pro107, pro108, pro109, pro110,
pro111, pro112, pro113, pro114, pro115, pro116, pro117, pro118, pro119, pro120,
pro121, pro122, pro123, pro124, pro125, pro126, pro127, pro128, pro129, pro130,
25 pro131, pro133, pro134, pro135, pro136, pro137, pro138, pro139, pro140, pro141,
pro142, pro143, pro144, pro145, pro146, pro147, pro148, pro149, pro150, pro152,
pro153, pro154, pro155, pro156, pro157, pro158, pro159, pro160, pro161, pro162,
pro163, pro164, pro165, pro166, pro167, pro168, pro169, pro171, pro172, pro173,
pro174, pro175, pro176, pro177, pro178, pro179, pro180, pro181, pro182, pro183,
30 pro184, pro185, pro187, pro189, pro191, pro193, pro194, pro195, pro196, pro197,
pro198, pro199, pro201, pro202, pro203, pro204, pro205, pro206, pro207, pro208,
pro209, pro210, pro211, pro212, pro213, pro215, pro216, pro217, pro219, pro220,
pro221, pro222, pro223, pro224, pro225, pro226, pro227, pro228, pro229, pro230,
pro231, pro232, pro233, pro234, pro235, pro236, pro237, pro238, pro239, pro240,
35 pro241, pro242, pro243, pro244, pro245, pro246, pro247, pro248, pro249, pro250,

pro251, pro253, pro254, pro255, pro256, pro257, pro258, pro259, pro260, pro262,
pro263, pro264, pro267, pro268, pro269, pro270, pro271, pro272, pro273, pro275,
pro277, pro278, pro279, pro280, pro282, pro283, pro284, pro285, pro286, pro287,
pro289, pro290, pro291, pro292, pro293, pro294, pro295, pro296, pro297, pro298,
5 pro299, pro300, pro301, pro302, pro303, pro304, pro305, pro306, pro307, pro308,
pro309, pro310, pro311, pro312, pro313, pro315, pro316, pro317, pro318, pro319,
pro320, pro321, pro322, pro323, pro324, pro326, pro327, pro328, pro329, pro330,
pro331, pro332, pro333, pro334, pro335, pro336, pro337, pro338, pro339, pro340,
pro341, pro344, pro346, pro347, pro348, pro349, pro352, pro353, pro354, pro355,
10 pro356, pro358, pro359 and pro361.

Even more preferably, the first nucleic acid sequences are selected from the group
consisting of pro221, pro210, pro71, pro41, pro30, pro2; pro209, pro14, pro4, pro8,
pro246, pro16, pro27, pro5, pro49, pro19, pro140, pro139, pro207, pro81, pro273
15 and pro362 and fragments thereof.

The first nucleic acid sequence may also comprise more than one fragment of
nucleotide sequences selected from the above-mentioned group.

20 It is also contained within the present invention that the first nucleic acid sequence
further comprises nucleic acid sequences not natively associated therewith. The
nucleic acid sequences not natively associated therewith may for example be a
transcription factor binding sites, preferably one or more steroid hormone receptor
binding sites.

25

In preferred embodiments of the present invention the first nucleic acid sequences
may be any first nucleic acid sequence as outlined herein above.

In certain embodiments, nucleic acid sequences are stably integrated into the ge-
30 nome of the cell. This integration may be in the cognate location and orientation via
homologous recombination (gene replacement) or it may be integrated in a random,
non-specific location (gene augmentation). In further embodiments, the nucleic acid
sequences may be stably maintained in the cell as a separate, episomal segment of
DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to

permit maintenance and replication independent of or in synchronisation with the host cell cycle.

5 The targeting complex may in addition to a binding partner and a bioreactive species further comprise additional components. Additional components may for example be protective components.

10 When the bioreactive species is a nucleic acid the targeting complex may further comprise a protective capping, wherein said protective capping consists of nucleic acid sequences attached to the first and/or second nucleic acid sequences.

The nucleic acid sequences with protective properties may for example comprise a modified nucleotide. The modified nucleotide may for example be modified with one or more amino acids, amine groups or biotin groups.

15 In one embodiment of the present invention the bioreactive species is a toxin. A toxin is any species which is toxic to a cell expressing the cell surface molecule. For example the toxin may be selected from the group consisting of ricin, diphtheria toxin, pseudomonas exotoxin, streptozotocin or cholera toxin. However, this list of toxins is not complete and should not be regarded as limiting to the invention.

20 In another embodiment of the present invention the bioreactive species is an inducer of apoptosis. Any compound, which is capable of inducing apoptosis directly or indirectly, in a cell expressing a cell surface molecule, is an inducer of apoptosis within the meaning of the present invention.

25 An inducer of apoptosis may be a polypeptide (see herein below) or it may be any other kind of compound. For example the inducer of apoptosis may be selected from the group consisting of retinoic acid, A23187, Okadaic Acid, Puromycin, Staurosporine, Thapsigargin, Actinomycin D, Camptothecin, Cycloheximide, 30 Dexamethasone, Etoposide and Glucocorticoid. However, any other inducer of apoptosis is also contained within the present invention.

In yet another embodiment of the present invention the bioreactive species is a radioactive isotope. A radioactive isotope may be selected from the group consisting of (125)I, (131)I, (123)I, (111)In, (205)Bi, (206)Bi, (213)Bi, (186)Re, (188)Re, 35

(225)Ac, 99mTc, (68)Ga, (62)Cu, (90)Y, (64)Cu, (211)At, (212)Bi, (147)Lu, (153)Sm and (157)Gd. In one embodiment, the radioactive active species may be covalently linked to another species, for example the radioactive species may be covalently linked to a binding partner.

5

In a still further embodiment of the present invention the bioreactive species is a cytostatica. A cytostatica may for example be a drug, which can be used for chemotherapy. Drugs suitable for use in chemotherapy are mentioned herein below.

10 The bioreactive species according to the present invention may be an antagonist of a hormone, preferably an antagonist of a hormone selected from the group consisting of estrogens, androgens, progesterones, LH and RH.

Androgens can for example be selected from the group consisting of testosterone, 15 dihydrotestosterone, androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S) and derivatives thereof.

Estrogens can for example be selected from the group consisting of estrion, estradiol, estriol and derivatives thereof.

20

Alternatively, the bioreactive species may be an aromatase inhibitor.

In one preferred embodiment of the present invention the bioreactive species comprises or essentially consists of a polypeptide. In particular such a polypeptide 25 may be a therapeutic protein.

The term "therapeutic protein" is intended to refer to any polypeptide introduced into a cell for the potential benefit of the cell or to an organism comprising said cell.

A therapeutic protein may belong to a number of different classes. For example a 30 therapeutic protein may be a tumour suppressor, a toxic substance or it may be an inducer of apoptosis. The therapeutic protein according to the present invention may be a protein, which can contribute to a cell cycle arrest.

In the context of cancer treatment modalities, a particularly useful gene is a tumour 35 suppressor. During the process of transformation of normal cells to neoplastic cells,

the mutation of tumour suppressor genes is thought to play an important role. One of the most important functions of a tumour suppressor gene is to attenuate cell division and mediate apoptosis of mutated cells. Tumour suppressor genes are highly effective, so that mutation of both alleles of the tumour suppressor gene is necessary to obviate its function. The introduction of a functional tumour suppressor gene into a cancer cell with a mutated phenotype is therefore often sufficient to induce cell cycle arrest and apoptosis. p53, p73 and p16 are tumour suppressor genes frequently mutated in lung cancer. Introduction of a wild type version of these genes into cancer cells using a therapeutic gene-delivering vector to induce apoptosis is a possible way to kill cancer cells selectively. There are numerous tumour suppressors well known to those in the art, preferred examples include p53, p73, p16, Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, BRCA1, VHL, FCC and MCC. This list is not intended to be exhaustive of the various tumour suppressors known in the art but, rather, is exemplary of the more common tumour suppressors.

Preferably, the therapeutic protein is a tumour suppressor selected from the group consisting of p73, p16, Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-1, MEN-II, BRCA1, VHL, FCC, MCC, MSH2, PTCH, DPCH, TSC2, CDKN2A and ARF. More preferably, the therapeutic protein is p53.

The important endpoint of therapy for cancer is the killing or elimination of cancer cells. One of the commonly used approaches for induction of this event is the introduction of wild type p53 into cancer cells with mutated p53, resulting in cell cycle arrest and induction of apoptosis. The use of p53 as a therapeutic gene is dependent on the status of the endogenous p53 in the cancer cell. Wild type overexpression is often efficient, however, overexpression of p53 in combination with overexpression of cell cycle regulating genes, such as p16, may enhance the effect. Other cell cycle regulating genes such as p15, p17, p18 or p19 may also be effective in combination with p53 or other genes from the p53 family, such as p73. It is also possible that combination therapy with chemotherapeutic drugs or ionising radiation can markedly augment the therapeutic response to p53 gene therapy.

The Bcl-2 family of proteins are important regulators of cell death. They are comprised of two opposing factions, the proapoptotic versus the antiapoptotic members. All bcl-2 family members share one or more of four highly conserved domains, BH1,

BH2, BH3 and BH4. Bcl-2 family members include, but are not limited to, A1, mcl-1, bcl-2, bcl-w, bcl-x, bax, bad and bak. A1, bcl-2, mcl-1, bcl-w and bcl-xl (a long form of bcl-x) genes encode intracellular membrane proteins shown to block or delay apoptosis. Overexpression of these genes has been shown to confer resistance to apoptosis including that induced by chemotherapy. Antisense oligonucleotides or ribozymes directed against these genes and their proteins can be used therapeutically to induce apoptosis.

In contrast, bax, bad, bak and bcl-xs (a short form of bcl-x) are presently known to promote cell death by inhibiting the protective effects of the antiapoptotic bcl-2 family members. A possible method of inducing apoptosis in tumour cells is by introduction and overexpression of these genes.

Caspases (cysteine-aspartic-acid-proteases) are a class of proteins central to the apoptotic program. These proteases are primarily responsible for the degradation of cellular proteins that lead to the morphological changes seen in cells undergoing apoptosis. Caspases are present as inactive pro-enzymes that are activated by proteolytic cleavage. At least 12 caspases has been identified in humans.

Caspases 8, 9 and 3 are situated at pivotal junctions in apoptosis pathways. Caspase 8 and caspase 9 activate caspase 3 by proteolytic cleavage and caspase 3 then cleaves vital cellular proteins or other caspases. It is contemplated that the introduction and overexpression of one of these caspases will lead to apoptosis in cancer cells.

Preferably, the therapeutic protein is an inducer of apoptosis selected from the group consisting of Fas/Apo1, TNF, TRAIL, TGF- β , caspases, Bak, Bax, Bid, Bik and GZMB.

The bioreactive species according to the present invention may furthermore be an antibody that bind oncogenic proteins or other proteins involved in the formation of cancer. A list of oncogenic protein are given herein above.

Cancer cells often produce growth factors and growth factor receptors to sustain autocrine or paracrine loops that mediate proliferation, angiogenesis and evasion of the immune system. Accordingly, the bioreactive species may be an antibody, for

example an intracellular single chain that inhibits one or more growth factors selected from the group consisting of TGF- β , VEGF, IGF and growth factor receptors such as EGFR.

- 5 Additionally the therapeutic protein may be a protein capable of protecting the cell against a toxic agent or it may be a protein which is capable of catalysing the synthesis of a toxic substance.

10 Different systems have been developed where a protein is introduced that mediates the conversion of a prodrug to a cytotoxic compound. The herpes simplex virus thymidine kinase (HSV-tk) gene converts specific protoxic nucleoside analogs such as acyclovir and gancyclovir into potent DNA synthesis inhibitors. Cells capable of expressing HSV-tk are rendered extremely sensitive to the drug, while non-HSV-tk expressing cells are relatively insensitive. The effects of the prodrug conversion is
15 not only seen in the HSV-tk transduced cell, but also in the surrounding cells. This effect is termed the bystander effect, which is a therapeutic advantage, as it avoids the need to transduce 100% of the tumour cells with the HSV-tk gene.

20 Another such drug susceptibility therapeutic protein is the cytosine deaminase (CD). The CD protein catalyses the conversion of the prodrug 5-fluorocytosine (5FC) to 5-fluorouracil (5FU); treatment of CD transduced cells with 5FC results in the conversion of the 5FC into the antitumour drug 5FU into CD-positive tumour cells.

25 The therapeutic protein may furthermore be a toxic protein, such as cytokines, to be introduced to interfere with the expression of oncogenes and thus inhibit neoplastic cell growth.

30 The targeting complex according to the present invention may comprise more than one different bioreactive species, such as 2, for example 3, such as 4, for example 5, such as more than 5 different bioreactive species. For example the targeting complex may comprise more than one first nucleotide sequence encoding a therapeutic protein or more than one therapeutic protein, for example 2, such as 3, for example 4, such as 5, for example more than 5 first nucleotide sequences encoding a therapeutic protein and/or therapeutic proteins.

In some embodiments of the present invention the targeting complex further comprises a nuclear targeting signal. The nuclear targeting signal directs translocation into the nucleus. Certain bioreactive species must enter the nucleus to be active and accordingly it is advantageous if they are attached to a nuclear
5 localisation signal. For example DNA sequences must enter the nucleus in order to be transcribed.

The nuclear targeting signal according to the present invention may be any nuclear targeting signal, which is capable of localising to the nucleus. The nuclear targeting
10 signal may for example be an oligopeptide, preferably the nuclear targeting signal is selected from the group consisting of oligopeptide with the following sequences:

RRMKWKK PDX (SEQ ID 310)

RVHPYQR QKI (SEQ ID NO 311)

KRPACTLKPECVQQLLVCSQEAKK HCDA (SEQ ID NO 312)

15 PKKKRKV (SEQ ID NO 313) (SV40 LrgT)

GKKRSKA (SEQ ID NO 314) (H2B)

KAKRQR (SEQ ID NO 315) (v-Rel)

RGRRRRQR (SEQ ID NO 316)

RKRRR (SEQ ID NO 317)

20 PPVKRERTS (SEQ ID NO 318) (RanBP3)

PYLNKRKGKP (SEQ ID NO 319) (Pho4p)

CYGSKNTGAKKRKIDDA (SEQ ID NO 320) (DNAhelicaseQ1)

KKKKRKREK (SEQ ID NO 321) (LEF-1)

KKKRRSREK (SEQ ID NO 322) (TCF-1)

25 Krx{7,9}PQPKKKP (SEQ ID NO 323) (p53)

KVTKRKHDNEGSGSKRPK (SEQ ID NO 324)(Hum-Ku70)

RLKKLKCSKx{19}KTKR (SEQ ID NO 325) (GAL4)

RKRIREDRKx{18}RKRRK.TCPTP (SEQ ID NO 326)

RRERx{4}RPRKIPR (SEQ ID NO 327) (BDV-P)

30 KKKKKEEEGEGKKK (SEQ ID NO 328) (act/inh betaA)

PRPRKIPR (SEQ ID NO 329) (BDV-P)

PPRIYPQLPSAPT (SEQ ID NO 330) (BDV-P)

- KKKQKK (SEQ ID NO 361)
- REKKEKEQKEKCA (SEQ ID NO 362)
- LEKKVKKKFDWCA (SEQ ID NO 363)
- TEKK[QG]KSILYDCA (SEQ ID NO 364)
- 5 SDKKVRSLIECA (SEQ ID NO 365)
- LKRKLQR (SEQ ID NO 366)
- RRKGKEK (SEQ ID NO 367)
- CKRKT TNADRRKA (SEQ ID NO 368)
- VNEAFETLKRC (SEQ ID NO 369)
- 10 MPTEERVRRKESNRESARRSR YRKA AHLK (SEQ ID NO 370)
- KVNSRKRRKEVPGPNGATEED (SEQ ID NO 371)
- PRRGPR HCV (SEQ ID NO 372)
- PRGRRQPIPKARQP (SEQ ID NO 373)
- KRSAEGGNPPKPLKKLR (SEQ ID NO 374)
- 15 KRKx{11}KKKSKK (SEQ ID NO 375)
- EYLSRKGKLEL (SEQ ID NO 376)
- PKRPRDRHDGELGGRKRARG (SEQ ID NO 377)
- KRPAATKKAGQAKKKK (SEQ ID NO 378)
- KRKKEMANKSAPEAKKKK (SEQ ID NO 379)
- 20 RKRAFHGDDPFGGPPDKK (SEQ ID NO 380)
- GGGx{3}KNRRx{6}RGGRN (SEQ ID NO 381)
- YNNQSSNFGPMKGGN (SEQ ID NO 382)
- PAAKRVKLD (SEQ ID NO 383)
- KRPAEDMEEEQAFKR SR SxGTKRSYxxM (SEQ ID NO 384)
- 25 MNKIPIKDLLNPG (SEQ ID NO 385)
- PKKARED (SEQ ID NO 386)
- VSRKRPR (SEQ ID NO 387)
- APTKRKGS (SEQ ID NO 388)
- PNKKKRK (SEQ ID NO 389)
- 30 EEDGPQKKKRRL (SEQ ID NO 390)
- PLLKKIKQ (SEQ ID NO 391)

PPQKKIKS (SEQ ID NO 392)

PQPKKKP (SEQ ID NO 393)

SKRVAKRKL (SEQ ID NO 394)

IKYFKKFPKD (SEQ ID NO 395)

5 KTRKHRG (SEQ ID NO 396)

KHRKHPG (SEQ ID NO 397)

PQSRKKLR (SEQ ID NO 398)

HRKYEAPRH_x{6}PRKR (SEQ ID NO 399)

KKEKKKSKK (SEQ ID NO 400)

10

Wherein the name of the protein from which they have been derived is indicated in brackets and wherein '[KR]' indicates 'K or R', i.e. any of the two amino acids valid at that position, 'x' for 'any amino acid', 'x₉' for '9 times x', and 'x_{7,9}' for 'at least 7, at most 9 times x'. Amino acids are given in their one-letter code.

15

Furthermore, nuclear localisation signal according to the present invention may also be mutants of the above mentioned sequences, such as mutants wherein 1, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10 amino acids have been substituted for any another amino acid, preferably it is a conservative amino acid substitution (see herein above).

20

Mutants wherein 1, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10 amino acids have been deleted are nuclear localisation signal according to the present invention.

25

More preferably, the nuclear targeting signal is the nuclear localisation signal of simian virus 40 large tumour antigen.

30

In certain embodiments of the present invention the targeting complex further comprises a endosomal lytic agent. The targeting complex is frequently taken up into cells expressing the cell surface molecule by a process known as receptor mediated endocytosis and accordingly the targeting complex enters the cell in an endosome, which it has to escape in order to avoid degradation. Hence, the targeting complex often comprise an endosomal lytic agent.

- KDCVINKHHRNRCQYCRLQR (SEQ ID NO 331) (TR2)
- Krx{9}KTKK (SEQ ID NO 332)(THOV NP)
- APKRKSGVSKC (SEQ ID NO 333) (PolyomaVP1)
- RKKRRQRRR (SEQ ID NO 334) (HIV-1 Tat)
- 5 RQARRNRRRRWR (SEQ ID NO 335) (HIV-1 Rev)
- MPKTRRRPRRSQRKRPT (SEQ ID NO 336) (Rex)
- KRPMNAFIVWSRDQRRK (SEQ ID NO 337) (SRY)
- PRRRK (SEQ ID NO 338) (SRY)
- KRPMNAFMVWAQAARRK (SEQ ID NO 339) (SOX9)
- 10 PRRRK (SEQ ID NO 338) (SOX9)
- [KAR]TPIQKHWRPTVLTEGPPVKIRIETGEWE[KA] (SEQ ID NO 340)
- PPRKKRTVV (SEQ ID NO 341)
- YKRPCKRSFIRFI (SEQ ID NO 342)
- LKDVRKRKLGPGRH (SEQ ID NO 343)
- 15 KRPRP (SEQ ID NO 344)
- RKRKK (SEQ ID NO 345)
- RRSMKRK hVDR (SEQ ID NO 346)
- PAKRARRGYK (SEQ ID NO 347)
- RKCLQAGMNLEARKTKK (SEQ ID NO 348)
- 20 RRERNKMAAAKCRNRRR (SEQ ID NO 349)
- KRMRNRIAASKCRKRKL (SEQ ID NO 350)
- KKSKKGRQEALERLKKA (SEQ ID NO 351)
- RKEWLTNFMEDRRQRKL (SEQ ID NO 352)
- KKQTTLAFKPIKKGKKR (SEQ ID NO 353)
- 25 RKRKKMPASQRSKRRKT (SEQ ID NO 354)
- RAIKRRPGLDFDDDGEGNSKFLR (SEQ ID NO 355)
- SxGTKRSYxxM (SEQ ID NO 356)
- TKRSxxxM (SEQ ID NO 357)
- RIRKKLR (SEQ ID NO 358)
- 30 KRAAEDDEDDVDTKKQK (SEQ ID NO 359)
- GRKRKKRT (SEQ ID NO 360)

Many viruses have developed strategies to escape the endosome and accordingly an attenuated virus or parts of a virus may be useful endosomal lytic agents.

Preferably, the endosomal lytic agent is selected from the group consisting of polyethylenimine (PEI), a replication defective virus and a viral protein capsid.

5 More preferably, the endosomal lytic agent may comprise a membrane destabilising polypeptide.

In one embodiment of the present invention the targeting complex further comprises chloroquine. Chloroquine may protect against endosomal degradation and its
10 presence is accordingly desirable in some embodiments of the invention.

In preferred embodiments of the present invention the bioreactive species and the binding partner associates with one another either directly or indirectly. If the bioreactive species is a nucleic acid sequence, the binding partner may for example
15 associate with the bioreactive species via a nucleic acid binding agent covalently attached to said binding partner.

Nucleic acid-binding agents include proteins, polypeptides, peptides, antibodies, nucleotides, carbohydrates, fatty acids, organic or inorganic compounds as well as a
20 combination of these and others.

Nucleic acid-binding agents may bind to single-stranded or double-stranded DNA, to single-stranded or double stranded RNA, by chemical or physical forces or by a combination of the two. A nucleic acid-binding agent may (i) have affinity only for the
25 nucleic acid itself, (ii) have affinity for both the nucleic acid and another molecule, thereby forming a bridge between the two or (iii) have indirect affinity for the nucleic acid via affinity for another molecule that has affinity for the nucleic acid.

According to the present invention, the coupling of a nucleic acid-binding agent and
30 the binding partner must occur in a manner that does not interfere with the binding of the binding partner with the cell surface molecule. Preferably, internalisation of the targeting complex via receptor-mediated endocytosis is also retained. In an even more preferred embodiment, this recognition and internalisation delivers the nucleic acid sequences into a target cell in a form suitable for the expression or for interac-
35 tion with target endogenous nucleic acid.

In one embodiment, the nucleic acid-binding agent may insert itself between base pairs of double-stranded nucleic acids in an intercalative manner or bind in the minor or major groves of double-stranded nucleic acids.

5

This binding may be sequence-specific or completely unrelated to sequence. In other embodiments, nucleic acids may be cross-linked with other molecules with chemically or photochemically reactive groups.

10

In another embodiment of the invention, the nucleic acid-binding agent covalently links the nucleic acid to another molecule. In one embodiment, the nucleic acid binding agent is one of the coupling agents, such as carbodiimide. However, covalent coupling of the nucleic acid may alter its specificity and preclude proper gene expression or target nucleic acid recognition. Furthermore, linear or single stranded nucleic acid may be a requirement for covalent coupling of the nucleic acid to the binding partner. Finally, nucleic acids are negatively charged molecules which means that they may be repelled from cell surfaces, making transfer difficult via the endosomal lysis pathway. Therefore, a size and type restriction may be necessary for the efficient delivery of nucleic acid directly bound to binding partner.

20

An example of a nucleic acid-binding agent, is a polycationic agent that depends on electrostatic-dominated binding involving sequence-neutral interactions between the cationic groups and the negatively charged phosphates on nucleic acid similar to the DNA-binding agent described in WO 96/30536.

25

The polycationic agent binds DNA strongly resulting in the formation of a toroid complex where the negative charge of nucleic acid molecule is completely neutralised. This soluble toroid complex may be internalised via normal receptor-mediated endocytosis.

30

Any type of nucleic acid may be used, from single stranded mRNA to double stranded circular plasmids.

35

Furthermore, any size of nucleic acid may be used, as long as there is a source of negative charge for the polycationic agent to bind. In certain embodiments, these

polycationic moieties may include a natural polyamine such as spermine and/or spermidine. In a preferred embodiment, the polycationic agent may be an artificially produced agent, such as polylysine or polyethyleneimine.

- 5 In order for the invention to function properly, certain criteria with regard to the nucleic acid-binding agent need to be fulfilled. First, the nucleic acid to be delivered into the cell must bind to the nucleic acid binding agent without losing its integrity in any way.
- 10 Secondly, the complex comprising of ligand, nucleic acid binding agent and nucleic acid must be in soluble form to allow greater accessibility of the complex to cells *in vitro* and *in vivo*. Thirdly, once the complex is internalised within the host cell, the nucleic acid must have access to its target sequence while avoiding degradation.
- 15 The nucleic acid binding agent may include agents such as carbodiimides, N-succinimidyl,3 (2-pyridyldithio) propionate, succinimidyl,4-(N-maleimidomethyl) cyclohexane-1-carboxylate, diisocyanates, glutaraldehyde, diazobenzenes, and hexamethylene diamines. This list is not intended to be exhaustive of the various coupling agents known in the art but, rather, is exemplary of the more common linking
- 20 agents that may be used.

Preferably, the nucleic acid binding agent is selected from the group consisting of poly-L-lysine (PLL), spermine, spermidine and histone proteins.

- 25 When the nucleic acid binding agent is PLL, PLL may be comprising from 15 to 1000, such as from 50 to 750, for example from 100 to 500, such as from 200 to 400 residues.

- 30 In one embodiment of the present invention the binding partner associates with the bioreactive species indirectly via a pair of specific interacting components wherein one component is covalently attached to the bioreactive species and the second component is covalently attached to the binding partner.

- 35 One example of such a pair of specific interacting components is biotin and streptavidin, however other pairs of interacting components may also be used.

Complex comprising cell surface molecule and targeting complex

5 It is one objective of the present invention to provide complexes that comprise a cell surface molecule, a binding partner and a bioreactive species. Example of cell surfaces molecules, binding partner and bioreactive species are given herein above.

10 Preferably, the complex may comprise a cell surface molecule identified according to any of the methods according to the present invention and a targeting complex as described herein above.

Alternatively, the complex may comprise a cell surface molecule and a targeting complex as described herein above, wherein said cell surface molecule preferably comprises or essentially consists of or for example is GRIA2, such as LPR8, for example is CHRNA5, such as TMEFF, for example is NPTXR, such as Transferrin receptor; such as type II membrane protein clone: for example is HP10481; such as type II membrane protein clone: such as HP10390; for example is PG40; such as TRC8 ; for example is TR2-11; such as OA3 antigenic surface determinant; for example is integrin alpha 6, For example GPIIb; such as vitronectin receptor alpha subunit; for example is integrin alpha-7; such as integrin alpha E precursor; for example is integrin alpha 6B; such as integrin alpha 5 subunit; for example is integrin beta-5 subunit; such as integrin alpha-3 chain; for example is RYK; such as amyloid precursor protein-binding protein 1; for example is putative transmembrane GTPase; such as membrane cofactor protein; FOR EXAMPLE GLVR1; for example is Mr 110,000 antigen; for example is syndecan-1; such as putative seven transmembrane domain protein; for example is LCA-homolog/ LAR protein; such as M6 antigen; for example is Me491/CD63 antigen; such as multispinning membrane protein; for example is DDR; such as autocrine motility factor receptor; for example is insulin receptor precursor; such as IGF1R, for example is insulin-like growth factor II receptor; such as SAS; for example is TAPA-1; such as MICB; for example is MHC class II HLA-DR7-associated glycoprotein beta-chain; such as HLA-DP; for example is bone small proteoglycan I biglycan; such as CAR; for example is MEA11; such as interferon-gamma receptor alpha chain; for example is Polymeric immunoglobulin receptor; such as metabotropic glutamate receptor type 4; for

example is metabotropic glutamate receptor 8; such as CLPTM1; for example is
 MAGE-4b; such as MAGE5a; for example is MAGE-3; such as MAGE-1; for
 example is MAGE6; such as MAGE-9; for example is MAGE11; such as CD24; for
 example is CD59; such as CD44; for example is low density lipoprotein receptor;
 5 such as very low density lipoprotein receptor; for example is N-CAM; such as lamin
 B receptor homolog TM7SF2; for example is putative T1/ST2 receptor binding
 protein precursor; such as NTR2 receptor; for example is RAGE-4; such as HLA-G1;
 for example is MOAT-C; such as alpha 2 delta calcium channel subunit isoform I; for
 example is LFA-3; such as L1-CAM; for example is AVPR2; such as C1 p115 C1;
 10 for example is TE2; such as RbP; for example is HCF1; such as IRAK; for example
 is CD151; such as surface antigen; for example is MAG; such as GPR19; for
 example is pcta-1; such as PRAME; for example is vasopressin activated calcium
 mobilizing receptor-like protein; such as serotonin receptor 5-HT4B; for example is
 serotonin 1D receptor (5-HT1D~); such as CD9; for example is LDL receptor
 15 member LR3; such as DR6; for example is tumor necrosis factor receptor; such as
 HG38; for example is urokinase-type plasminogen receptor; such as FGF receptor;
 for example is nerve growth factor receptor; such as cystine/glutamate transporter;
 for example is CB1 cannabinoid receptor (CNR1); such as PSG; for example is
 PSG13'; such as CPE-receptor; for example is CRH2R; such as OCI5; for example
 20 is TRAIL receptor 2; such as HNMP-1; for example is kidney alpha-2-adrenergic
 receptor; such as erythropoietin receptor; for example is chondroitin sulphate
 proteoglycan versican V1; for example is mGluR1beta; such as CD97; for example
 is L6; such as NY-ESO-1; for example is T-cell receptor alpha delta; such as ror1;
 for example is ror2; such as SSTR2; for example is VESPR; such as IgG Fc
 25 receptor; for example is glutamate receptor subunit GluRC; such as HEK2; for
 example is PVR; such as CEA; for example is CC-chemokine-binding receptor
 JAB61; such as HER2; for example is HER3; such as hypothetical protein FLJ22357
 similar to Epidermal growth factor receptor-related protein; for example is putative
 endothelin receptor type B-like protein; such as GLVR2; for example is P2X4
 30 purinoreceptor; such as FPRL1; for example is Atrial natriuretic peptide clearance
 receptor; for example is gastrin/CCK-B receptor; such as Neuromedin B receptor;
 for example is GFRA3; such as GRPR; for example is CDH1; such as CDH2; for
 example is TGFBR1; such as TGFBR2; for example is TGFBR3; such as precursor
 of epidermal growth factor receptor.

More preferably, the cell surface molecule may be selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, GRIA2, GRM8, ITGAV, ITGAE, TNFRSF12, L1CAM, GPR49 and TMEFF1.

5 **Conditions**

A premalignant and/or malignant conditions may for example be cancer or a conditions which may develop into a cancer. The term cancer within the scope of the present invention covers both malignant and benign tumours, as well as leukaemia.

10

Cancer may for example be adenomas, carcinomas or sarcomas. Cancer may for example be selected from the group consisting of melanoma, brain tumours, neuroblastomas, breast cancer, lung cancer, prostate cancer, cervix cancer, uterine cancer, ovarian cancer, leukaemia, colon cancer, rectum cancer, cancer of the testis, cancer of the kidney, cancer of the liver, cancer of the lip, cancer of the tongue, cancer of the stomach, skin cancer, sarcomas, mesotheliomas, bladder cancer, bone tumours, malignant pleural effusions, ascites, meningeal carcinomatosis, head and neck cancers and cancers of endocrine organs such as: thyroid gland, pituitary gland and suprarenal gland.

20

Lung cancer may for example be cancers selected from the group comprising small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Preferably, the premalignant and/or malignant conditions is small cell lung cancer.

25

In one preferred embodiment the premalignant and/or malignant conditions is breast cancer.

30

In another preferred embodiment the premalignant and/or malignant conditions is a brain tumour. Brain tumours may for example be selected from the group comprising glioblastomas, neuroblastomas, astrocytomas, oligodendrogliomas, meningiomas, medulloblastomas, neuronomas, ependymomas, craniopharyngiomas, pineal tumours, germ cell tumours and schwannomas.

Administration and pharmaceutical compositions

The individual to receive treatment is any animal, however, preferably the individual is a human being.

- 5 The treatment according to the present invention may be ameliorating treatment, it may be curative treatment and/or it may be prophylactic treatment.

- 10 The main routes of drug delivery according to the present invention are intravenous, oral and subcutaneous, as will be described below. Other drug-administration methods, such as topical delivery, which are effective to deliver the drug to a target site or to introduce the drug into the bloodstream, are also contemplated. The compounds may also be administered by inhalation, that is by intranasal and oral inhalation administration.

- 15 The mucosal membrane to which the pharmaceutical preparation of the invention is administered may be any mucosal membrane of the mammal to which the biologically active substance is to be given, e.g. in the nose, vagina, eye, mouth, genital tract, lungs, gastrointestinal tract, or rectum.

- 20 Compounds of the invention may preferably be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques.

- 25 Preferably, the targeting complex according to the present invention is administered parenterally, more preferably the targeting complex is administered by intravenous injection and/or by subcutaneous injection.

- 30 The compounds according to the invention may be administered with at least one other compound. The compounds may be administered simultaneously, either as separate formulations or combined in a unit dosage form, or administered sequentially.

The dosage requirements will vary with the particular drug composition employed, the route of administration and the particular individual being treated. Ideally, an individual to be treated by the present method will receive a pharmaceutically effective amount of the compound in the maximum tolerated dose, generally no higher than that required before drug resistance develops.

The individual dosages of a targeting complex will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

The term "unit dosage form" as used herein refers to physically discrete units suitable as unitary dosages for human and animal individuals, each unit containing a predetermined quantity of a compound, alone or in combination with other agents, calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier, or vehicle. The specifications for the unit dosage forms of the present invention depend on the particular compound or compounds employed and the effect to be achieved, as well as the pharmacodynamics associated with each compound in the host. The dose administered should be an "effective amount" or an amount necessary to achieve an "effective level" in the individual patient.

Since the "effective level" is used as the preferred endpoint for dosing, the actual dose and schedule can vary, depending on interindividual differences in pharmacokinetics, drug distribution, and metabolism. The "effective level" can be defined, for example, as the blood or tissue level desired in the individual that corresponds to a concentration of one or more compounds according to the invention.

Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing

Company, 19th edition, Easton, Pa. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.

- 5 Pharmaceutical acceptable salts of the compounds according to the present invention should also be considered to fall within the scope of the present invention. Pharmaceutically acceptable salts are prepared in a standard manner. If the parent compound is a base it is treated with an excess of an organic or inorganic acid in a suitable solvent. If the parent compound is an acid, it is treated with an inorganic or
- 10 organic base in a suitable solvent.

- The compounds of the invention may be administered in the form of an alkali metal or earth alkali metal salt thereof, concurrently, simultaneously, or together with a pharmaceutically acceptable carrier or diluent, especially and preferably in the form
- 15 of a pharmaceutical composition thereof, whether by oral, rectal, or parenteral (including subcutaneous) route, in an effective amount.

- Examples of pharmaceutically acceptable acid addition salts for use in the present inventive pharmaceutical composition include those derived from mineral acids,
- 20 such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, p-toluenesulphonic acids, and arylsulphonic, for example.

- 25 Whilst it is possible for the compounds or salts of the present invention to be administered as the raw chemical, it is preferred to present them in the form of a pharmaceutical formulation. Accordingly, the present invention further provides a pharmaceutical formulation, for medicinal application, which comprises a compound of the present invention or a pharmaceutically acceptable salt thereof, as herein
- 30 defined, and a pharmaceutically acceptable carrier therefor.

- The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms. The pharmaceutical compositions and dosage forms may comprise the compounds of the invention or its pharmaceutically acceptable
- 35 salt or a crystal form thereof as the active component. The pharmaceutically accept-

able carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilisers, lubricants, suspending agents, binders, preservatives, wetting agents, tablet disintegrating agents, or an encapsulating material.

Preferably, the composition will be about 0.5% to 75% by weight of a compound or compounds of the invention, with the remainder consisting of suitable pharmaceutical excipients. For oral administration, such excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like.

In powders, the carrier is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably containing from one to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be as solid forms suitable for oral administration.

Drops according to the present invention may comprise sterile or non-sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour. Alternatively, the solution may be sterilised by filtration and transferred to the container aseptically. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or

acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

5 Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and
10 the like.

Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, toothpaste, gel dentrifice, chewing gum, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in
15 solutions in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as
20 natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.
25

The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume
30 infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting,
35

emulsifying or suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.

5

Oils useful in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils useful in such formulations include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid.

10

Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.

15

Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides; (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkano-lamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-beta.-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.

20

25

The parenteral formulations typically will contain from about 0.5 to about 25% by weight of the active ingredient in solution. Preservatives and buffers may be used. In order to minimise or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be

30

prepared from sterile powders, granules, and tablets of the kind previously described.

5 The compounds of the invention can also be delivered topically. Regions for topical administration include the skin surface and also mucous membrane tissues of the vagina, rectum, nose, mouth, and throat. Compositions for topical administration via the skin and mucous membranes should not give rise to signs of irritation, such as swelling or redness.

10 The topical composition may include a pharmaceutically acceptable carrier adapted for topical administration. Thus, the composition may take the form of a suspension, solution, ointment, lotion, sexual lubricant, cream, foam, aerosol, spray, suppository, implant, inhalant, tablet, capsule, dry powder, syrup, balm or lozenge, for example. Methods for preparing such compositions are well known in the pharmaceutical industry.

The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

35 Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the

preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturiser such as glycerol or an oil such as castor oil or arachis oil.

5 The pharmaceutical active compound described herein can be administered transdermally. Transdermal administration typically involves the delivery of a pharmaceutical agent for percutaneous passage of the drug into the systemic circulation of the patient. The skin sites include anatomic regions for transdermally administering the drug and include the forearm, abdomen, chest, back, buttock, mastoidal area, and
10 the like.

Transdermal delivery is accomplished by exposing a source of the active compound to a patient's skin for an extended period of time. Transdermal patches have the added advantage of providing controlled delivery of a pharmaceutical agent-
15 chemical modifier complex to the body. See Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery: Fundamentals and Applications, Robinson and Lee (eds.), Marcel Dekker Inc., (1987); and Transdermal Delivery of Drugs, Vols. 1-3, Kydonieus and Berner (eds.), CRC Press, (1987). Such dosage forms can
20 be made by dissolving, dispersing, or otherwise incorporating the pharmaceutical active compound in a proper medium, such as an elastomeric matrix material. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.

25 The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient
30 sized molds, allowed to cool, and to solidify.

The active compound may be formulated into a suppository comprising, for example, about 0.5% to about 50% of a compound of the invention, disposed in a polyethylene glycol (PEG) carrier (e.g., PEG 1000 [96%] and PEG 4000 [4%]).
35

The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

- 5 When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.

Pharmaceutical compositions usually comprise a carrier. Illustrative solid carrier include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium
10 stearate, stearic acid and the like. A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the
15 active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions, and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl
20 cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Illustrative liquid carriers include syrup, peanut oil, olive oil, water, etc. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a
25 pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of
30 liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl
35 oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form

compositions for parenteral administration. The liquid carrier for pressurised compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilised by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally either in liquid or solid composition form.

The carrier or excipient may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate along or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the like. When formulated for oral administration, 0.01% Tween 80 in PHOSAL PG-50 (phospholipid concentrate with 1,2-propylene glycol, A. Nattermann & Cie. GmbH) has been recognised as providing an acceptable oral formulation for other compounds, and may be adapted to formulations for various compounds of this invention.

Combination therapies

The targeting complex according to the present invention may be administered in combination with one or more second treatments, for example treatments which are currently used to treat cancer.

For example such second treatments may be selected from the group consisting of surgical treatment, chemotherapy, radiation therapy, therapy with cytokines, Hormone therapy, gene therapy, immunotherapy and treatments using laser light.

Chemotherapy comprise administration of a chemotherapeutical agent, such as a cytostatica. Cytostatica according to the present invention may for example be selected from the group consisting of carboplatin, cisplatin, cyclophosphamide, ifosfamide, hexamethylmelamine, doxorubicin, epirubicin, etoposide (VP-16), teniposide (VM-26), vincristine, vindecine, taxans, irinotecan, tyrosin kinase inhibitors, nimustine, lomustine, BCNU, farnesyl transferase inhibitors, anti angiogenetic compounds, anti metastatic compounds, 5-fluoruracil \pm leucovorin, topoisomerase inhibitor I and II and Temozolamide.

In addition, chemotherapy may for example comprise administration of Anti-estrogen, Anti-progesteron, anti-androgen, LH-RH antagonists or aromatase inhibitors

5 Examples

The following are examples of embodiments of the invention and should not be regarded as limiting for the present invention.

10 Example 1

Culture of small cell lung cancer (SCLC) cell lines:

The following small cell lung cancer cell lines were used for analysis

Cell line	Cell line established	Growth: A= adherent S= suspension	Growth medium
CPH 54A	University of Copenhagen, Denmark (Engelholm et al., 1986)	A	MEM (EAGLE) + 10% FCS
CPH 54B		A	MEM (EAGLE) + 10% FCS
GLC 2	Groningen Lung Cancer Centre, The Netherlands (de Leij et al., 1986; Berendsen et al., 1988, Bulte et al., 1993)	A (S)	RPMI + 10% FCS
GLC 3		S (A)	RPMI + 10% FCS
GLC 14		S	RPMI + 10% FCS
GLC 16		S	RPMI + 10% FCS
GLC 19		S	RPMI + 10% FCS
GLC 26		S	RPMI + 10% FCS
GLC 28		S	RPMI + 10% FCS
DMS 53	Dartmouth Medical School, NH, USA (Pettengill et al., 1980)	A	Waymouth + 10% FCS
DMS 79		S	RPMI + 10% FCS
DMS 92		A (S)	Waymouth + 10% FCS
DMS 114		A	Waymouth + 10% FCS
DMS 153		A	Waymouth + 10% FCS
DMS 273		A	Waymouth + 10% FCS
DMS 406		A (S)	Waymouth + 10% FCS

DMS 456		A (S)	Waymouth + 10% FCS
NCI H69	National Cancer Institute, MD, USA (Camey et al., 1985)	S	RPMI + 10% FCS
NCI N417		S	RPMI + 10% FCS
MAR H24	Philips University, Marburg, Germany (Bepler et al., 1987)	S	RPMI + 10% FCS
MAR 86 MI		S	RPMI + 10% FCS

All cells were maintained at 37°C in 5% CO₂ in a humidified atmosphere in medium without antibiotics and passaged twice weekly. All media and serum were obtained from Life Technologies.

5

Xenografts

0.5-1.2 x 10⁷ cells were inoculated bilaterally, subcutaneously in the flanks of 12-13 weeks old Balb/c nude mice. The mice were sacrificed and the xenografted tumors were harvested when one of the tumors had reached a maximal diameter of 1 cm. Necrotic tissue was removed. The cell line CPH 136A was only propagated in nude mice by inoculation of a 2 mm tumor block. Tumors for RNA isolation were either processed immediately or stored 24 hours in RNA *later* (Ambion) followed by storage at -70°C and processed as described below. Tumors used for lysates for Western blot analyses were processed immediately as described below.

15

RNA from normal tissues

Total RNA from normal, human tissues were obtained from either Clontech (fetal brain, brain, lung, kidney, heart, trachea, adrenal gland, prostate, salivary gland, thyroid) or from Ambion (lung, liver, brain, pancreas, spleen, small intestine, skeletal muscle, colon, stomach, testes). Only one sample was analysed in duplicate (lung RNA from Clontech and Ambion) and one in triplicate (brain RNA from 2 different batches from Clontech and one from Ambion). Fetal brain was included as a reference for embryonal, neuroendocrine tissue.

25

Isolation of RNA from cell lines.

Cells from semi-confluent cultures were harvested (by trypsinisation for adherent cells) and total RNA from approx. 10⁷ cells was isolated using RNeasy Kit (Qiagen)

30

according to manufacturers instructions. Xenografted tumors (fresh or after storage in RNA *later*) were homogenised in TRIzol (Life Technologies) and RNA purified according to the manufacturers instruction. The TRIzol isolated RNA was further purified using RNAeasy kit (Qiagen).

- 5 The concentration of the RNA was estimated by the absorption at 260nm (A_{260}). The integrity of the RNA was verified by measuring the ratio of $A_{260/280}$ to be 1.9 or more and by estimating the ratio of 28S rRNA to 18S rRNA analysed by formaldehyde (denaturing) gel analysis to being approximately 2.

10 Preparation of cDNA.

- 10 µg total RNA in 10 µl H₂O was hybridised to 100 pmol T7-(dT)₂₄ primer (HPLC purified 5'- GGCCAGTGAATTGTAATACGACTCACTATAGGGAGG-CGG(T)₂₄ (SEQ ID NO 401) obtained from GENSET) after denaturation at 70°C for
- 15 10 min. The following reactions were performed using reagents from Gibco BRL, Life Technologies. First strand synthesis was performed using 400 U SuperScript RnaseH⁻ Reverse Transcriptase kit in a 20 µl reaction in first strand buffer (50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl₂) 10 mM DTT, 0.5 mM dNTPs (each) at 42°C for 1 hour. The second strand synthesis was performed in a 150 µl reaction in
- 20 second strand buffer (20 mM Tris-Cl (pH 6.9), 5 mM MgCl₂, 100 mM KCl, 0.15 mM β-NAD⁺, 10 mM(NH₄)₂SO₄ containing 0.26 mM dNTPs, 0.07 U/µl E. coli DNA ligase, 0.27 U/µl E. coli DNA polymerase, 0.013 U/µl E. coli Rnase H by incubation for 2 hours at 16°C. DNA ends were filled out by addition of 0.07 U/µl T4 DNA polymerase and incubation for 5 min at 16°C. The reactions were terminated by addition of
- 25 EDTA to 33 µM final concentration. The cDNA was purified by extraction with 1 volume phenol:chloroform:isoamylalcohol (25:24:1) saturated with 10 mM Tris-HCl (pH 8.0), 1 mM EDTA followed by precipitation in 2.5 M NH₄Ac in 63% ethanol with addition of 2 µl Pellet Paint (Novagen) for visualization of pellet. After 2 consecutive rinsing of the pellet with 80% ethanol, the pellet was air dried and dissolved in 12 µl
- 30 water. An aliquot was analysed by agarose gel electrophoresis to ensure the length of the cDNA to be in the range of 0.1->10 kb.

Preparation of biotin labelled cRNA (IVT-cRNA)

In vitro transcription generating biotin labelled cRNA (complementary RNA) with T7 RNA polymerase using biotin labelled ribonucleotides was performed with the BioArray™, High Yield™ RNA transcript labelling kit from Enzo Diagnostics, NY, USA) using 6 µl cDNA (estimated to contain approx. 1µg cDNA) in a 40 µl reaction according to manufacturers specifications. The biotin labelled cRNA was purified using RNeasy spin columns kit (Qiagen) according to manufacturers specified method for RNA cleanup. An aliquot of the IVT-cRNA was analysed by denaturing agarose gel electrophoresis to ensure full length transcripts (.1->10 kb). The concentration of the cRNA was estimated by the absorption at 260nm and corrected for contribution of total RNA initially used for the cDNA reaction. The yield varied from 25-100 µg per reaction.

Fragmentation of IVT-cRNA

22 µg IVT-cRNA was fragmented by incubation in 0.04 M Tris-Acetate (pH 8.1), 0.03 M MgAc, 0.1 M KAc in a 20 µl reaction for 35 min at 94°C. An aliquot of the fragmented IVT-cRNA was analysed by agarose gel electrophoresis to ensure fragmentation to the size of 30-200 bases.

Hybridisation to Affymetrix GeneChip™ and analysis of data (CHIPs analysis)

A hybridisation mixture containing 20 µg of fragmented IVT-cRNA in a volume of 400 µl containing 0.1 M MES, 0.75, [Na⁺], 0.1 mg/ml herring sperm DNA, 0.1 mg/ml acetylated BSA, 0.05 nM biotinylated control oligo B2 (5'- GTCGTCAA-
GATGCTACCGTTCAGGA (SEQ ID NO 402)) and control biotin labelled IVT-cRNA for spiking prepared from the plasmids pglks-bioB (150 pM), pglks-bioC (500 pM), pglks-bioD (2.5 nM) and pglks-cre (10 nM) (American Tissue Culture Collection). The control oligo and control cRNAs were obtained from Affymetrix. 100 µl was hybridised to an Affymetrix test2 CHIP followed by staining with a streptavidin-phycoerythrin conjugate and labelling with biotinylated anti-streptavidin goat antibody followed by a final staining with streptavidin-phycoerythrin conjugate (according to the manufacturers protocol Mini-euk1) or 300 µl was hybridised to an Affymetrix U95A GeneChip and stained according to the manufacturers protocol EukGE-WS2 in an Affymetrix Fluidics station and scanned at 560 nm in a confocal laser scanner (Hewlett Packard GeneArray Scanner G2500A). The digitalized image

data was first processed using Affymetrix Microarray Suite™ version 4.0 for evaluation of the quality of the RNA and hybridisation and Affymetrix Data Mining Tool (version 2.0) for selection of candidate genes. The data was re-analysed using Affymetrix Microarray Suite™ version 5 (see results) for selection of surface molecules.

Data was only used from analyses where: the control oligos BioB, BioC, BioD and Cre were all detected as present; the scaled noise (Q) was below 10; the ratio of detection of the mRNA levels of the 5' ends relative to the 3' end of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin were below 2 ; at least 40% of all probe sets were identified as present. For comparison between samples, the global intensity was set at 100.

RT-PCR

Semi-quantitative RT-PCR was performed on selected genes for validation of the Chips analysis. cDNA prepared as described above was used for the RT-PCR but as an independent preparation than used for Chips analysis. The PCR reaction was performed using cDNA from 350 ng total RNA in a 25 µl reaction with 200 nM primers (DNA Technology A/S), 1.5 mM MgCl₂, 0.2 mM each dNTPs, 0.1U/µl Platinum Taq Polymerase (Life Technologies) in the buffer provided with the enzyme with 0.008% cresol red and 12% sucrose as loading buffer.

All reactions were run 94°C, 2 min, 1 cycle; 94°C, 30 sec, annealing temperature as indicated for each primer set, 30 sec, 72°C, 30 sec for 25 cycles and a final extension step of 72°C 10 min. Using only 25 cycles makes the reaction semi-quantitative.

The primer sets used were:

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

512 bp PCR product spanning GenBank Acc. no. NM_002046 bp. 608-1119,

Sense: 5'-TCCATGCCATCACTGCCACCCA (SEQ ID NO 403)

Antisense: 5'-TCTTGTGCTCTTGCTGGGGCTG (SEQ ID NO 404) Annealing temp. 56°C

One RT-PCR reaction has been performed.

Pro 30 (KIAA0042)

432 bp PCR product spanning GenBank Acc. no. D26361 bp. 5181-5612 ,

Sense: 5'- GTTTTGAATCTGAAGAAAGCCC (SEQ ID NO 405)

Antisense: 5'-TCAAACCTCCTGACCTTGTGATCT (SEQ ID NO 406) Annealing

5 temp. 49°C.

2 independent RT-PCR reactions have been performed.

Pro 41 (MAD2)

525 bp PCR product spanning GenBank Acc. no. AJ000186 bp. 643-1167 ,

10 Sense: 5'- GTAAATAGCATGGTGGCCTACA (SEQ ID NO 407)

Antisense: 5'-GGTCCAAAGGAGCTATACAGCA (SEQ ID NO 408) Annealing temp.
45°C.

2 independent RT-PCR reactions were performed.

15

Pro 221 (insulinoma-associated antigen, IA-1)

532 bp PCR product spanning GenBank Acc. no. M93119 bp. 1549-2080 ,

Sense: 5'- GTGTTCCCCTGCAAGTACTGCCC (SEQ ID NO 409)

Antisense: 5'-CAGAGATTGGTAGGCGAGGCGA (SEQ ID NO 410) Annealing

20 temp. 52°C

2 independent RT-PCR reactions were performed.

Pro 210 (lamin B1)

25 439 bp PCR product spanning GenBank Acc. no. L37747 bp. 424-862 ,

Sense: 5'-ACTGTGTACTGTTCGGAAGGG (SEQ ID NO 411)

Antisense: 5'-TAGAGAAACCCTTCCCTCCC (SEQ ID NO 412) Annealing temp.
46°C.

Only one RT-PCR reaction has been performed. RT-PCR was not performed on
30 testis

Pro 71(p16INK4/MTS 1, CDKN2A)

437 bp PCR product spanning GenBank Acc. no. U26727 bp.176-612 ,

35 Sense: 5'- TGAGGAGCCAGCGTCTAGGG (SEQ ID NO 413)

Antisense: 5'-GTGGCCCTGTAGGACCTTCG (SEQ ID NO 414) Annealing temp. 57°C

Only one RT-PCR reaction has been performed. RT-PCR was not performed on testis

5

DR6 (TNFRS12, tumor necrosis factor receptor superfamily member 21)

559 bp PCR product spanning GenBank Acc. no. AF068868 bp. 1081-1639 ,

Sense: 5'- GTGCTTGTGGTGATTGTGGTGTG (SEQ ID NO 415)

Antisense: 5'-TGTTCTTGTCTGTGGGAAGG (SEQ ID NO 416) Annealing temp.

10 56°C.

2 independent RT-PCR reactions were performed.

NCAM1 (neural cell adhesion molecule)

456 bp PCR product spanning GenBank Acc. no. HSU63041 bp 2045-2500,

15 Sense: 5'- TATGAGGTCTACGTGGTGGC (SEQ ID NO 417)

Antisense: 5'- CTCCTGGCACTCTGGCTTTG (SEQ ID NO 418) Annealing temp. 53 °C.

Only one RT-PCR reaction has been performed. RT-PCR was not performed on testis

20

NPTXR (Neuronal pentraxin receptor)

482 bp PCR product spanning GenBank Acc. no. HS327J16 bp.46012-46493 ,

Sense: 5'- CACACGCACACATGTTGCAGC (SEQ ID NO 419)

Antisense: 5'- GCTCTGAGAGGCCAAAGCC (SEQ ID NO 420) Annealing temp.

25 55°C.

Only one RT-PCR reaction has been performed. RT-PCR was not performed on testis

GLUR2 (ionotropic glutamate receptor 2; GRIA2)

30 522 bp PCR product spanning GenBank Acc. no. L20814 bp. 2449-2970 ,

Sense: 5'- AGGAACCCAGTAAATCTTGCGAG (SEQ ID NO 421)

Antisense: 5'- TCAGTCACACTGACATTCATTCCC (SEQ ID NO 422) Annealing temp. 51°C

Only one RT-PCR reaction has been performed. RT-PCR was not performed on testis

35

ITGAV (integrin alpha V subunit)

533 bp PCR product spanning GenBank Acc. no. M14648 bp. 3867-4399 ,

Sense: 5'- AATTTTAGGTCAAATCCTTCAAGCCAAC (SEQ ID NO 423)

5 Antisense: 5'-TGACAGCCGAGACTGATTTTACACATTA (SEQ ID NO 424) Annealing temp. 50°C.

Only one RT-PCR reaction has been performed. RT-PCR was not performed on testis

10 *LRP8 (apolipoprotein E receptor 2)*

459 bp PCR product spanning GenBank Acc. no. HSZ75190 bp. 2016-2474 ,

Sense: 5'- GCTCCATATAGGGAGAACTGCTCAG (SEQ ID NO 425)

Antisense: 5'-CCCCAGCAACCAAACATCTTCT (SEQ ID NO 426) Annealing temp. 50°C.

15 Only one RT-PCR reaction has been performed. RT-PCR was not performed on testis.

Western blotting

20 Protein samples

Whole cell lysates were extracted from cell lines and xenografted tumors for validation of protein expression of selected genes. The lysates were prepared from semi confluent cultures of cell lines by scraping with a rubber policeman (for adherent cells) and washing in ice-cold 20 mM Tris-Cl pH 7.5. The cell pellet was lysed in ice

25 cold 20 mM Tris-Cl pH 7.5, 2% Triton X-100 containing Protease Inhibitor Cocktail set II and III (Calbiochem) diluted 1:100. After vortexing the lysates were cleared by centrifugation at 15.000 x g for 5 min, 4°C. Lysates from xenografted tumors was

prepared immediately after harvesting of the tumors and a lysate from an adult rat brain was processed in a similar manner. The tumors were weighed and homogenised using a Heindolph DIAX 900 homogenised in 5 volumes (w/w) ice cold 20 mM
30 Tris-Cl pH 7.5, 2% Triton X-100 containing Protease Inhibitor Cocktail set II and III (Calbiochem) diluted 1:100. cleared by centrifugation at 15.000 x g for 5 min, 4°C. Protein concentration of the lysates was determined using the BCA Protein Assay (Pierce) as recommended by the manufacturer.

Commercial cell lysates of Jurkat (Santa Cruz) and A431 (Neomarkers) were used as positive controls in some western blots.

SDS-PAGE and blotting.

- 5 5-15 µg lysate was loaded per lane in LDS sample buffer with reducing agent (Nu-PAGE) and separated on 3-8% Tris Acetate SDS gels, run for 150 V 1 hr in Tris-Acetate SDS running buffer (NuPAGE) and transferred to PVDF LC 2002 (Novex) membrane in Transfer Buffer (NuPAGE). Protein size marker was ProSieve colour protein marker. For probing with anti-NCAM1 antibodies, the lysates were pre-
- 10 treated for 5 min at 37°C with 40 ng/µl recombinant EndoN-HIS (gift from E. Bock) to remove polysialylation.

- The membranes were blocked in washing buffer (10 mM Tris-Cl pH 7.5, 100 mM NaCl, 0.1% Tween 20) containing 5% low fat milk for 60 min at room temperature (for antibodies against Integrin αE (CD103), For ITGAE a Tris-Cl buffer pH 10.2 was
- 15 used for all incubation and washing procedures. The blots were incubated with primary antibodies and secondary antibodies in blocking buffer as described below and bound antibodies visualised by ECL (Amersham) or alkaline phosphatase using NBT/BCIP tablets (Roche) as recommended by the manufacturers.

- 20 *NCAM1 (neural cell adhesion molecule)*

Primary antibody: Mouse monoclonal anti-NCAM1 clone 123C3 (Santa Cruz) diluted 1: 100 Incubation 16 hours at 4°C. Secondary antibody: Alkaline phosphatase conjugated rabbit anti-mouse Ig (DAKO) diluted 1: 500. Incubation 1 hour at room temperature. Development by alkaline phosphatase.

25

GluR2 (ionotropic glutamate receptor 2)

Primary antibody: Mouse monoclonal anti GluR2 and 4 (clone3A11) (Pharmingen) diluted 1:500. Incubation 16 hours at 4°C. Secondary antibody: Alkaline phosphatase rabbit anti mouse Ig (DAKO) diluted 1: 500 Incubation 1 hour at room temperature. Development by alkaline phosphatase.

30

GRM8 (GluR8 (metabotropic glutamate receptor 8))

Primary antibody: Rabbit polyclonal anti-mGluR8 (Upstate Biotechnology, TriChem) diluted 1: 500. Incubation 16 hours at 4°C. Secondary antibody: Horseradish peroxi-

dase swine anti rabbit Ig (DAKO) diluted 1: 1000 Incubation 1 hour at room temperature. Development by ECL.

NPTXR (neuronal pentraxin receptor)

5 Primary antibody: Goat polyclonal anti NPTXR (C-17)(Santa Cruz) diluted 1: 500 Incubation 16 hours at 4°C. Secondary antibody: Horseradish peroxidase rabbit anti goat Ig (DAKO) diluted 1: 1000 Incubation 1 hour at room temperature. Development by ECL

10 *ITGAE (integrin alpha E subunit)*

Primary antibody: Goat polyclonal anti Integrin α E (N-19) (Santa Cruz) diluted 1:1000. Incubation 16 hours at 4°C.

Secondary antibody: Alkaline phosphatase rabbit anti goat Ig (sc-2771) (Santa Cruz) diluted 1: 500. Incubation 1 hour at room temperature

15 Development by alkaline phosphatase.

Cluster analysis of obtained Chips analysis data.

20 To interpret the variation in expression patterns seen between the normal tissues analysed and the small cell lung cancer cell lines we took advantage of the properties of both SOMs (self-organising maps) and hierarchical clustering. These were used consecutively to group genes on the basis of similarity in the pattern of expression. Genes used for the analysis were those that had an average difference of more than 50 and were scored present in any one of the samples.

25

SOMs

30 Self-Organising maps (SOMs) is a method of cluster analysis that is somewhat related to k-means clustering. The basic principle behind the SOM algorithm is that the weight vectors of neurons, which are first initialised randomly, come to represent a number of original measurement vectors during an iterative data input (Toronen et al, 1999). The following parameters were used in the calculations: **Genes**: Xdim: 1, Ydim: 10, Iterations: 100000, **Samples**: Xdim: 1, Ydim: 10, Iterations: 20000.

35 Hierarchical Clustering

The basic idea behind hierarchical clustering is to assemble a set of items (genes or arrays) into a tree, where items are joined by very short branches if they are very similar to each other, and by increasingly longer branches as their similarity decreases. The output file from the SOM clustering is used for the hierarchical clustering, meaning that the ordering by the SOM clustering is used to guide the flipping of nodes in the hierarchical tree (Eisen et al., 1998). The following parameters were used in the calculations: **Genes**: Cluster: Yes, Calculate weights: Yes, Similarity matrix: correlation uncentered, **Samples**: Cluster: Yes, Calculate weights: Yes, Similarity matrix: correlation uncentered. Subsequently an Average Linkage cluster analysis was performed.

Results of clustering analysis

Clustering of the X-axis (samples) (Fig 2) showed as expected that the SCLC cell lines clustered together, with Mar86MI and CPH54A being furthest apart. CPH54A and B clustered very close (B is a clonal variant of A), as did GLC14, GLC16 and GLC19 (derived from the same patient). Of the normal tissues expression from lung RNA obtained from Ambion and lung RNA obtained from CLONTECH clustered very close, as did 2 different batches of brain RNA obtained from CLONTECH with brain RNA obtained from Ambion. Expression from RNA obtained from fetal brain likewise clustered close to the mature brain and was the closest of all normal tissues to the SCLC cell lines. This confirms that SCLC lines are of neuro-endocrinal origin. Clustering of the Y-axis (genes) clearly found 4 very distinct clusters of genes with higher expression in the SCLC cell lines. The smallest contained 19 genes, the second and third 65 each, and the fourth and largest gene cluster 268.

Selection criterias for candidate promoters (first nucleic acid sequences).

The candidate promoters were chosen based on expression level of the gene, which the promoter controls. The selection was performed on all 21 SCLC cell lines, but not xenografts and on 7 normal tissues (brain, adrenal gland, lung, kidney, heart, prostate, pancreas).

Selection was based on several criteria. Only genes, which scored present (P) in the absolute call and with an Average difference >50 (level of expression) were included. These output data were further processed in Microsoft Excel 2000. Genes were selected which were scored present in at least 11 of the 21 SCLC lines and if

the gene was scored present in one or more normal tissues, the median Average difference value of the SCLC cell lines must be 4 times or more above the median Average difference value of the normal tissue. After a second screening using RNA from more normal tissues, the selected candidates are submitted to the same criteria as above and discarded if they do not fulfil the above requirements.

Validation of Chips analysis by RT-PCR

Selected genes were analysed by semi-quantitative RT-PCR for verification of expression identified by Chips analysis. The quality of the cDNA was tested using primers for GADPH (Glyceraldehyde-3-phosphate dehydrogenase) (Fig. 2). All cDNA samples were very positive showing that the quality of the cDNA for further analysis was good.

RT-PCR with primers for Pro 221 (IA-1, insulinoma associated antigen 1) (Fig. 3) showed that in normal tissue adrenal gland and brain and fetal brain are weakly positive in both Chips and RT-PCR analysis. 4 SCLC lines or xenografts are negative in both analyses. All others are weak to very strongly positive. The RT-PCR and Chips analysis correlate extremely well.

RT-PCR with primers for Pro 30 (KIA0042) (Fig. 4) showed that in normal tissue testes is positive for both Chips and RT-PCR. Other normal tissues are low or negative by both analysis methods. All SCLC cells and xenografts are positive in both Chips and RT-PCR analysis. There are a few samples where the relative amounts in Chips and RT-PCR do not correlate (e.g. high in one and low in the other analysis).

RT-PCR with primers for Pro 41 (MAD2) (Fig. 5) shows low expression in most normal tissues and high expression in testes measured both by Chips analysis and RT-PCR. All SCLC cell lines and xenografts show very high expression by both Chips and RT-PCR analysis.

RT-PCR with primers for Pro 210 (lamin B1) (Fig. 6) showed very low or no expression in normal tissues (colon positive for both assays). All SCLC and xenografts have high expression by Chips analysis – all except 2 are very positive by RT-PCR. RT-PCR values are arbitrarily chosen to match Chips signal.

RT-PCR with primers for Pro 71 (CDKN2A) (Fig. 7) showed very low or no expression in normal tissues and high expression in all but 4 SCLC. Excepto for one sam-

ple negative in RT-PCR and positive in Chips analysis, the RT-PCR and Chips data correlate very well.

Conclusion on validation of Chips analysis by RT-PCR.

5

The Chips data and RT-PCR data correlate extremely well. The low to none expression in most normal tissues observed by Chips analysis is confirmed by the semi-quantitative RT-PCR reaction. The expression of the selected genes in SCLC cell lines and xenografts are very high and in all or most cell lines. Therefore using
10 Chips analysis for identification of promoters with high and specific expression is an applicable method.

Selection criteria's for candidate cell surface molecules identified by Chips analysis.

15 The first generation of candidate cell surface molecules were selected on basis of several criteria. The selection was performed on all 21 SCLC cell lines, but not xenografts and on 7 normal tissues (brain, adrenal gland, lung, kidney, heart, prostate, pancreas). Only genes, which scored present (P) in the absolute call and with an Average difference >50 were included. These output data were further processed
20 in Microsoft Excel 2000. A gene was set to score one point for each cell line or tissue. The total scores for each gene were summarised for normal tissue and the SCLC cell lines, respectively. Genes were selected which were scored present in at least 5 of the 21 SCLC lines. A search was performed among these and candidate genes selected if one of the following words is included in the gene name: "receptor,
25 membrane, adhesion, integrin, surface, antigen, syndecan, transport, channel, hormone, binding, glycoprotein, matrix, CAM, desmosome, gap junction, delta, immunoglobulin, MHC, CD, (HSPG, CSPG, integral, notch)". The functions and cellular localisations of the proteins were unravelled based on database searches (NCBI: Nucleotide, Protein, Nucleotide, OMIM, PubMed, LocusLink). The best candidate
30 genes were then selected based on these informations with emphasis on the function, cellular localisation and scores on expression (i.e. higher "expression score" for SCLC than for normal tissue). Furthermore, the expression in the different normal tissue is evaluated according to the specific tissues, in order to estimate the theoretical side effects. A second selection was performed on RNA from 21 SCLC cell
35 lines, 8 of the cell lines grown as xenografts and 17 normal tissues (brain, lung, kidney, heart, trachea, adrenal gland, prostate, salivary gland, thyroid, liver, pancreas,

spleen, small intestine, skeletal muscle, colon, stomach, testes) using the Affymetrix Microarray Suite™ version 5. Only expressed genes, which scored present (P) in the absolute call and with a signal >20 in at least 6 SCLC cell lines or xenografts were included. Further selection was performed as described above.

5

Validation of Chips analysis by RT-PCR

Selected genes were analysed by semi-quantitative RT-PCR for verification of expression identified by Chips analysis. RT-PCR with primers for DR6 (TNFR related death receptor 6) (Fig. 8) shows medium expression in most normal tissues and medium to high in all except one SCLC line or xenograft. Chips analysis shows high expression in 2 normal tissues and high expression in 8 SCLC lines or xenografts. All positive by Chips analysis are also positive in RT-PCR.

RT-PCR with primers for LRP8 (Apolipoprotein E receptor 2) (Fig. 9) shows low expression in 6 normal tissues and high expression in all SCLC lines and xenografts are positive by RT-PCR. All positives in Chips analysis are also positive in RT-PCR. RT-PCR values are arbitrarily chosen to match Chips signal.

RT-PCR with primers for NTPXR (neuronal pentraxin receptor) (Fig. 10) showed that all positive by Chips analysis are also positive by RT-PCR. There are more tissues and SCLC with positive expression as measured by RT-PCR, but expression is averagely higher in SCLC. Two SCLC samples are negative. RT-PCR values are arbitrarily chosen to match Chips signal.

RT-PCR with primers for NCAM1 (neural cell adhesion molecule) (Fig. 11) showed all samples positive by Chips analysis were also positive by RT-PCR. Several tissues and all except one SCLC are positive by RT-PCR only. One SCLC cell line is negative in both RT-PCR and Chips analysis. RT-PCR values are arbitrarily chosen to match Chips signal.

RT-PCR with primers for GluR2 (ionotropic glutamate receptor 2)(Fig. 12A) showed all samples positive by Chips analysis were also positive by RT-PCR. Both analysis showed very high expression in brain and RT-PCR low expression in adrenal gland. 4 SCLC cell lines are negative in both RT-PCR and Chips analysis. RT-PCR values are arbitrarily chosen to match Chips signal.

RT-PCR with primers for ITGAV (integrin alpha v subunit) (Fig. 12B). 5 samples are positive in Chips analysis, but negative by RT-PCR. Otherwise good correlation

between Chips analysis and RT-PCR analysis. High expression in SCLC, but also in many tissues.

RT-PCR values are arbitrarily chosen to match Chips signal.

5 Conclusion on validation of Chips analysis of expression of surface molecules by RT-PCR.

Except for ITGAV all genes identified as expressed by Chips analysis were also found expressed when analysed by RT-PCR. More samples were positive when
10 measured by RT-PCR. The expression of the selected genes in SCLC cell lines and xenografts are high and in many cell lines. Therefore using Chips analysis for identification of mRNA for surface molecules expressed by SCLC is an applicable method.

15 Validation of Chips analysis by western blotting

Expression of selected gene products was analysed by western blotting using specific antibodies for comparison to of expression of mRNA identified by Chips analysis. Western blot analysis was only performed on SCLC cell lines and xenografts.
20 Western blot analysis using antibodies to mGluR8 (metabotropic glutamate receptor 8) (Fig. 13) showed expression of mGluR8 protein in all SCLC cell lines and xenografts, whereas Chips analysis only detected expression in 8 samples. The intensities of the western blot do not correlate to the Chips values, but clearly show expression of mGluR8. Rat brain homogenate was used as positive control.
25 Western blot analysis using antibodies to NPTXR (neuronal pentraxin receptor) (Fig. 14) showed protein expression in all SCLC samples identified as having expression by Chips analysis. All samples are weak to strongly positive except GLC 28. DMS 153 has a prominent high molecular weight band also present in rat brain, which may be unprocessed or dimerised receptor. The protein amounts do not directly
30 correlate with the Chips data, but clearly show expression in most SCLC. Rat brain homogenate was used as positive control.
Western blot analysis using antibodies to NCAM1 (neural cell adhesion molecule) (Fig. 15) showed expression of two isoforms of NCAM1 by all SCLC cell lines and xenografts except one, whereas Chips analysis identified expression in 14 samples.
35 All samples positive by Chips analysis are positive by western blotting.

There is no obvious correlation between relative amounts in Chips analysis and western blotting.

Western blot analysis using antibodies to GluR2 (ionotropic glutamate receptor 2) (Fig. 16) showed expression in 9 samples. 6 samples were positive by Chips analysis, but negative by western blotting. However, the sensitivity of the antibody was not high. The other positive samples correlate well with the Chips analysis.

Western blot analysis using antibodies to ITGAE (integrin alpha E subunit) (Fig. 17) showed expression in most SCLC samples. One sample was positive in Chips analysis and negative by Western blotting. The relative intensities of expression between Chips analysis and western blotting do not correlate for many samples. A431 cell lysate was used as positive control.

Conclusion of western blot validation of Chips analysis on surface molecules

For the selected surface molecules all genes identified as expressed by Chips analysis are also identified as expressed by western blotting showing that gene expression measured by Chips analysis is reflected in protein synthesis. For several genes western blotting identified expression in more samples than Chips analysis. Therefore the Chips analysis is an applicable method to identify surface molecules expressed by SCLC.

Example 2

Surface molecules expressed by SCLC cell lines identified by RT-PCR

Other expressed cell surface molecules were identified by the method of RT-PCR. mRNA was prepared from all 21 of the above listed cell lines using Quick-Prep® mRNA Purification Kit (Pharmacia) according to manufacturers specifications. mRNA or total RNA from 29 different tissues was obtained from CLONTECH. The RNA was obtained from the following tissues: whole brain, spinal cord, small intestine, kidney, heart, lung, testis, retina, bladder, stomach, uterus, liver, spleen, leukocyte, adipocyte, pituitary gland, ovary, mammary gland, prostate, trachea, thymus, adrenal gland, colon, pancreas, salivary gland, bone marrow, thyroid, lymph node and skeletal muscle.

Single-stranded cDNA synthesis was performed using the 1st strand cDNA synthesis Kit for RT-PCR (Boehringer Mannheim) according to manufacturers instructions using an oligo-(dT)₁₅ primer.

- Subsequent PCR with the cDNAs as template was performed in 10 mM Tris-Cl (pH 8.3), 50 mM KCl, 1 mM MgCl₂, 0.8 mM dNTPs, 0.4 µM primers and 0.12 U/µl Thermoprimase plus DNA polymerase (Advanced Biotechnologies) with amplifications of 35 or 40 cycles of 95°C for 30 sec, 62°C for 30 sec and 72°C for 1 min. A control reaction using GAPDH primers was performed on all cDNAs. The PCR products were analysed by agarose gel electrophoresis. Listed below are the gene products analysed, the sequence of primers with their position in the nucleotide sequence in the GenBank database and the percent of cell lines or tissues, which were positive for mRNA from the corresponding gene.

Molecule	GenBank Acc. No.	Primer sequence	Position	% RT-PCR positive	
				Normal tissue	SLCL lines
Atrial natriuretic peptide clearance receptor	AF025998	5'- AGCGGAACTGCTACTTC ACC (SEQ ID 427)	629-648	95.5 %	95.5 %
		5'- TAGTCTCCACTGGTCAT GCC (SEQ ID 428)	851-832		
Gas-trin/CCK-B receptor	XM_006034	5'-GTGCGA- ATGTTGCTGGTGATCG (SEQ ID 429)	994-1015	100 % #	100 %
		5'-ACGGTGCATGAAGCAG TAGACC (SEQ ID 430)	1185-1164		
Neuromedin B receptor	M73482	5'AGATGGAAACACGGAA ACGCCTGG (SEQ ID 431)	909-932	96.5 %	95.2 %
		5'-GGCTGTTGAA-	1151-1128		

		GGCTGTTGAA- ATGCCTCCTGAAGC (SEQ ID 432)			
Glial cell line derived neuro- trophic factor α receptor	NM_001496	5'- TCTGCTTCTCCGACCCG CTT (SEQ ID 433)	761-780	96.5 %	95.2 %
		5'-TAGCTGCA- ATGGCCTCCGTG (SEQ ID 434)	1042-1023		
Bombesin receptor (GRPR)	XM_010317	5'- CATGCTCCACTTTGTCA CCAGC (SEQ ID 435)	1289-1310	100 % [#]	100 %
		5'- GAGGTCATGCAGGTTGT ACTCC (SEQ ID 436)	1477-1456		
Metabo- tropic glu- tamate receptor 8	U92459	5'CCAGAGCTAAGTGATA ACACCAGG (SEQ ID 437)	598-621	21.1 %	95.2 %
		5'- TTCACGTGGGATTTTCT GTGACTG (SEQ ID 438)	801-825		

[#] analysed on RNA from 7 normal tissues

5 The data from the RT-PCR experiments clearly suggest, that the metabotropic glutamate receptor 8 is a candidate receptor, as it is expressed in 95.2% of the SCLC cell lines, but only in 21.1 % of normal tissues. Other receptors are also candidates, as they are expressed in more than 95% of the cell lines. A quantification of the relative levels of the RNA expression by real-time RT-PCR or northern blotting will further identify the suitable receptors.

Example 3Surface molecules expressed by SCLC cell lines identified by Western blotting

18 of 19 tested SCLC lines from the same panel as above were found to express the surface molecules: the neural cell adhesion molecule (NCAM1) and cadherin (Rygaard et al., 1992). The expression in the SCLC cell lines was determined by western blotting utilizing polyclonal antibodies on protein extracts from the cell lines propagated both *in vitro* and as xenografts in nude mice. NCAM1 was detected by immunohistochemical methods in 20 of 20 surgically resected SLCL tumours demonstrating that SCLC cells express NCAM1 *in vivo* (Kibbelaar, et al., 1991). NCAM1 is widely expressed during embryonic development, but is highly down regulated in the adult (reviewed in Gegelashvili and Bock, 1996), and therefore expressed at low levels in normal tissues from SCLC patients. It has already been demonstrated that NCAM1 expression is in part regulated by endocytosis (Minana et al., 2001) and that NCAM1 can be induced to internalise by antibody binding (Michalides et al., 1994). Cadherins has also been found to be endocytosed under normal (Kamei et al., 1999; Le et al., 1999) and pathological conditions (reviewed in Parkes and Hart, 2000). Therefore, these molecules are potential candidates for surface receptors for gene transfer.

Example 4Surface molecules expressed by SCLC cell lines identified by other methods

Several other cell surface receptors have been shown to be expressed by many SCLC cell lines and therefore are also potential candidates for surface receptors for gene transfer.

The expression of high affinity transforming growth factor-beta receptors (TGF- β R) was demonstrated in several of the cell lines from the above panel by chemical crosslinking (Damstrup et al., 1993). By Northern blot analysis, the presence of the mRNA for TGF- β RI was found in 9 of 9 SCLC, TGF- β RII in 6 of 9 SCLC lines and

of TGF- β RIII (betaglycan) in 9 of 9 SCLC lines (Nørgaard et al., 1996). Binding of the ligand to these receptors induce internalisation of the receptor (Anders et al., 1997, Dore et al., 2001).

5 The presence of insulin-like growth factor receptors (IGF-R) mRNA has been determined by RT-PCR and was found present in 14 of 14 examined SCLC lines (Quinn et al., 1996). The presence of both IGF-R1 (Rotsch et al., 1992) and IGF-RII (Schardt et al., 1993) in 11 of 11 SCLC lines was demonstrated by Northern blotting, competitive binding assays and chemical crosslinking. Both receptors are known to
10 internalise after ligand binding (Dore et al., 1997)

The epidermal growth factor receptor (EGF-R) and various homologues, variations or mutants (*v-erb-B*, HER2/neu (*c-erb-2*), ErbB3 and ErbB4 and EGF-R VIII) have been found expressed on a large number of cancer cell lines and tumours and several forms internalise after ligand binding (reviewed in Wells, 1999; Huang and
15 Harari, 1999). By Northern blot analysis 11 of the 21 SCLC lines in the above panel were found to express EGF-R. The expression was verified by radioreceptor and affinity labelling analysis in 10 of the cell lines (Damstrup et al., 1992). Indeed, the EGF-R has been demonstrated to mediate targeted gene delivery in several of
20 these SCLC lines (Cristano and Roth, 1996, Frederiksen et al., 2000).

Example 5

25 Comparisons of gene expression of SCLC cell lines with gene expression of additional types of normal human tissues and other tumour cell lines.

In order to further compare gene expression profiles between SCLC cell lines and normal tissues, total RNA from normal tissues from leukocyte will be obtained from
30 commercial sources (CLONTECH, Stratagene, Ambion or ResGen). Biotin labelled cRNA will be prepared as described above.

It is of importance to determine if the genes highly expressed in SCLC cell compared to normal tissues is a phenomena general for cancer cells or is SCLC specific. Therefore total RNA will be isolated from cell lines from other types of human
35 cancers (e.g. commercially available cell lines derived from breast carcinoma, gli-

oma, non small cell lung cancer (NCLC), colon carcinoma, neuroblastoma) and analysed as described above.

5 Comparison of gene expression of SCLC cell lines *in vitro* with gene expression from SCLC cells *in vivo*.

Analysis of gene expression of SCLC lines propagated *in vivo*

Selected cell lines are propagated *in vivo* as xenografts in both flanks of BALB/c nude mice according to Rygaard et al., 1992. When one of the tumours has reached
10 the size of approximately 1 cm x 1 cm the mice will be sacrificed and tumours removed. For total RNA isolation from the tumour, the tumour will be stored for 24-48 hours in RNAlater™ (Ambion) and subsequently removed from the storage solution and stored at -70°C until RNA preparation. Total RNA will be prepared from the tumours by extraction with Trizol (Life Technologies) according to manufacturers
15 specifications. The total RNA will be further purified on RNeasy columns (Qiagen) according to the manufacturers method for RNA cleanup. Analysis of isolated total RNA and preparation of cDNA and biotin labelled cRNA and analysis of gene expression by Affymetrix Chips will be performed as described above. Protein extracts for Western blot analysis are prepared from freshly removed tumours by homogeni-
20 sation on ice with a teflon pestel in 5 volumes (w/v) of 20 mM Tris-Cl (pH 7.5), 2 % Triton X-100 with addition of protease and phosphatase inhibitors (Protease Inhibitor Cocktail Set III and Phosphatase Inhibitor Cocktail Set II from Calbiochem) and subsequent clearing by high speed centrifugation (13.000 x g).

25 ***Analysis of gene expression of biopsies from patients with small cell lung cancer***

Biopsies from patients with diagnosed small cell lung cancer (obtained from Herlev Hospital) will be stored for 24-72 hours in RNAlater™ (Ambion) and subsequently removed from the storage solution and stored at -70°C. The tumours will be micro
30 dissected by an experienced pathologist and RNA isolated from the tumours as above. RNA from several tumours will be pooled. Should the total RNA amount obtained not be sufficient for direct preparation of biotin labelled cDNA, the labelling procedure will be modified to include 2 further amplification steps as described in Ohyama et al., 2000.

Example 6Experimental procedures for identification of cell surface molecules

- 5 Candidate cell surface molecules (receptors) expressed by SCLC cells are identified by Gene Chip analysis, Northern blotting, RT-PCR or by Western blotting. The specific splice form(s) expressed by the SCLC cells will be determined by RT-PCR and/or by sequencing (performed at GATC Biotech AG, Germany). The protein expression and subcellular localization of molecules, which are identified only on
10 mRNA level, must be verified by other methods. If commercially antibodies are available, identification by western blotting (using protein extracts prepared from SCLC cell lines from the above panel propagated *in vitro* and *in vivo* as described above) and immunostaining of SCLC cell lines will be performed using the manufacturers recommendations.
- 15 For molecules with known ligands, which are commercially available or can be produced recombinantly (see below), this can additionally or alternatively be accomplished by binding or crosslinking studies. The labelled ligands (e.g. radio-, biotin- or fluorescent labelled ligands) will also be used to determine the affinity of the receptor, number of receptor molecules per cell and their ability for internalisation of the
20 ligand.

For cell surface molecules without known ligands, both the expression of the surface molecule and identification of ligands must be determined. As the mRNA encoding the cell surface molecule is readily available from the SCLC lines, the cDNA encoding the extracellular part can be cloned by standard RT-PCR methods into an ex-
25 pression vector to allow expression of a recombinant protein to be used for immunization. Preferably expression in a bacterial system (e.g. Qiagen pQE vectors) as a fusion with a suitable tag (e.g. 6 x HIS) for easy purification of the recombinant protein will be used. Immunization for generation of polyclonal antibodies in rabbits will
30 be performed at the Department of Experimental Medicine, The Panum Institute, University of Copenhagen. Generation of mouse monoclonal hybridomas will be performed at the Serum Institute, Copenhagen. Sera from immunized animals and conditioned medium from hybridomas will be screened for antigen binding using the recombinantly produced protein as immobilized antigen (in microtiter wells or on
35 membranes). In addition, the specificity of the antibodies on the surface molecule,

when expressed by mammalian cells, must be performed. This will be achieved by cloning the cDNA encoding the full length molecule into an eukaryotic expression vector (e.g. pcDNA 3.1 from Invitrogen or pCMV-Tag from CLONETECH) using RT-PCR. After transient transfection of a cell line, which does not endogenously express the molecule, the specificity of the antibodies will be determined using indirect immunofluorescence staining.

When a suitable antibody or serum has been identified, the protein expression will be analysed by immunostaining on the SCLC cell lines grown *in vitro* and *in vivo* and additionally on SCLC biopsies to verify of expression both *in vitro* and *in vivo*. The expression in normal tissues will be evaluated using a human tissue array containing 200 distinct tissue samples spotted on glass microscope slides (VastArray™ from GenRes).

Alternatively, human single chain antibodies isolated from a phage display library can be utilized (see below).

Example 7

Experimental procedures for identification of ligands to a cell surface molecule and determination of their capacity for internalisation

Known ligands, which are commercially available, will, when possible, be obtained in either a radio-, biotin- or fluorescent labelled form. For analyses of integrins as candidate surface molecules, the specific integrin alpha and beta subunit combination found in the cell lines must first be determined to identify the extracellular matrix ligand. This can be performed by immunostaining, as many antibodies against specific integrin combinations are commercially available.

If the ligand is commercially available, but not in a labelled form, the ligand can be labelled with ¹²⁵I (e.g. using the chloramine-T method) or with a fluorescent dye or biotin (e.g. using FluoReporter Kits from Molecular Probes). Binding assays will be performed to determine the specificity and capacity of ligand binding to the surface molecule. Using the labelled ligand, the ability of the surface molecule to internalise at 37°C (with incubation at 0-4°C as control) can be monitored after stripping of externally bound ligand (e.g. by acid or protease treatment) and measurement of internalised radioactivity for radio-labelled ligand; staining with enzyme or fluorescent

labelled streptavidine for biotin labelled ligand or direct evaluation for fluorescent labelled ligand by microscopy.

If the ligand is known, but not commercially available, the gene encoding the ligand will be cloned into an expression vector using RT-PCR or obtaining a cDNA library from a suitable tissue or cell line or (when available) obtain the clone from commercial sources (GeneStorm® clones from Invitrogen or GeneConnection™ from CLONTECH). A suitable tag (e.g. 6 x HIS) should be included in the recombinant ligand for easy purification. A bacterial expression system will be preferred. Recombinant expression will also enable the possibility to express the ligand as a fusion with EGFP for facilitating the analysis of binding and internalisation. Alternatively, antibodies against the tag can be used for analysis of binding and internalisation. However, should posttranslational modifications such as glycosylation or sulfatation be essential for binding of the ligand to its receptor, expression as a secreted protein can be achieved in a yeast system (*Pichia pastorius*), in an insect system (*Baculovirus*) or in mammalian cells (e.g. HEK293, COS-7 or CHO cells).

If the ligand of a cell surface molecule is unknown, homology studies based on the genomic sequence or amino acid sequence of the receptor may result in identification of a superfamily of receptors to which the particular receptor belongs. A panel of ligands specific for this superfamily can then be tested using the methods described above. Alternatively, screening with a bacterial peptide expression library (e.g. FliTrx Random Peptide Display Library from Invitrogen) may identify one or more peptide ligands. These peptide ligands can subsequently either be cloned for recombinant expression or obtained commercially. For this screening it would be optimal to use a cell line, which does not express the candidate surface molecule as screening for non-specific binding and the same cell line transfected with an expression plasmid for the surface molecule for identification of specific peptide ligands.

If mouse monoclonal antibodies towards the cell surface molecule have been generated, an alternative is to screen these antibodies for the capacity of internalising by detection of endocytosed antibodies by fluorescent labelled anti-mouse antibodies. Recombinantly expressed single chain antibodies cloned from the antibody producing hybridoma will also be tested. For clinical trials, these antibodies must be humanized for example by the method described in Losman et al., 1999. If no internalising monoclonal antibodies are available, a phage library expressing human single chain antibody fragments can be used for isolation of internalising antibodies. By removing unspecific binding of phage displayed antibodies by incubation with a

cell line negative for the cell surface molecule in question and selection with a transfected cell line expressing the molecule (as described above) specific and internalising antibodies can be identified and subsequently cloned from the phagemid DNA taken up by the cell after endocytosis (Nielsen and Marks, 2000; Heitner et al., 5 2001) (collaboration with Prof. J. Engberg, Royal Danish School of Pharmacy).

Example 8

Identification of a promoter for expression of a therapeutic gene.

10

The promoter region from genes, whose expression by GeneChips analysis has been found to be high in SCLC cell lines and xenografts and low or negative in normal tissues, are potential candidates to control and mediate expression of a therapeutic gene in targeted gene therapy. The expression by candidate promoters determined by GeneChips analysis will first be verified by RT-PCR or Northern blotting using several different primer sets or probes covering the entire molecule on the same RNAs used for GeneChips analysis (from SCLC cells and normal tissues) to ensure the cancer cell specificity of the promoter (as alternatively spliced variants expressed by the same promoter in normal tissues may not be recognized by the Affymetrix Chip). As the activity and specificity of a promoter can be encoded in a very large portion of DNA, it is essential to define the region(s) of the promoter, which are sufficient for specific and high expression in SCLC cells in order to limit the size of the DNA encoding the therapeutic gene to enhance delivery by a surface molecule. We set this limit to 15 kb, which is within the feasible size for cloning by PCR. Initially, a region of approx 15 kb upstream from the coding region of the candidate gene, including the region coding for the 5' untranslated part of the mRNA, will be cloned by PCR using a thermostable polymerase, which is capable of extending large PCR products with genomic DNA as template (e.g. Herculase from Stratagene). The primers used for PCR will be designed from the genomic sequence in the HUGO database and will be designed to contain either rare restriction sites for cloning by restriction cleavage or to contain loxP sites for direct cloning without restriction cleavage by addition of Cre recombinase. The vector to be used for testing the promoter regions will be constructed to contain a promoterless gene encoding the Enhanced Green Fluorescent Protein (EGFP) from CLONTECH preceded by rare restriction sites in the multiple cloning sites (e.g. pd2EGFP-1 from 35

CLONTECH) and/or a loxP site. The activity of the promoter will be estimated visually in a semi quantitative manner after transfection into the SCLC lines (e.g. using Lipfectamine Plus™ from Life Technologies) using fluorescence microscopy or quantitatively using a fluorometer (e.g. Victor 1420 from Wallac). As control for transfection efficiency, a low amount of plasmid encoding a red fluorescent protein under the control of a CMV promoter (pDsRed2-N1 from CLONTECH) will be used.

Promoters, which are active in the above assay, will be subcloned into smaller fragments (by PCR as described above or by standard restriction enzyme digestion) and tested for promoter activity as above. The relative activities of the promoters and subclones thereof can be determined quantitatively by recloning into a promoterless vector encoding a firefly luciferase and as transfection control, co-transfection with a plasmid encoding a *renilla* luciferase expressed from a SV40 promoter. Using the Dual-Luciferase® Reporter Assay System from Promega, the transcription from both plasmids in an extract of transiently transfected cells will be quantified using a luminometer (Lumat LB9507 from EG&G). In a similar manner, chimerics of the active parts of different, strong SCLC specific promoters can be tested for optimal expression and regulation. Alternatively, addition of enhancer sequences from other genes (e.g. viral enhancers) can be inserted. To ensure that the specificity of the selected promoter regions for SCLC cells compared to normal tissues is not lost in the various constructions, these will additionally be tested by transfection into commercially available cell lines of various origin derived from normal tissues. If higher specificity is needed, an additional specificity for cancer cells with mutations in p53 gene will be incorporated in the system. By inserting loxP sites adjacent to the promoter for the therapeutic gene and inserting the gene encoding Cre recombinase under the control of a p53 activated promoter, normal cells expressing wt p53 will express Cre recombinase which excises the promoter for the therapeutic gene, which therefore is not expressed.

If the transcriptional activity of the tumour specific promoter is not sufficient to achieve high enough levels of transcript encoding the therapeutic gene, it will be possible to utilize the specific promoter for activation of a second tissue-unspecific, but highly active promoter e.g. CMV. An example of this system is the encoding of Cre recombinase by the specific promoter, which after expression in the tumour tis-

sue activates a CMV promoter by recombinational removal of a silencing element flanked by loxP sequences (Kijama et al., 1999).

5 In addition, the presence of endogenous transcriptional enhancers (e.g. steroid hormone receptor binding regions and receptors) will be determined. This will be analysed by transfection with the promoter controlling expression of EGFP or luciferase as described above, after addition of steroid hormones (e.g. retinoic acid, estrogen, progesteron or glucocorticoids). If present, these will give the opportunity to enhance the expression of the therapeutic gene by adjuvant administration of the hormone. Alternatively, these sequences can be inserted into the promoter for enhancement of transcriptional activity if the corresponding receptor is expressed by the SCLC cells.

Example 9

15

Optimisation methods for complexing DNA with a ligand

A complex formation between the DNA encoding the tissue specific promoter controlling expression of a therapeutic gene and the ligand must be achieved for specific internalisation. Several different possibilities will be tested. Biotin labelled ligand bound via streptavidine to biotin labelled poly-cationic poly-L-lysine (PLL) will complex with negatively charged DNA, thus forming a compacted ligand/DNA polyplex, which can be internalised via the ligand (Frederiksen et al., 2000). Biotinylation of ligand and poly-L-lysine of different sizes can be performed as described by Cristiano et al., 1996 or Wagner et al., 1990.

Alternatively, the commercially available branched cationic polymer polyethylenimine (PEI) can be used for forming the ligand/DNA complex. PEI/DNA complexes in themselves have a low activity of gene transfer. However, the activity and specificity can be substantially increased by covalent crosslinking of a ligand to PEI (Kircheis et al., 1997). Another possibility will be to test biotin labelled PEI combined with biotin labelled ligand and streptavidine, as described for PLL above.

A further advantage of this system over using PLL is that inclusion of an endosomal lysis agent in the complex is unnecessary (see below).

If the ligand is produced recombinantly, a different approach will also be tested. By including peptide sequences in the recombinant ligand, which can bind strongly to specific DNA sequences encoded in the DNA containing a therapeutic gene, it is possible to achieve a DNA/ligand complex, which then can be neutralized and compacted by PLL. The DNA binding domain from the yeast transcriptional activator GAL4 produced as a recombinant fusion with the ligand will be tested in this manner using DNA, where tandem repeats of the GAL4 recognition sequences have been incorporated into the DNA.

The above described complexes will initially be tested using DNA encoding EGFP controlled by a CMV promoter with a ligand known to bind a cell surface receptor capable of internalisation. The efficacy and specificity of will be determined by visual evaluation by fluorescence microscopy and/or by fluorometric quantification after administering to cells with and without expression of the receptor for the ligand.

Example 10

Optimisation of endosomal lysis of complex.

To avoid lysosomal degradation of the endocytosed complex, it is essential to include an endosomal lysis agent in the complex for release of the DNA into the cytoplasm or an agent such as Chloroquine, which raises the endosomal pH and thereby inhibits degradation by lysosomal enzymes (reviewed in Guy et al., 1995). Replication deficient adenovirus has been demonstrated as a potent endosmolytic agent, when directly coupled to the ligand/DNA polyplex (Yoshimura et al., 1993). However, the drawbacks of using deficient adenovirus or viral capsids is unwanted immunological response, unspecific uptake of the complex via viral receptors, safety precautions and difficulty in preparation and stability. Therefore, to avoid these disadvantages and in order to reduce the size of the complex, smaller, preferably non viral endosomolytic agents will be tested. The influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides (Wagner et al., 1992), N-terminal rhino virus peptides, the pseudomonas exotoxin A translocation domain (Fominaya and Wels, 1996) and synthetic peptides (Gottschalk et al., 1996) have been found to mediate endosomal lysis or endosomal escape. Biotin labelled endosomolytic peptides can be included

in the ligand/DNA complex, when generated by biotin labelled poly-L-lysine (PLL) coupled to streptavidin. Alternatively, when the ligand is produced recombinantly, the peptide sequences can be included in the N- or C-terminal part of the ligand. The efficiency of these peptides (added either separately or incorporated into a recombinant ligand) will be tested using DNA encoding a reporter gene (EGFP or luciferase) controlled by a CMV promoter complexed to a ligand known to internalise and the endosomal lysis monitored by evaluation of expression of the reporter gene. If the ligand/DNA complex is assembled by PEI, this agent can alone mediate endosomal swelling and subsequent lysis and release of the complex (Boussif et al., 1995).

Example 11

Optimisation of methods for protection and nuclear targeting of the therapeutic gene.

To enhance the transport of endosomally released DNA encoding the therapeutic gene to the nucleus, the DNA will be covalently linked to a peptide encoding a nuclear targeting sequence (NLS – nuclear localization sequence). By excision of the therapeutic gene together with the promoter with restriction enzymes, protection of the DNA ends from digestion by exonucleases can be achieved by hybridisation to and ligation of oligonucleotides, which generate a protective stem-loop cap at the double stranded DNA ends. By including an amino-modified nucleotide in the oligonucleotide, this residue can be used for covalent crosslinking to a C-terminal amidated peptide encoding a nuclear localization signal (Zanta et al., 1999) (the peptides can be commercially obtained from e.g. Genosys, TX, USA). A number of potential sequences are mentioned herein above. Initially, the enhancement of expression by coupling of a NLS peptide of simian virus 40 large tumour antigen to the DNA will be tested using a DNA fragment encoding EGFP with a CMV promoter and expression analysed by transient transfection of SCLC cell lines. Other peptides encoding NLS from other proteins (see herein above) will be tested for determination of the most efficient nuclear transport.

Example 12Experimental procedures for selection of therapeutic gene.

5

Potential therapeutic genes will be selected from the group of: apoptosis inducing gene products, toxic gene products, gene products which introduce sensitivity towards harmless drugs, antisense RNA for oncogenes, Ribozymes targeted against oncogenes or genes encoding antibodies against oncogenes. The cDNA encoding the gene products for expression of protein or antisense RNA will either be obtained by cloning via RT-PCR, PCR on a cDNA library or obtained from commercial sources. To evaluate the efficacy of therapeutic genes for promoting cell death, these will be inserted into a vector under the control of a CMV promoter and the effect of expression tested after transient transfection (e.g. using LipofectaminePlus, Life Technologies) into SCLC cell lines from the above panel, using a plasmid expressing EGFP for co-transfection for identification of transfected cells. For apoptosis inducing genes the effect of expression on transfected cells will be monitored by specific staining (e.g. by use of Vybrant Apoptosis Assay Kit from Molecular Probes). In addition, cell death of transfected cells will be monitored by the use of fluorescent "live stains" (e.g. LIVE/DEAD Viability/Cytotoxicity Kit from Molecular Probes). Therapeutic genes selected from the experiments above will subsequently be re-cloned to be expressed under the control of one or more SCLC specific promoters and the efficiency of the expression analysed by transfection as described above.

10

15

20

25

Example 13Transduction experiments *in vivo*.

30

Once potential surface molecules and their ligands have been selected, a DNA/ligand complexing method including an endosomal lysis agent and nuclear targeting of a gene has been developed, the specificity and efficiency of the delivery system will be tested *in vivo* by administration of the complex to SCLC tumour xenografts of selected cell lines from the list above propagated in nude mice. A complex containing a reporter gene (e.g. β -galactosidase or EGFP) with a CMV

promoter in an appropriate pharmaceutical formulation will be administered to the tumour xenografted mice by intravenous injection in the tail vein. After 24, 48 or 72 hours, the mice will be sacrificed and the tumours and tissues from lung, liver, heart, brain, spleen, kidney and skeletal muscle will be excised and stained or analysed for the product of the reporter gene (e.g. β -galactosidase).

Transduction experiments using therapeutic genes *in vivo*.

To test the ability of the DNA/ligand to deliver a therapeutic gene *in vivo*, transduction experiments using therapeutic genes selected by *in vitro* experiments and DNA/ligand complexes selected from *in vivo* experiments will be performed as described above. If the therapeutic gene encodes a thymidine kinase, it will be accompanied by administration of a nucleotide analogue (e.g. gancyclovir). Tumour development will be monitored by size determination, flow cytometry of cells from biopsies and after sacrifice of the mice, the tumours will be analysed for apoptosis and necrosis.

References

Anders RA, Arline SL, Dore JJ, Leof EB.

Distinct endocytic responses of heteromeric and homomeric transforming growth factor beta receptors.

5 Mol Biol Cell. 1997 Nov;8(11):2133-43

Batt DG, Petraitis J J, Houghton G C, Modi D P, Cain G A, Corjay M H, Mousa S A, Bouchard P J, Forsythe M S, Harlow P P, Barbera F A, Spitz S M, Wexler R R and Jadhav P K (2000) Disubstituted Indazoles As Potent Antagonists of the Integrin Alpha(v)Beta(3). *J Med Chem* 43: pp 41-58.

10

: Bepler G, Jaques G, Neumann K, Aumuller G, Gropp C, Havemann K.

Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines.

J Cancer Res Clin Oncol. 1987;113(1):31-40.

15

Berendsen HH, de Leij L, de Vries EG, Mesander G, Mulder NH, de Jong B, Buys CH, Postmus PE, Poppema S, Sluiter HJ, et al.

Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up.

20 Cancer Res. 1988 Dec 1;48(23):6891-9.

Boger DL, Goldberg J, Silletti S, Kessler T and Cheresh D A (2001) Identification of a Novel Class of Small-Molecule Antiangiogenic Agents Through the Screening of Combinatorial Libraries Which Function by Inhibiting the Binding and Localization of Proteinase MMP2 to Integrin Alpha(V)Beta(3). *J Am Chem Soc* 123: pp 1280-1288.

25

Brenner, M. B. and Cepek, K. L. Methods and compositions for modulating heterotypic E-cadherin interactions with T lymphocytes. [Patent Number: US6300080]. 2001.

Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor P J and Nicoletti F (2001) Metabotropic Glutamate Receptor Subtypes As Targets for Neuro-protective Drugs. *J Cereb Blood Flow Metab* 21: pp 1013-1033.

5 Bräuner-Osborne H, Egebjerg J, Nielsen E O, Madsen U and Krogsgaard-Larsen P (2000) Ligands for Glutamate Receptors: Design and Therapeutic Prospects. *J Med Chem* 43: pp 2609-2645.

Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP.

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.

Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301

10

Brenner, M. B. and Cepek, K. L. Methods and compositions for modulating heterotypic E-cadherin interactions with T lymphocytes. [Patent Number: US6300080]. 2001.

15

Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor P J and Nicoletti F (2001) Metabotropic Glutamate Receptor Subtypes As Targets for Neuro-protective Drugs. *J Cereb Blood Flow Metab* 21: pp 1013-1033.

Bräuner-Osborne H, Egebjerg J, Nielsen E O, Madsen U and Krogsgaard-Larsen P (2000) Ligands for Glutamate Receptors: Design and Therapeutic Prospects. *J Med Chem* 43: pp 2609-2645.

20

: Bulte JW, Go KG, Zuiderveen F, The TH, de Leij L.

Intracerebral and subcutaneous xenografts of human SCLC in the nude rat: comparison of monoclonal antibody localization and tumor infiltrating lymphocytes.

J Neurooncol. 1993 Apr;16(1):11-8.

: Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, Minna JD.

25

Establishment and identification of small cell lung cancer cell lines having classic and variant features.

Cancer Res. 1985 Jun;45(6):2913-23.

30

Cavalheiro EA and Olney J W (2001) Glutamate Antagonists: Deadly Liaisons With Cancer. *Proc Natl Acad Sci U S A* 98: pp 5947-5948.

Chen CY, Chang YN, Ryan P, Linscott M, McGarrity GJ, Chiang YL.

Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect".

Hum Gene Ther. 1995 Nov;6(11):1467-76

5

:Chomczynski P, Sacchi N.

Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Anal Biochem. 1987 Apr;162(1):156-9.

Cristiano RJ, Roth JA.

10

Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor.

Cancer Gene Ther. 1996 Jan-Feb;3(1):4-10

:Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS.

15

Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines.

Cancer Res. 1992 Jun 1;52(11):3089-93.

:Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard Poulsen H.

20

Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines.

Br J Cancer. 1993 May;67(5):1015-21.

:de Leij L, Postmus PE, Buys CH, Elema JD, Ramaekers F, Poppema S, Brouwer M, van der Veen AY, Mesander G, The TH.

25

Characterization of three new variant type cell lines derived from small cell carcinoma of the lung.

Cancer Res. 1985 Dec;45(12 Pt 1):6024-33.

Dodds DC, Omeis I A, Cushman S J, Helms J A and Perin M S (1997) Neuronal Pentraxin Receptor, a Novel Putative Integral Membrane Pentraxin That Interacts With Neuronal Pentraxin 1 and 2 and Taipoxin- Associated Calcium-Binding Protein 49. *J Biol Chem* 272: pp 21488-21494.

30

Dore S, Kar S, Quirion R.

Presence and differential internalization of two distinct insulin-like growth factor receptors in rat hippocampal neurons.

Neuroscience. 1997 May;78(2):373-83

5

: Dore JJ Jr, Yao D, Edens M, Garamszegi N, Sholl EL, Leof EB.

Mechanisms of Transforming Growth Factor-beta Receptor Endocytosis and Intracellular Sorting Differ between Fibroblasts and Epithelial Cells.

Mol Biol Cell. 2001 Mar;12(3):675-84.

: Engelholm SA, Spang-Thomsen M, Vindelov LL, Brunner N, Nielsen MH, Hirsch F, Nielsen A, Hansen HH.

10 Comparison of characteristics of human small cell carcinoma of the lung in patients, in vitro and transplanted into nude mice.

Acta Pathol Microbiol Immunol Scand [A]. 1986 Sep;94(5):325-36.

15 Evans JP (2001) Fertilin Beta and Other ADAMs As Integrin Ligands: Insights into Cell Adhesion and Fertilization. *Bioessays* 23: pp 628-639.

Foley AG, Hartz B P, Gallagher H C, Ronn L C, Berezin V, Bock E and Regan C M (2000) A Synthetic Peptide Ligand of Neural Cell Adhesion Molecule (NCAM) Igl Domain Prevents NCAM Internalization and Disrupts Passive Avoidance Learning. *J Neurochem* 74: pp 2607-2613.

: Fominaya J, Wels W.

20 Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system.

J Biol Chem. 1996 May 3;271(18):10560-8.

Frederiksen KS, Petri A, Abrahamsen N, Poulsen HS.

Gene therapy for lung cancer.

25 Lung Cancer. 1999 Mar;23(3):191-207. Review

Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS.

Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor.
Cancer Gene Ther. 2000 Feb;7(2):262-8

5

Gegelashvili, G. and Bock, E. (1996),
Cell recognition molecules of the immunoglobulin superfamily in the nervous system.,
Biomembranes, vol 3, 33-75

Gottschalk S, Cristiano RJ, Smith LC, Woo SL.

10 Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results
in enhanced gene expression.
Gene Ther. 1994 May;1(3):185-91.

Gottschalk S, Sparrow JT, Hauer J, Mims MP, Leland FE, Woo SL, Smith LC.

15 A novel DNA-peptide complex for efficient gene transfer and expression in mam-
malian cells.
Gene Ther. 1996 May;3(5):48-57.

Goula D, Benoist C, Mantero S, Merlo G, Levi G, Demeneix BA.

Polyethylenimine-based intravenous delivery of transgenes to mouse lung.
Gene Ther. 1998 Sep;5(9):1291-5.

20

Gunji Y, Ochiai T, Shimada H, Matsubara H.

Gene therapy for cancer.
Surg Today. 2000;30(11):967-73. Review.

Guy J, Drabek D, Antoniou M.

25 Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene
therapy.
Mol Biotechnol. 1995 Jun;3(3):237-48. Review.

Hartman GD and Duggan M E (2000) Alpha(v)Beta(3) Integrin Antagonists As Inhibitors of
Bone Resorption. *Expert Opin Investig Drugs* 9: pp 1281-1291.

30

Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD.

Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library.

J Immunol Methods. 2001 Feb 1;248(1-2):17-30.

Huang SM, Harari PM.

- 5 Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.

Invest New Drugs. 1999;17(3):259-69. Review

- 10 Huang TF (1998) What Have Snakes Taught Us About Integrins? *Cell Mol Life Sci* **54**: pp 527-540.

Jane DE, Hoo K, Kamboj R, Deverill M, Bleakman D and Mandelzys A (1997) Synthesis of Willardiine and 6-Azawillardiine Analogs: Pharmacological Characterization on Cloned Homomeric Human AMPA and Kainate Receptor Subtypes. *J Med Chem* **40**: pp 3645-3650.

Jane.D. AMPA/Kainate receptors. WWW . 2001.

- 15 <http://www.bris.ac.uk/synaptic/info/pharmacology/AMPA.html>

: Kamei T, Matozaki T, Sakisaka T, Kodama A, Yokoyama S, Peng YF, Nakano K, Takaishi K, Takai Y.

Coendocytosis of cadherin and c-Met coupled to disruption of cell-cell adhesion in MDCK cells--regulation by Rho, Rac and Rab small G proteins.

Oncogene. 1999 Nov 18;18(48):6776-84.

20

Kang IC, Lee Y D and Kim D S (1999) A Novel Disintegrin Salmosin Inhibits Tumor Angiogenesis. *Cancer Res* **59**: pp 3754-3760.

Karecla PI, Green S J, Bowden S J, Coadwell J and Kilshaw P J (1996) Identification of a Binding Site for Integrin AlphaEbeta7 in the N- Terminal Domain of E-Cadherin. *J Biol Chem* **271**: pp 30909-30915.

25

Kaufmann, O., Georgi, T., and Dietel, M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. *Hum.Pathol.* **28**[12], 1373-1378. 1997.

Kerr JS, Slee A M and Mousa S A (2000) Small Molecule Alpha(v) Integrin Antagonists: Novel Anticancer Agents. *Expert Opin Investig Drugs* **9**: pp 1271-1279.

30

Kibbelaar, R. E., Moolenaar, K. E., Michalides, R. J., Van Bodegom, P. C., Vanderschueren, R. G., Wagenaar, S. S., Dingemans, K. P., Bitter-Suermann, D., Dalesio, O., van Zandwijk, N., and . Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. *Eur.J.Cancer* 27[4], 431-435. 1991.

5

Kijima T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H, Tachibana I, Tanio Y, Kishimoto T.

Application of the Cre recombinase/loxP system further enhances antitumour effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.

Cancer Res. 1999 Oct 1;59(19):4906-11

Kirchels R, Kichler A, Wallner G, Kursa M, Ogris M, Felzmann T, Buchberger M, Wagner E.

10 Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery.

Gene Ther. 1997 May;4(5):409-18

Kirkpatrick LL, Matzuk M M, Dodds D C and Perin M S (2000) Biochemical Interactions of the Neuronal Pentraxins. Neuronal Pentraxin (NP) Receptor Binds to Taipoxin and Taipoxin-Associated Calcium-Binding Protein 49 Via NP1 and NP2. *J Biol Chem* 275: pp 17786-17792.

15

Kiselyov VV, Berezin V, Maar T E, Soroka V, Edvardsen K, Schousboe A and Bock E (1997) The First Immunoglobulin-Like Neural Cell Adhesion Molecule (NCAM) Domain Is Involved in Double-Reciprocal Interaction With the Second Immunoglobulin-Like NCAM Domain and in Heparin Binding. *J Biol Chem* 272: pp 10125-10134.

20

Krogsgaard-Larsen, P., Brehm, L., Johansen, J. S., Vinzents, P., Lauridsen, J., and Curtis, D. R. Synthesis and structure-activity studies on excitatory amino acids structurally related to ibotenic acid. *J Med Chem.* 28[5], 673-679. 1985.

: Le TL, Yap AS, Stow JL.

25 Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics.

J Cell Biol. 1999 Jul 12;146(1):219-32

: Losman MJ, Qu Z, Krishnan IS, Wang J, Hansen HJ, Goldenberg DM, Leung SO.

Generation and monitoring of cell lines producing humanized antibodies.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3101s-3105s.

30

Madsen U, Stensbøl T B and Krogsgaard-Larsen P (2001) Inhibitors of AMPA and Kainate Receptors. *Curr Med Chem* 8: pp 1291-1301.

5 Mercer B, Markland F and Minkin C (1998) Contortrostatin, a Homodimeric Snake Venom Disintegrin, Is a Potent Inhibitor of Osteoclast Attachment. *J Bone Miner Res* 13: pp 409-414.

Michalides R, Kwa B, Springall D, van Zandwijk N, Koopman J, Hilkens J and Mooi W (1994) NCAM and Lung Cancer. *Int J Cancer Suppl* 8: pp 34-37.

10 Minana R, Duran J M, Tomas M, Renau-Piqueras J and Guerri C (2001) Neural Cell Adhesion Molecule Is Endocytosed Via a Clathrin-Dependent Pathway. *Eur J Neurosci* 13: pp 749-756.

Montgomery AM, Becker J C, Siu C H, Lemmon V P, Cheresch D A, Pancook J D, Zhao X and Reisfeld R A (1996) Human Neural Cell Adhesion Molecule L1 and Rat Homologue NILE Are Ligands for Integrin Alpha v Beta 3. *J Cell Biol* 132: pp 475-485.

15

Mountain A.

Gene therapy: the first decade.

Trends Biotechnol. 2000 Mar;18(3):119-28. Review.

Nettelbeck DM, Jerome V, Muller R.

20 Gene therapy: designer promoters for tumour targeting.
Trends Genet. 2000 Apr;16(4):174-81. Review

Nielsen LL, Maneval DC.

P53 tumor suppressor gene therapy for cancer.

Cancer Gene Ther. 1998 Jan-Feb;5(1):52-63. Review

25

Nielsen UB, Marks JD.

Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries.

Pharm. Sci. Technol. Today. 2000 Aug;3(8):282-291.

: Norgaard P, Spang-Thomsen M, Poulsen HS.

Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines.

Br J Cancer. 1996 May;73(9):1037-43.

: Ohyama H, Zhang X, Kohno Y, Alevizos I, Posner M, Wong DT, Todd R.

- 5 Laser capture microdissection-generated target sample for high-density oligonucleotide array hybridization.

Biotechniques. 2000 Sep;29(3):530-6.

: Parkes RJ, Hart SL.

- 10 Adhesion molecules and gene transfer.
Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):135-52. Review

: Pettengill OS, Sorenson GD, Wurster-Hill DH, Curphey TJ, Noll WW,
Cate CC, Maurer LH.

Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung.

- 15 Cancer. 1980 Mar 1;45(5):906-18.

: Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL,
Cuttitta F.

Insulin-like growth factor expression in human cancer cell lines.

J Biol Chem. 1996 May 10;271(19):11477-83.

- 20 Riddell DR, Vinogradov D V, Stannard A K, Chadwick N and Owen J S (1999) Identification and Characterization of LRP8 (ApoER2) in Human Blood Platelets. *J Lipid Res* **40**: pp 1925-1930.

Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK,
Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh
GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ,
Mukhopadhyay T, Cai D.

- 25 Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.

Nat Med. 1996 Sep;2(9):985-91.

: Rotsch M, Maasberg M, Erbil C, Jaques G, Worsch U, Havemann K.

Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines.

J Cancer Res Clin Oncol. 1992;118(7):502-8.

5

: Rygaard K, Moller C, Bock E, Spang-Thomsen M.

Expression of cadherin and NCAM in human small cell lung cancer cell lines and xenografts.

Br J Cancer. 1992 Apr;65(4):573-7.

10

Rønn LC, Olsen M, Ostergaard S, Kiselyov V, Berezin V, Mortensen M T, Lerche M H, Jensen P H, Soroka V, Saffell J L, Doherty P, Poulsen F M, Bock E, Holm A and Saffells J L (1999) Identification of a Neuritogenic Ligand of the Neural Cell Adhesion Molecule Using a Combinatorial Library of Synthetic Peptides. *Nat Biotechnol* 17: pp 1000-1005.

15

: Schardt C, Rotsch M, Erbil C, Goke R, Richter G, Havemann K.

Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines.

Exp Cell Res. 1993 Jan;204(1):22-9.

20

Taraszkas KS, Higgins J M, Tan K, Mandelbrot D A, Wang J H and Brenner M B (2000) Molecular Basis for Leukocyte Integrin Alpha(E)Beta(7) Adhesion to Epithelial (E)-Cadherin. *J Exp Med* 191: pp 1555-1567.

25

Thomas NK, Wright R A, Howson P A, Kingston A E, Schoepp D D and Jane D E (2001) (S)-3,4-DCPG, a Potent and Selective mGlu8a Receptor Agonist, Activates Metabotropic Glutamate Receptors on Primary Afferent Terminals in the Neonatal Rat Spinal Cord. *Neuropharmacology* 40: pp 311-318.

Turner JP and Salt T E (1999) Group III Metabotropic Glutamate Receptors Control Corticothalamic Synaptic Transmission in the Rat Thalamus in Vitro. *J Physiol* 519 Pt 2: pp 481-491.

30

Yoshimura K, Rosenfeld MA, Seth P, Crystal RG.

Adenovirus-mediated augmentation of cell transfection with unmodified plasmid vectors.

J Biol Chem. 1993 Feb 5;268(4):2300-3

Wagner E, Zenke M, Cotten M, Beug H, Birnstiel ML.

Transferrin-polycation conjugates as carriers for DNA uptake into cells.

Proc Natl Acad Sci U S A. 1990 May;87(9):3410-4

Wagner E, Plank C, Zatloukal K, Cotten M, Birnstiel ML.

- 5 Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle.

Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7934-8

Wells A.

EGF receptor.

- 10 Int J Biochem Cell Biol. 1999 Jun;31(6):637-43. Review

Yoneda Y, Kawajiri S, Sugimura M, Osanai K, Kito F, Ota E and Mimura T (2001) Synthesis of Diaminobutane Derivatives As Potent Ca(2+)-Permeable AMPA Receptor Antagonists.

Bioorg Med Chem Lett 11: pp 2663-2666.

- 15 Yu A, Choi J, Ohno K, Levin B, Rom W N and Meruelo D (2000) Specific Cell Targeting for Delivery of Toxins into Small-Cell Lung Cancer Using a Streptavidin Fusion Protein Complex. *DNA Cell Biol* 19: pp 383-388.

Zanta MA, Belquise-Valladier P, Behr JP.

- 20 Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus.

Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):91-6

Claims

1. A method for identifying a plurality of cell surface molecules, which are expressed at a different level in malignant cells compared with normal cells, comprising the steps of:
- 5
- i) providing at least 3 malignant cell lines selected from the group consisting of CPH 54 A, CPH 54 B, GLC 2, GLC 3, GLC 14, GLC 16, GLC 19, GLC 26, GLC 28, DMS 53, DMS 79, DMS 92, DMS 114, DMS 153, DMS 273, DMS 406, DMS 456, NCI H69, NCI N417, MAR H24, MAR 86 MI, SHP-77, NCI-H2171, NCI-H2195, NCI-H2196, NCI-H2198, NCI-H2227, NCI-H2286, NCI-H2330, NCI-H735, NCI-H1339, NCI-H1963, NCI-H2107, NCI-H2108, NCI-H1304, NCI-H1341, NCI-H1417, NCI-H1436, NCI-H1522, NCI-H1618, NCI-H1672, NCI-H1694, NCI-H1836, NCI-H1870, NCI-H1876, NCI-H1882, NCI-H1926, NCI-H1930, NCI-H1994, NCI-H2029, NCI-H2059, NCI-H2066, NCI-H2081, NCI-H2141, NCI-H211, NCI-H220, NCI-H250, NCI-H524, NCI-H592, NCI-H711, NCI-H719, NCI-H740, NCI-H748, NCI-H774, NCI-H841, NCI-H847, NCI-H865, NCI-H1048, NCI-H1059, NCI-H1092, NCI-H1105, NCI-H1184, NCI-H1238, NCI-H1284, NCI-H1688, NCI-H187, NCI-H378, NCI-H526, NCI-H660, NCI-H889, NCI-H60, NCI-H196, NCI-H446, NCI-H209, NCI-H146, NCI-H82, NCI-H460, NCI-H345, NCI-H510A, NCI-128, NCI-446, SW 1271; and
- 10
- 15
- 20
- 25
- 30
- ii) providing at least 3 total RNA samples derived from normal tissue selected from the group consisting of liver, heart, kidney, lung, adrenal gland, colon, pancreas, small intestine, spleen, skeletal muscle, trachea, prostate, placenta, salivary gland, testes, leucocytes, brain, adipose tissue, bladder, breast, cervix, esophagus, larynx, ovary, rectum, skin, spinal cord, stomach, thymus, thyroid and uterus; and
- iii) comparing the expression of mRNA in the cell lines according to i) and tissue samples according to ii); and
- iv) identifying nucleic acid sequences, wherein
- a) there is a difference between the amount of mRNA expressed in one or more cell lines according to i) and the amount of mRNA

expressed in one or more tissues according to ii);
and/or

b) there is essentially no difference in the amount of
mRNA expressed in at least two cell lines

5 according to i); and/or

c) there is essentially no difference in the amount of
mRNA expressed in at least two tissue samples
according to ii); and

10 v) selecting among the nucleic acid sequences according to iv), nucleic
acid sequences encoding for potential cell surface molecules.

2. The method according to claim 1, wherein step i) involves providing at least 5
malignant cell lines.

15 3. The method according to claim 1, wherein step ii) involves tissue samples
derived from lung, liver, heart, and kidney.

4. The method according to claim 1, wherein step ii) involves providing at least 5
total RNA samples.

20 5. The method according to claim 1, wherein step iii) comprises the steps of:

i) isolating RNA comprising mRNA from the malignant cell lines; and

25 ii) preparing cDNA populations from said RNA, wherein one cDNA
population is prepared from RNA isolated from one cell line or one tissue
sample; and

iii) labelling each cDNA population with a detectable label; and

iv) providing solid supports on which an array of known nucleic acid
sequences has been immobilised; and

30 v) incubating each cDNA population with a solid support under conditions
which allows for hybridisation; and

vi) detecting said detectable label on the solid supports

35 6. The method according to claim 5, wherein said detectable label is a
fluorescent label.

7. The method according to claim 5, wherein the solid support is a glass plate.
8. The method according to claim 5, wherein at least 1000 known nucleic acid sequences are immobilised on the solid support.
9. The method according to claim 1, wherein the difference in step iv), a) is at least 2-fold in mRNA expression.
10. The method according to claim 1, wherein the difference in step iv), a) is in principle unlimited number of fold.
11. The method according to claim 1, wherein step iv), b) involves at least 3 malignant cell lines.
12. The method according to claim 1, wherein step iv), c) involves at least 3 RNA samples.
13. The method according to claim 1, wherein nucleic acid sequences encoding for potential cell surface molecules according to step v) are selected according to information available in commonly accessible databases selected from the group consisting of PubMed (NCBI), Nucleotide (NCBI), Protein (NCBI), Structure (NCBI), OMIM (NCBI) and LocusLink (NCBI).
14. The method according to claim 1, wherein nucleic acid sequences encoding for potential cell surface molecules according to step v) are selected according to sequence homology with known cell surface molecules, there is at least 20% sequence identify.
15. The method according to claim 1, wherein nucleic acid sequences encoding for potential cell surface molecules according to step v) are selected according to sequence homology with domains comprised within known cell surface molecules.

16. The method according to claim 1, wherein nucleic acid sequences encoding potential cell surface molecules according to step v) are selected such as the potential cell surface molecules comprise a domain selected from the group consisting of hydrophobic regions and potential glycosylation sites.

5

17. A method of identifying first nucleic acid sequences, which are capable of directing expression of second nucleic acid sequences operably linked thereto, wherein the level of said expression is different in malignant cells compared with normal cells comprising the steps of:

10

- i) providing at least 3 malignant cell lines selected from the group consisting of CPH 54 A, CPH 54 B, GLC 2, GLC 3, GLC 14, GLC 16, GLC 19, GLC 26, GLC 28, DMS 53, DMS 79, DMS 92, DMS 114, DMS 153, DMS 273, DMS 406, DMS 456, NCI H69, NCI N417, MAR H24, MAR 86 MI, SHP-77, NCI-H2171, NCI-H2195, NCI-H2196, NCI-H2198, NCI-H2227, NCI-H2286, NCI-H2330, NCI-H735, NCI-H1339, NCI-H1963, NCI-H2107, NCI-H2108, NCI-H1304, NCI-H1341, NCI-H1417, NCI-H1436, NCI-H1522, NCI-H1618, NCI-H1672, NCI-H1694, NCI-H1836, NCI-H1870, NCI-H1876, NCI-H1882, NCI-H1926, NCI-H1930, NCI-H1994, NCI-H2029, NCI-H2059, NCI-H2066, NCI-H2081, NCI-H2141, NCI-H211, NCI-H220, NCI-H250, NCI-H524, NCI-H592, NCI-H711, NCI-H719, NCI-H740, NCI-H748, NCI-H774, NCI-H841, NCI-H847, NCI-H865, NCI-H1048, NCI-H1059, NCI-H1092, NCI-H1105, NCI-H1184, NCI-H1238, NCI-H1284, NCI-H1688, NCI-H187, NCI-H378, NCI-H526, NCI-H660, NCI-H889, NCI-H60, NCI-H196, NCI-H446, NCI-H209, NCI-H146, NCI-H82, NCI-H460, NCI-H345, NCI-H510A, NCI-128, NCI-446 and SW 1271, and
- ii) providing at least 3 RNA samples derived from normal tissue samples derived from the group consisting of liver, heart, kidney, lung, adrenal gland, colon, pancreas, small intestine, spleen, skeletal muscle, trachea, prostate, placenta, salivary gland, testes, leucocytes, brain, adipose tissue, bladder, breast, cervix, esophagus, larynx, ovary, rectum, skin, spinal cord, stomach, thymus, thyroid and uterus; and
- iii) comparing the expression of mRNA in the cell lines according to i) and tissue samples according to ii); and

15

20

25

30

35

- iv) identifying second nucleic acid sequences, wherein
- a) there is a difference between the amount of mRNA expressed in one or more cell lines according to i) and the amount of mRNA expressed in one or more tissues according to ii); and/or
 - b) there is essentially no difference in the amount of mRNA expressed in at least two cell lines according to i); and/or
 - c) there is essentially no difference in the amount of mRNA expressed in at least two tissue samples according to ii); and
- v) identifying first nucleic acid sequences operably linked to the second nucleotide sequences identified in step iv)
18. The method according to claim 17, wherein step i) involves providing at least 5 malignant cell lines.
19. The method according to claim 17, wherein step ii) involves tissue samples derived from the group consisting of lung, liver, heart and kidney.
20. The method according to claim 17, wherein step ii) involves providing at least 5 RNA samples.
21. The method according to claim 17, wherein step iii) comprises the steps of:
- i) isolating RNA from the malignant cell lines; and
 - ii) preparing cDNA populations from said RNA, wherein one cDNA population is prepared from RNA isolated from one cell line or one tissue sample; and
 - iii) labelling each cDNA population with a detectable label; and
 - iv) providing solid supports on which an array of known nucleic acid sequences has been immobilised; and
 - v) incubating each cDNA population with a solid support under conditions which allows for hybridisation; and
 - vi) detecting said detectable label on the solid supports
22. The method according to claim 21, wherein said detectable label is a fluorescent label.

23. The method according to claim 21, wherein the solid support is a glass plate.
24. The method according to claim 21, wherein at least 1000 different known
5 nucleic acid sequences are immobilised on the solid support.
25. The method according to claim 17, wherein the difference in step iv), a) is at least 2-fold difference in mRNA expression.
- 10 26. The method according to claim 17, wherein the difference in step iv), a) is an in principle unlimited number of fold.
27. The method according to claim 17, wherein step iv), b) involves at least 3 malignant cell lines.
15
28. The method according to claim 17, wherein step iv), c) involves at least 3 tissue samples.
29. The method according to claim 17, wherein any first nucleic acid sequence
20 operably linked to a second nucleic acid sequence comprise at least 15,000 base pairs upstream of the translation start codon of said second nucleic acid sequence on the chromosome.
30. The method according to claim 17, wherein any first nucleic acid sequence
25 operably linked to a second nucleic acid sequence comprise at least 5,000 base pairs upstream of the translation start codon of said second nucleic acid sequence on the chromosome.
31. The method according to claim 17, wherein any first nucleic acid sequence
30 operably linked to a second nucleic acid sequence comprises up to up to 5000 base pairs upstream of the translation start codon of said second nucleic acid sequence on the chromosome.
32. The method according to claim 17, wherein any first nucleic acid sequence
35 operably linked to a second nucleic acid sequence comprise intron sequences

found upstream of the translation start codon of said second nucleic acid sequence on the chromosome.

- 5 33. The method according to claim 17, wherein any first nucleic acid sequence operably linked to a second nucleic acid sequence comprise intron sequences found downstream of the translation start codon of said second nucleic acid sequence on the chromosome.
- 10 34. The method according to claim 17, wherein any first nucleic acid sequence operably linked to a second nucleic acid sequence comprise an enhancer sequence located more than 10,000 base pairs upstream or downstream from the translation start codon of said second nucleic acid sequence on the chromosome.
- 15 35. The method according to claim 17, wherein any first nucleic acid sequence operably linked to a second nucleic acid sequence comprise up to 5000 base pairs upstream from the translation start codon of said second nucleic acid sequence on the chromosome, from which at least 10 internal bp have been deleted.
- 20 36. The method according to claim 17, wherein any first nucleic acid sequence operably linked to a second nucleic acid sequence comprise up to 5000 base pairs upstream from the translation start codon of said second nucleic acid sequence on the chromosome, from which at least one silencer has been deleted.
- 25 37. A targeting complex comprising:
- 30 i) a binding partner capable of binding a cell surface molecule identified by the method according to any of the claims 1 to 16, wherein said cell surface molecule is selected from the group consisting of *GRIA2*, *GRM8*, *ITGAV*, *ITGAE*, *NCAM1*, *NPTXR*, *LRP8* and *CHRNA5* ; and
- ii) a bioreactive species
- 35 38. The targeting complex according to claim 37, wherein the cell surface molecule comprises or essentially consists of *GRIA2*.

39. The targeting complex according to claim 37, wherein the cell surface molecule comprises or essentially consists of GRM8.
- 5 40. The targeting complex according to claim 37, wherein the cell surface molecule comprises or essentially consists of ITGAV.
41. The targeting complex according to claim 37, wherein the cell surface molecule comprises or essentially consists of ITGAE.
- 10 42. The targeting complex according to claim 37, wherein the binding partner is selected from the group consisting of L-glutamate, kainate, 5-(bromomethyl)-4-isoxazolepropionic acid, analogues of glutamate, substituted quinoxaline 2,3 diones, GYKI52466, 5-I-Willardine, 5-F-Willardine, agonist and antagonist ligands to the AMPA ((RS)- α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, NBQX, CNQX, DNQX, GYKI 52466, 6-Chlorokynurenic acid, JSTX, L-APA, L-SOP, ACPT, (R,S)-PPG, CPPG, MAP4, (S)-3,4-DCPG, vitronectin, cytoactin, fibronectin, fibrinogen, laminin, MMP-2, osteopontin, prothrombin, thrombospondin, von Willebrandts Factor, recombinant fragments of L1CAM, 20 salmosin, E-cadherin and peptides thereof, including the peptide: NRDKETKV, NCAM1 domain Ig I+II, NCAM1 domain IgIII and peptides thereof, peptides C3: ASKKPKRNIKA, D3: AKKERQRKDTU, D4: ARALN WGAKP, monoclonal antibody 123C3, NPTX1, NPTX2, taipoxin, TCBP49, Oxyrinor, ApoE2, ApoE3, ApoE4, peptides from ApoE (E₁₄₁₋₁₅₅; LRKLRKRLLRDADDL and its tandem 25 E₍₁₄₁₋₁₅₅₎₂; LRKLRKRLLRDADDL-LRKLRKRL RDADDL) reelin, nicotine, acetylcholine, α -bungarotoxin, carbachol and specific antibodies against any of said surface molecules.
43. The targeting complex according to claim 37, wherein said cell surface 30 molecule is capable of internalising the targeting complex.
44. The targeting complex according to claim 37, wherein said bioreactive species comprises a nucleic acid.

45. The targeting complex according to claim 44, wherein the nucleic acid comprises a second nucleic acid operably linked to a first nucleic acid sequence comprising an expression signal.
- 5 46. A targeting complex comprising
- 10 i) a binding partner capable of binding a cell surface molecule identified by the method according to any of the claims 1 to 16, wherein said cell surface molecule is capable of internalising the targeting complex; and
- ii) a bioreactive species comprising a nucleic acid sequence comprising a second nucleic acid operably linked to a first nucleic acid sequence comprising an expression signal, wherein said first nucleic acid sequence has been identified by the method according to any of claims 17 to 36.
- 15 47. The targeting complex according to claim 46, wherein the cell surface molecule comprises or essentially consists of a cell surface molecule selected from the group consisting of NCAM1, NPTXR, LRP8 and CHRNA5.
- 20 48. The targeting complex according to claim 46, wherein the cell surface molecule comprises or essentially consists of NCAM1.
49. The targeting complex according to claim 46, wherein the cell surface molecule comprises or essentially consists of NPTXR.
- 25 50. The targeting complex according to claim 46, wherein the cell surface molecule comprises or essentially consists of LRP8.
51. The targeting complex according to claim 46, wherein the cell surface molecule comprises or essentially consists of CHRNA5.
- 30 52. The targeting complex according to claim 46, wherein the binding partner is selected from the group consisting of NCAM1 domain Ig I+II, NCAM1 domain IgIII and peptides thereof, peptides C3: ASKKPKRNIKA, D3: AK-KERQRKDTU, D4: ARALNWGAKP, monoclonal antibody 123C3, NPTX1, NPTX2, taipoxin, TCBP49, Oxynor, ApoE2, ApoE3, ApoE4, peptides from
- 35

ApoE (E_{141;-155}; LRKLRKRLLRDADDL and its tandem E_{(141;-155)2}; LRKLRKRLLRDADDL-LRKLRKRLLRDADDL) reelin, nicotine, acetylcholine, α -bungarotoxin, carbachol and specific antibodies to said surface molecules.

5

53. The targeting complex according to claim 46, wherein said first nucleic acid sequence comprises an expression signal which direct a higher level of expression of said second nucleic acid sequence in malignant cells compared with non-malignant cells.

10

54. The targeting complex according to claim 46, wherein said first nucleic acid sequence comprise an expression signal which directs a lower level of expression of said second nucleic acid sequence in malignant cells compared with non-malignant cells.

15

55. The targeting complex according to any of claims 46 to 47, wherein said first nucleic acid sequence is selected from the group consisting of pro221, pro210, pro71, pro41, pro30, pro2, pro209, pro14, pro4, pro8, pro246, pro16, pro27, pro5, pro49, pro19, pro140, pro139, pro207, pro81, pro273 and pro362.

20

56. The targeting complex according to any of claims 46 to 47, wherein said first nucleic acid sequence comprises fragments of nucleotide sequences selected from the group consisting of pro221, pro210, pro71, pro41, pro30, pro2, pro209, pro14, pro4, pro8, pro246, pro16, pro27, pro5, pro49, pro19, pro140, pro139, pro207, pro81, pro273 and pro362.

25

57. The targeting complex according to any of claims 46 to 47, wherein said first nucleic acid sequence comprises more than one fragment of nucleotide sequences selected from the group consisting of pro221, pro210, pro71, pro41, pro30, pro2, pro209, pro14, pro4, pro8, pro246, pro16, pro27, pro5, pro49, pro19, pro140, pro139, pro207, pro81, pro273 and pro362..

30

58. The targeting complex according to any of claims 46 to 47, wherein said first nucleic acid sequence comprises pro221 or one or more fragments thereof.

35

59. The targeting complex according to any of claims 46 to 47, wherein said first nucleic acid sequence comprises pro210 or one or more fragments thereof
- 5 60. The targeting complex according to any of claims 46 to 47, wherein said first nucleic acid sequence comprises pro71 or one or more fragments thereof
61. The targeting complex according to claim 46, wherein said first nucleic acid sequence further comprises nucleic acid sequences not natively associated therewith.
- 10 62. The targeting complex according to claim 61, wherein said nucleic acid sequences not natively associated therewith is a steroid hormone receptor binding site.
- 15 63. The targeting complex according to any of claims 44 and 46, wherein said second nucleic acid sequence encodes a therapeutic protein.
64. The targeting complex according to any of claims 44 and 46, wherein said second nucleic acid sequence encodes or comprises an antisense RNA or part of an antisense RNA.
- 20 65. The targeting complex according to any of claims 44 and 46, wherein said second nucleic acid sequence encodes or comprises a ribozyme.
- 25 66. The targeting complex according to any of claims 44 and 46, wherein said antisense RNA or said ribozyme is targeted against RNA of an oncogene or proto-oncogene.
- 30 67. The targeting complex according to claim 66, wherein said oncogene or proto-oncogene is selected from the group consisting of Ras, Raf, Myc, Syn, Pim, BMI-1, FOP, Sis, KGF, Fms, Flg, Neu, Trk, Kit, Met, Src, Fyn, Mas, Fes/Fps, Tre, Mer, ABL, BCL3, int-2, Cym, Ets, Elk, RhoA, Ski, Wnt-5a, Spi-1, Rap2, p55 and c-tyr.

- 5 68. The targeting complex according to any of claims 37 and 46, wherein the complex further comprises a protective capping, wherein said protective capping consists of nucleic acid sequences attached to the first and/or second nucleic acid sequences.
69. The targeting complex according to claim 68, wherein the protective capping comprises a modified nucleotide.
- 10 70. The targeting complex according to claim 37, wherein said bioreactive species is a toxin.
71. The targeting complex according to claim 70, wherein said toxin is selected from the group consisting of ricin, diphtheria toxin, pseudomonas exotoxin, streptozotocin or cholera toxin.
- 15 72. The targeting complex according to claim 37, wherein said bioreactive species is an inducer of apoptosis.
- 20 73. The targeting complex according to claim 72, wherein said inducer of apoptosis is selected from the group consisting of retinoic acid, A23187, Okadaic Acid, Puromycin, Staurosporine, Thapsigargin, Actinomycin D, Camptothecin, Cycloheximide, Dexamethasone, Etoposide and Glucocorticoid.
- 25 74. The targeting complex according to claim 37, wherein said bioreactive species comprises a radioisotope.
75. The targeting complex according to claim 37, wherein said bioreactive species comprises a cytostatica.
- 30 76. The targeting complex according to claim 37, wherein said bioreactive species comprises or essentially consists of a polypeptide.
- 35 77. The targeting complex according to claim 76, wherein said polypeptide is a therapeutic protein.

78. The targeting complex according to any of claims 63 and 77, wherein said therapeutic protein is a tumour suppressor.
- 5 79. The targeting complex according to any of claims 63 and 77, wherein said therapeutic protein is an inducer of apoptosis.
80. The targeting complex according to claim 63 and 77, wherein said therapeutic protein is a protein, which can contribute to a cell cycle arrest.
- 10 81. The targeting complex according to any of claims 63 and 77, wherein said therapeutic protein is a protein capable of protecting the cell against a toxic agent.
- 15 82. The targeting complex according to any of claims 63 and 77, wherein said therapeutic protein is protein capable of catalysing the synthesis of a toxic substance.
- 20 83. The targeting complex according to any of claims 63 and 77, wherein said therapeutic protein is p53.
84. The targeting complex according to any of claims 63 and 77, wherein said therapeutic protein is a tumor suppressor selected from the group consisting of p73, p16, Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-1, MEN-II, BRCA1, VHL, FCC, MCC, MSH2, PTCH, DPCH, TSC2, CDKN2A and ARF.
- 25 85. The targeting complex according to any of claims 63 and 77, wherein said therapeutic protein is an inducer of apoptosis selected from the group consisting of Fas/Apo1, TNF, TRAIL, TGF- β , caspases, Bak, Bax, Bid, Bik and GZMB.
- 30 86. The targeting complex according to any of claims 63 and 77, which comprises more than one first nucleotide sequence encoding a therapeutic protein or more than one therapeutic protein, for example 2, such as 3, for example 4
- 35 therapeutic protein.

87. The targeting complex according to any of claims 37 to 86, wherein the complex further comprises a nuclear targeting signal.
- 5 88. The targeting complex according to claim 87, wherein the nuclear targeting signal is an oligopeptide.
89. The targeting complex according to claim 87, wherein the nuclear targeting signal is the nuclear localisation signal of simian virus 40 large tumour antigen.
- 10 90. The targeting complex according to any of claim 37 to 89, wherein the complex further comprises an endosomal lytic agent.
- 15 91. The targeting complex according to claim 90, wherein the endosomal lytic agent is selected from the group consisting of polyethylenimine (PEI), a replication defective virus and a viral protein capsid.
92. The targeting complex according to any of claims 37 to 89, wherein the targeting complex further comprises chloroquine.
- 20 93. The targeting complex according to claim 90, wherein both the endosomal lytic agent comprises a membrane destabilising polypeptide.
- 25 94. The targeting complex according to any of claims 37 to 93, wherein the binding partner associates with the bioreactive species via a nucleic acid binding agent covalently attached to said binding partner.
95. The targeting complex according to claim 94, wherein the nucleic acid binding agent is selected from the group consisting of poly-L-lysine (PLL), spermine, spermidine and histone proteins.
- 30 96. The targeting complex according to claim 94, wherein the nucleic acid binding agent is PLL comprising from 15 to 1000 residues.

- 5 97. The targeting complex according to any of claims 37 to 93, wherein the binding partner associates with the bioreactive species indirectly via a pair of specific interacting components wherein one component is covalently attached to the bioreactive species and the second component is covalently attached to the binding partner.
98. The targeting complex according to claim 97, wherein said interacting components are biotin and streptavidin.
- 10 99. Use of a cell surface molecule identified according to any of claims 1 to 16 as a drug target, wherein said drug target is capable of binding a binding partner and internalising said binding partner into cells expressing said cell surface molecule.
- 15 100. The use according to claim wherein the cell surface molecule is selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, *GRIA2*, *GRM8*, *ITGAV*, *ITGAE*, TNFRSF12, L1CAM, GPR49 and *TMEFF1*.
- 20 101. A method of identifying and/or preparing specific binding partners comprising the steps of
- 25 i) Providing a cell surface molecule identified by the method according to any of the claims 1 to 16, wherein the cell surface molecule is selected from the group consisting of TNFRSF12, L1CAM, GPR49 and *TMEFF1*; and
- ii) Identifying and/or preparing binding partners capable of associating with said cell surface molecules
- 30 102. The method according to claim 101, wherein said binding partners can be used in pharmaceutical compositions for the treatment of a premalignant and/or malignant conditions.
- 35 103. The method according to claim 101, wherein said binding partner is prepared by the following steps

- i) immunising an animal with said cell surface molecule or part of said cell surface molecule; and
- ii) obtaining antibodies from said animal; or
- iii) obtaining cells producing antibodies from said animal and obtaining antibodies from said cells

5

104. The method according to claim 101, wherein said binding partners are selected from an expression library expressing polypeptides and/or oligopeptides.

10

105. The method according to claim 101, wherein said binding partners are selected from a synthetic combinatorial library expressing polypeptides and/or oligopeptides.

15

106. The method according to claim 101, wherein said binding partner is identified by screening a phage display library of antibodies.

107. The method according to claim 101, wherein said binding partner is identified by screening a phage display library of human antibodies.

20

108. The method according to claim 101, wherein said binding partners are selected from a library of small chemical compounds

109. An isolated and/or purified specific binding partner capable of associating with a cell surface molecule, which is expressed at a different level in malignant cells compared with normal cells, identified by the method according to any of the claims 101 to 108.

25

110. The binding partner according to claim 109, wherein said binding partner comprises or essentially consists of a polypeptide.

30

111. The binding partner according to claim 109, wherein said binding partner is an antibody or a fragment of an antibody.

112. The binding partner according claim 109, wherein said binding partner is a polyclonal antibody or a fragment thereof.
- 5 113. The binding partner according to claim 109, wherein said binding partner is a monoclonal antibody or a binding fragment thereof.
114. The binding partner according claim 109, wherein said binding partner is a murine monoclonal antibody.
- 10 115. The binding partner according to claim 109, wherein said binding partner is a humanised antibody.
116. The binding partner according to claim 109, wherein said binding partner is a human antibody identified from a phage display library.
- 15 117. The binding partner according to any of claims 111 to 116, wherein said antibody can interact with the extracellular part of the cell surface molecule.
- 20 118. The binding partner according to any of claims 111 to 116, wherein said antibody can interact with a posttranslational modification of the extracellular part of the cell surface molecule.
- 25 119. The binding partner according to any of claims 111 to 118, wherein said antibody is capable of being internalised upon association with said cell surface molecule.
120. The binding partner according to claim 109, wherein said binding partner is a naturally occurring ligand for said cell surface molecule.
- 30 121. The binding partner according to claim 109, wherein said binding partner is a recombinantly produced ligand for said cell surface molecule.
- 35 122. The binding partner according to claim 109, wherein said binding partner is a viral protein.

123. The binding partner according to claim 109, wherein said binding partner is a viral capsid protein.
124. The binding partner according claim 109, wherein said binding partner is a recombinantly produced and comprise viral capsid protein sequences.
125. The binding partner according to claim 109, wherein said binding partner is a small chemical compound.
126. The targeting complex according to any of claims 37 to 98, wherein the binding partner is a binding partner according to any of claims 109 to 125.
127. A method of identifying novel drug targets, comprising the steps of
- i) Providing a binding partner according to any of claims 109 to 125
 - ii) Identifying potential drug targets capable of associating with said binding partner
128. The method according to claim 127, wherein said drug target comprise a polypeptide, which is a cell surface molecule expressed at a different level in malignant cells compared with normal cells.
129. A drug target identified by the method according to any of the claim 127 to 128.
130. A complex comprising a cell surface molecule identified according to any of the claims 1 to 16 and a targeting complex according to any of the claims 37 to 98.
131. The complex according to claim 130, wherein the cell surface molecule is selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, *GRIA2*, *GRM8*, *ITGAV*, *ITGAE*, TNFRSF12, L1CAM, GPR49, *TMEFF*.
132. A use of the binding partner according to any of claims 109 to 125 for the preparation of a targeting complex according to any of claims 37 to 98.

133. A pharmaceutical composition comprising of the targeting complex according to any of the claims 37 to 98 together with a pharmaceutically acceptable carrier.
- 5
134. A method of treatment of a premalignant and/or malignant conditions in an individual in need thereof, comprising administering to said individual a pharmaceutically effective amount of the targeting complex according to any of the claims 37 to 98.
- 10
135. The method according to claim 134, wherein said treatment is ameliorating treatment.
136. The method according to claim 134, wherein said treatment is curative treatment.
- 15
137. The method according to claim 134, wherein said treatment is prophylactic treatment.
- 20
138. The method according to claim 134, wherein said condition is a cancer selected from the group consisting of melanoma, brain tumour, neuroblastoma, breast cancer, lung cancer, prostate cancer, cervix cancer, uterine cancer, ovarian cancer, leukaemia, colon cancer, rectum cancer and bladder cancer.
- 25
139. The method according to claim 134, wherein said condition is lung cancer selected from the group comprising small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- 30
140. The method according to claim 134, wherein said condition is small cell lung cancer.
141. The method according to claim 134, wherein said condition is breast cancer.

142. The method according to claim 134, wherein said clinical condition is a brain tumour selected from the group comprising glioblastomas, neuroblastomas, astrocytomas, oligodendrogliomas, meningiomas, medulloblastomas, neuronomas, ependymomas, craniopharyngiomas, pineal tumours, germ cell tumours and schwannomas.
143. The method according to claim 134, wherein said targeting complex is administrated parenterally.
144. The method according to claim 134, wherein said targeting complex is administrated by intravenous injection.
145. The method according to claim 134, wherein said targeting complex is administrated by subcutaneous injection.
146. The method according to claim 134, wherein said method further comprises one or more second treatments.
147. The method according to claim 146, wherein said second treatments are selected from the group consisting of surgical treatment, chemotherapy, radiation therapy, therapy with cytokines, Hormone therapy, gene therapy, immunotherapy and treatments using laser light.
148. A use of the targeting complex according to any of the claims 37 to 98 for the preparation of a medicament for the treatment of a premalignant and/or malignant conditions in an individual in need thereof.
149. The use according to claim 148, wherein said treatment is ameliorating treatment.
150. The use according to claim 148, wherein said treatment is curative treatment.
151. The use according to claim 148, wherein said treatment is prophylactic treatment.

152. The use according to claim 148, wherein said condition is a cancer selected from the group consisting of melanoma, brain tumour, neuroblastoma, breast cancer, lung cancer, prostate cancer, cervix cancer, uterine cancer, ovarian cancer, leukaemia, colon cancer, rectum cancer and bladder cancer.
- 5
153. The use according to claim 148, wherein said condition is lung cancer selected from the group comprising small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- 10
154. The use according to claim 148, wherein said condition is small cell lung cancer.
155. The use according to claim 148, wherein said condition is breast cancer.
- 15
156. The use according to claim 148, wherein said condition is a brain tumour selected from the group comprising glioblastomas, neuroblastomas, astrocytomas, oligodendrogliomas, meningiomas, medulloblastomas, neuronomas, ependymomas, craniopharyngiomas, pineal tumours, germ cell tumours and schwannomas.
- 20
157. The use according to claim 148, wherein said medicament is suitable for parenteral administration.
158. The use according to claim 148, wherein said medicament is suitable for intravenous injection.
- 25
159. The use according to claim 148, wherein said medicament is suitable for subcutaneous injection.
- 30
160. A use of a pharmaceutically effective amount of cell surface molecule identified according to any of claims 1 to 16 for the preparation of a vaccine.
161. A use of a pharmaceutically effective amount of a nucleic acid sequence encoding a cell surface molecule identified according to any of claims 1 to 16 for the preparation of a vaccine.
- 35

- 5 162. The use according to any of claims 160 and 161, wherein the cell surface molecule is selected from the group consisting of NCAM1, NPTXR, LRP8, CHRNA5, *GRIA2*, *GRM8*, *ITGAV*, *ITGAE*, TNFRSF12, L1CAM, GPR49 and *TMEFF1*.
- 10 163. The use according to any of 160 and 161, wherein said vaccine furthermore comprise a non-self antigen covalently linked to said cell surface molecule.
- 15 164. The use according to any of 160 and 161, wherein said vaccine furthermore comprises second nucleic acid sequences encoding a non-self antigen linked to the nucleic acid sequences.
165. The use according to any of 160 and 161, wherein said vaccine furthermore
15 comprise more than one antigen.
166. The use according to any of claims 160 and 161, wherein said vaccine furthermore comprise an adjuvant.
- 20 167. The use according to any of claims 160 and 161, wherein said vaccine is suitable for ameliorating and/or curative and/or prophylactic treatment of a premalignant and/or malignant conditions.

1/18

Fig. 1




Fig. 2

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)





Fig. 3

Pro 221
Insulinoma-associated antigen, IA-1



4/18




Fig. 4

5/18

Pro 41
MAD2, mitotic arrest deficient, yeast homolog-like 1




Fig. 5

6/18




Fig. 6

7/18

437 bp

pro 71
p16INK4/MTS1, MTS1, cyclin-dependent kinase inhibitor 2A, CDKN2A




Fig. 7

8/18




Fig. 8

9/18




Fig. 9

10/18





Fig. 10

Fig. 11



12/18




Fig. 12A

13/18




Fig. 12B

14/18





Fig. 13

15/18

Fig. 14



16/18

NCAM, neural cell adhesion molecule





Fig. 15


17/18

Fig. 16



18/18

Fig. 17



(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 January 2003 (03.01.2003)

PCT

(10) International Publication Number
WO 2003/000928 A3

(51) International Patent Classification⁷: **C12Q 1/68**,
G01N 33/574, A61K 38/00, G01N 33/50, C07K 16/18,
14/47

(21) International Application Number:
PCT/IB2002/003534

(22) International Filing Date: 19 June 2002 (19.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2001 00992 25 June 2001 (25.06.2001) DK
60/301,818 2 July 2001 (02.07.2001) US

(71) Applicant (for all designated States except US): **BUADBO APS** [DK/DK]; c/o Mercodan A/S, Baadehavns-gade 12, DK-2450 Copenhagen SV. (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **POULSEN, Hans**, Skovgaard [DK/DK]; Tuborg Boulevard 24 st, th, DK-2900 Hellerup (DK). **PEDERSEN, Nina** [DK/DK]; Lundtoftegade 46, st.tv., DK-2200 Copenhagen N. (DK). **MORTENSEN, Shila** [DK/DK]; Middelvej 29, DK-2820 Gentofte (DK). **Sørensen, Susanne, Berg** [DK/DK]; Lille Strandvej 26, l.mf., DK-2900 Hellerup (DK). **PETERSEN, Mikkel, Wandahl** [DK/DK]; Osterbrogade 139, 3.tv., DK-2100 Copenhagen Ø (DK). **ELSNER, Henrik, Irgang** [DK/DK]; Svend Gønges Vej 36, DK-2700 Brønshøj (DK).

(74) Agent: **HØIBERG A/S**; Store Kongensgade 59 B, DK-1264 Copenhagen K. (DK).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:
3 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR IDENTIFICATION OF CANCER CELL SURFACE MOLECULES AND CANCER SPECIFIC PROMOTERS, AND THERAPEUTIC USES THEREOF

(57) Abstract: The present invention describes methods for identification of molecules expressed at a different level on the cell surface of cancer cells compared to non-malignant cells and methods of identification of cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer. The invention furthermore describes targeting complexes targeted to cell surface molecules identified by the methods of the invention. In embodiments of the invention said targeting complexes comprise the promoters identified by the methods of the invention. In addition the invention describes methods of identifying binding partners for the cell surface molecules and the binding partners per se. Methods of treatment using the targeting complexes and uses of the targeting complexes for the preparation of a medicament are also disclosed by the invention. Furthermore, the invention describes uses of the cell surface molecules or fragments thereof for preparation of vaccines.



WO 2003/000928 A3

INTERNATIONAL SEARCH REPORT

Application No.

PCT/IB 02/03534

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N 574 A61K38/00 G01N33/50 C07K16/18
C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NORGAARD P ET AL: "EXPRESSION AND AUTOREGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR MRNA IN SMALL-CELL LUNG CANCER CELL LINES" BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 73, no. 9, May 1996 (1996-05), pages 1037-1043, XP001041824 ISSN: 0007-0920 the whole document	1
Y	NORGAARD P ET AL: "Acquired TGFb1 sensitivity and TGFb1 expression in cell lines established from a single small cell cancer patient during clinical progression" LUNG CANCER, vol. 14, 1996, pages 63-73, XP002246276 the whole document	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

3 July 2003

Date of mailing of the international search report

15/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

" nat Application No
PCT/IB 02/03534

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>FREDERIKSEN K S ET AL: "GENE DELIVERY BY AN EPIDERMAL GROWTH FACTOR/DNA POLYPLEX TO SMALL CELL LUNG CANCER CELL LINES EXPRESSING LOW LEVELS OF EPIDERMAL GROWTH FACTOR RECEPTOR" CANCER GENE THERAPY, NORWALK, CT, US, vol. 7, no. 2, February 2000 (2000-02), pages 262-268, XP001041826 ISSN: 0929-1903 the whole document</p> <p>---</p>	1
Y	<p>FREDERIKSEN K ET AL: "Gene therapy for lung cancer" LUNG CANCER, vol. 23, 1999, pages 191-207, XP002246277 the whole document</p> <p>---</p>	1
Y	<p>MANDA R ET AL: "Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display" GENOMICS, vol. 61, 1999, pages 5-14, XP002246278 the whole document</p> <p>---</p>	1
Y	<p>RETTIG W J ET AL: "CELL-SURFACE GLYCOPROTEINS OF HUMAN SARCOMAS: DIFFERENTIAL EXPRESSION IN NORMAL AND MALIGNANT TISSUES AND CULTURED CELLS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 85, May 1988 (1988-05), pages 3110-3114, XP000882805 ISSN: 0027-8424 the whole document</p> <p>---</p>	1
Y	<p>TANIMOTO H ET AL: "HEPSIN, A CELL SURFACE SERINE PROTEASE IDENTIFIED IN HEPATOMA CELLS, IS OVEREXPRESSED IN OVARIAN CANCER" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 14, 15 July 1997 (1997-07-15), pages 2884-2887, XP000867297 ISSN: 0008-5472 the whole document</p> <p>---</p>	1
	<p>---</p> <p>-/--</p>	

INTERNATIONAL SEARCH REPORT

PCT/IB 02/03534

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
Y	ROSS DT ET AL: "Systematic variation in gene expression patterns in human cancer cell lines" NATURE GENETICS, vol. 23, no. 4, March 2000 (2000-03), pages 227-36, XP002246279 the whole document	1
Y	WANG K ET AL: "Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 229, no. 1-2, 18 March 1999 (1999-03-18), pages 101-108, XP004161163 ISSN: 0378-1119 the whole document	1
Y	WO 98 53319 A (KINZLER KENNETH W ;VOGELSTEIN BERT (US); UNIV JOHNS HOPKINS (US)) 26 November 1998 (1998-11-26) the whole document	1
Y	WO 00 28032 A (INCYTE PHARMA INC ;AZIMZAI YALDA (US); CORLEY NEIL C (US); YUE HEN) 18 May 2000 (2000-05-18) page 1 -page 6, line 11	1
Y	FUNG L F ET AL: "DIFFERENTIAL GENE EXPRESSION IN NASOPHARYNGEAL CARCINOMA CELLS" LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 67, no. 8, 2000, pages 923-936, XP001041803 ISSN: 0024-3205 the whole document	1

INTERNATIONAL SEARCH REPORT

ational application No.
PCT/IB 02/03534

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 2-167
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 2-167

In view of the large number of claims (167) and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and/or conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible.

Moreover, all present claims relate to an extremely large number of possible of methods, products and use of products. In fact, the claims contain so many options, variables, possible permutations that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Independent of the above reasoning, present claims 134-147 relate to methods of treatment of the human body. normally a search would be made on the alleged effects of the compounds. However, considering the shortcomings with respect to conciseness and clarity already referred to above, no meaniful search could be performed.

Consequently, based on the objections outlined above, a meaniful search of the complete claimed subject matter was not possible. However, a search limited to an understanding of the general principal underlying the first independent claim (claim 1), i. e . a method for identifying cell surface molecules expressed at a different level in malignant and normal cells using the first mentioned 3 malignant cell lines of claim 1, was performed.

INTERNATIONAL SEARCH REPORT

in International Application No.

PCT/IB 02/03534

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9853319	A	26-11-1998	AU	7499198 A		11-12-1998
			WO	9853319 A2		26-11-1998
WO 0028032	A	18-05-2000	AU	1618500 A		29-05-2000
			CA	2349815 A1		18-05-2000
			EP	1129189 A2		05-09-2001
			WO	0028032 A2		18-05-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.